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ABSTRACT

THE INFLUENCE OF AGE, GENDER, AND THIOL REPLETION IN AN IN VIVO MODEL
OF LEWY BODY DISORDERS

By
Daniel M. Mason
July 2018

Dissertation supervised by Dr. Rehana K. Leak
Lewy body disorders are a family of neurological brain disorders associated with olfactory,
motor, and cognitive deficits and are collectively defined as α-synucleinopathies, as they are
characterized by hallmark “Lewy bodies” composed of aggregated, fibrillar α-synuclein. It is not
certain but often posited that fibrillar α-synuclein seeds the progressive, self-propagating spread
of Lewy pathology through neuroanatomical circuitry. Furthermore, the site of disease induction
is still debated. In Aim I, we developed a novel protocol for generating reproducible and robust αsynucleinopathy in the limbic temporal lobe of the mouse brain following infusions of preformed
α-synuclein fibrils into the olfactory bulb, which is often the first brain region to display Lewy
pathology in humans. Our tract-tracer studies revealed that all areas displaying dense Lewy-like
pathology were indeed connected to the induction site. However, the specific pattern of αsynucleinopathy resembled that of Stage IIb of Beach’s unified staging theory rather than
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Parkinson’s disease as it remained confined to the limbic system and did not enter motor brain
regions. In Aim 2, we further observed that α-synucleinopathy remained confined to the limbic
connectome regardless of gender, age, or incubation period. Any Lewy pathology that developed
in the ventral mesencephalon was confined to the ventral tegmental area, which is associated with
limbic rather than motor functions. Furthermore, our studies are the first to show that females are
more resistant to the development of α-synucleinopathy and neurodegeneration than males, and
that fibril infusions hasten mortality in aged mice. In Aim 3, N-acetyl cysteine protected primary
neuron cultures against proteotoxicity, including that of α-synuclein fibrils, and the mechanism
appeared to be partly dependent on the chaperone activity of heat shock protein 70. These findings
were expanded to an in vivo study, in which mice were fed N-acetyl cysteine for 90 days after
induction of olfactory α-synucleinopathy. Oral N-acetyl cysteine reduced Lewy-like pathology,
but only in the anterior olfactory nucleus, the area of densest α-synucleinopathy in this model. In
conclusion, we have developed a robust model of early-stage limbic-predominant Lewy body
disorders that appears to mimic the higher risk of Lewy body disorders in men and the acceleration
of mortality in these conditions.
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Introduction

The impact of Lewy body disorders

The term “Lewy body disorders” is used to encompass several related diseases characterized by
the progressive accumulation of protein aggregates known as Lewy bodies and Lewy neurites.
Parkinson’s disease (PD) is the most common clinically diagnosed Lewy body disorder and affects
1-3% of people over 50 (Dehay et al., 2015) and 2-3% of the population over 65 year of age (Poewe
et al., 2017). Within the United States, the financial burden of PD is estimated to be on average
$22,800 (in 2010 dollars) per patient per year, and this number substantially increases with age
(Kowal et al., 2013). Beyond the well characterized motor symptoms associated with PD, 75% of
PD patients who survive for more than 10 years will develop Parkinson’s disease dementia (PDD)
(Aarsland & Kurz, 2010a), and this percentage increases to 83% if they survive for more than 20
years (Aarsland et al., 2001; Hely et al., 2008). Dementia with Lewy bodies (DLB) is another
common Lewy body disorder and represents approximately 15% of dementia cases (Rahkonen et
al., 2003; Stevens et al., 2002). DLB is diagnosed when dementia symptoms appear before or
within a year of motor symptoms (McKeith et al., 2005). Individuals with PD, PDD, and DLB all
have an increased risk of dying younger than the general population (Savica et al., 2017).

Asymptomatic and cognitively normal people may also present with Lewy pathology upon
postmortem examination, suggesting that incidental Lewy body disease (ILBD) represents the
earliest stages of Lewy body disorders (Beach, Adler, et al., 2009). Approximately 10-30% of
cognitively normal elderly people present with Lewy bodies at autopsy, which is a greater
1

prevalence than those diagnosed with PD (Beach, Adler, et al., 2009; de Rijk et al., 1997),
suggesting that ILBD is the most common Lewy Body disorder. The prevalence of Lewy bodies
in the brains of otherwise healthy elderly people increases from 3.8% in the 6 th decade to 12.8%
in the 9th decade of life (de Rijk et al., 1997), suggesting that Lewy body disorders will become
more frequent as humans live longer. Current therapies only manage the symptoms of Lewy body
disorders, and there is no treatment available to decrease the accumulation of Lewy aggregates in
the central nervous system, as this process is still not well understood.

α-synucleinopathies

Alpha-synuclein is a small 140 amino acid protein that is located primarily at presynaptic terminals
(Iwai et al., 1995), but can also be found in the nucleus, mitochondria, and endoplasmic reticulum
(Maroteaux et al., 1988). It has been detected extracellularly in cerebrospinal fluid and plasma,
suggesting that α-synuclein is not exclusively an intracellular protein (Mollenhauer et al., 2008;
Tokuda et al., 2006). While the role of α-synuclein is still not known, it is likely involved in
synaptic vesicle dynamics, intracellular trafficking, and mitochondrial homeostasis (Vekrellis et
al., 2011; Wales et al., 2013). In aqueous solutions, α-synuclein is an unfolded monomer that does
not adopt a distinct and well-defined structure (Stefanis, 2012). When associated with lipid
micelles, α-synuclein can adopt an alpha-helical conformation (Burre et al., 2014; Dev et al., 2003)
that may coalesce into tetramers, which could be the more prevalent form within neurons (Bartels
et al., 2011; Dettmer et al., 2013). Regardless of the exact conformation, the form of α-synuclein
associated with vesicles is more prone to aggregation than the cytosolic form (Galvagnion et al.,
2015).
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Figure 1. The structural domains of α-synuclein. The protein sequence of α-synuclein can be
divided into three structurally unique domains: the N-terminus amphipathic region, the non-amyloid-β
component (NAC) domain, and the c-terminus acidic tail. The six missense mutations known to cause
familial PD are in the N-terminus amphipathic region.

Alpha-synuclein has three distinct structural domains; the N-terminus (amino acids 1-60), the
hydrophobic non-amyloid component (amino acids 61-95), and the C-terminus (amino acids 96140) (Stefanis, 2012). The N-terminus region is responsible for binding membranes and is
predicted to adopt an α-helical structure upon binding (Figure 1). This portion of α-synuclein can
be glycated, which reduces membrane binding and promotes the accumulation of α-synuclein
oligomers (Vicente Miranda et al., 2017). The central region is the amyloidogenic component
(Rodriguez et al., 2015). It is highly hydrophobic and when exposed, will readily bind to other
hydrophobic domains (Ueda et al., 1993). The C-terminus domain is negatively charged and able
to bind calcium, which helps localize α-synuclein to the synapse (Lautenschlager et al., 2018).
Misfolding of α-synuclein exposes the hydrophobic core and encourages the formation of β-sheets
that are prone to interact with other proteins and form detergent insoluble protein aggregates
(Saxena & Caroni, 2011).
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As it relates to Lewy body disorders, α-synuclein is the primary component of Lewy bodies and
Lewy neurites (Baba et al., 1998; Duda et al., 2000; Spillantini et al., 1997), but cortical Lewy
aggregates can contain approximately 300 different proteins (Leverenz et al., 2007). Other proteins
found in Lewy bodies include vimentin, γ-tubulin, synphilin-1, proteasome subunits, as well as
chaperone proteins (Junn et al., 2002). Most but not all Lewy aggregates also contain ubiquitin
(Kuzuhara et al., 1988; Spillantini et al., 1998), a modification that directs proteins to the cell’s
degradation machinery. Lewy bodies are found within neuronal perikarya and Lewy neurites are
found within dendrites and axons (Pollanen et al., 1993). For these insoluble inclusions to form,
the native α-synuclein monomers must aggregate into oligomers, which range in size from 4 to 24
nm (S.W. Chen et al., 2015), then transient protofibrils (Lashuel et al., 2002), and eventually

Figure 2. Pathway for insoluble α-synuclein fibril formation. Toxic forms of α-synuclein (red) are
formed as α-synuclein monomers (blue) aggregate into oligomers, protofibrils, and finally insoluble
fibrils.

coalesce into large insoluble protein aggregates with a dense amyloid core (Gallea & Celej,
2014)(Figure 2). Large somatic inclusions appear to undergo different stages of maturation
ultimately forming a dense and compact phenotype coinciding with a reduction of soluble αsynuclein (Osterberg et al., 2015). It has also been posited that there may be different forms or
strains of aggregated α-synuclein that may have unique characteristics including potentially
different seeding and aggregation properties (Bousset et al., 2013; Peelaerts et al., 2015; Pieri et
al., 2016; Yonetani et al., 2009). Similarly, different forms of α-synuclein oligomers have been
detected in the brains of patients with Lewy pathology (Ingelsson, 2016). Oligomers are
4

heterogeneous in structure and may from spheres, chains, or annular structures (Cremades et al.,
2017).

It is still not resolved whether Lewy bodies and Lewy neurites are toxic themselves, but it has
been shown that α-synuclein oligomers can cause toxicity by disrupting synaptic membrane
dynamics and seeding the misfolding and aggregation of endogenous α-synuclein (Danzer et al.,
2007; Danzer et al., 2009; Winner et al., 2011). In neuroblastoma cells, oligomer-induced
membrane disruption resulted in nanopore formation that altered neuronal ion homeostasis and
activated the nitric oxide synthase machinery leading to S-nitrosylation of many cytoplasmic
proteins including Hsp70 and Parkin (Kumar et al., 2018). The oligomers are particularly likely to
disrupt lipid bilayer integrity as they are comprised of a highly lipophilic region that readily
attaches to membranes as well as a rigid structural component that can insert into and disrupt the
lipid bilayer (Fusco et al., 2017). Oligomers can also interact with metal ions and increase the
generation of hydrogen peroxide and superoxide (Deas et al., 2016). It has also been reported that
α-synuclein oligomers impair both the ubiquitin proteasome system and autophagy-lysosomal
pathway (Xilouri et al., 2013). For these reasons, oligomers are suggested to be the most toxic
species of α-synuclein (el-Agnaf et al., 1997; El-Agnaf et al., 2003; Goldberg & Lansbury, 2000).
Indeed, soluble α-synuclein oligomers are elevated in brain homogenates of patients with DLB
and PD compared to healthy controls (Paleologou et al., 2009; Sharon et al., 2003).

Patterns of neurodegeneration

5

The symptoms of Lewy body disorders can be divided into three categories: physical symptoms,
cognitive impairment, and psychiatric/behavioral issues (Donaghy & McKeith, 2014). The
physical symptoms can be further subdivided into motor and nonmotor symptoms. The
prototypical motor symptoms associated with PD include rigidity, bradykinesia, resting tremor,
and postural instability, which are attributable to the loss of dopaminergic neurons within the
substantia nigra (SN) pars compacta and subsequent decrease of dopamine (DA) levels within the
striatum (Alexander, 2004; Jankovic, 2008). According to one stereological assessment, PD
patients have 82% nigra neuron loss, and ILBD patients have 40% loss compared to controls
(Iacono et al., 2015). Neuron loss in the SN has also been observed in DLB (Seidel et al., 2015).

Dopaminergic neurons may be particularly vulnerable to Lewy pathology for several reasons. DA
neurons are autonomous oscillators, neurons that rhythmically generate action potentials even in
the absence of external post-synaptic depolarization (Grace & Bunney, 1983). Nigral DA neurons
also have long, unmyelinated axons with approximately 1-2.4 million synapses each (Bolam &
Pissadaki, 2012; Pissadaki & Bolam, 2013). This high level of neuronal activity requires increased
levels of mitochondrial activity, and mitochondria generate reactive oxygen species (ROS) like
superoxide as a by-product of metabolism. Nigral DA neurons also lack myelination, a fatty axon
sheath that decreases the energy requirements of signal transmission. With constant stimulation
and relatively inefficient transmission, DA neurons rely heavily on detoxification of ROS. A loss
of homeostatic balance in these mechanisms can rapidly cause oxidative stress leading to
apoptosis.

6

DOPAL (3,4-dihydroxyphenylacetaldehyde) is a toxic intermediary formed through dopamine
metabolism (Kristal et al., 2001). As Lewy aggregates can interfere with vesicular dynamics and
impair synaptic function (Volpicelli-Daley et al., 2011), DA can accumulate which leads to the
generation of more DOPAL (Goldstein et al., 2012) within the cell. This can function as a negative
feedback loop as DOPAL can induce the oligomerization of α-synuclein (Burke et al., 2003;
Werner-Allen et al., 2017). Alpha-synuclein may also be involved with regulating dopamine
biosynthesis as it shares sequence homology with the chaperone molecule 14-3-3, which is
reported to activate tyrosine hydroxylase, the rate-limiting enzyme in the DA synthesis pathway
(Perez et al., 2002)

Neuron loss in the SN is particularly damaging because loss of these neurons reduces DA within
the striatum. The striatum is a hub that regulates goal-oriented actions, and loss of DA reduces the
ability of this region to respond to cortical and thalamic signals (Zhai et al., 2018). DA is an
inhibitory neurotransmitter and without it, the cortostriatal glutamatergic excitatory input from the
indirect pathway is no longer inhibited (Braak & Del Tredici, 2008), leading to loss of control of
motor functions. Glutamate excitotoxicity is also particularly toxic to dopaminergic neurons
(Sawada et al., 1996), which may further increase the vulnerability of the striatum. PD patients are
typically prescribed L-DOPA, a DA precursor that can increase DA levels within the brain and
reduce some of the symptoms associated with the striatal DA deficit. L-DOPA is not stored or
buffered well within the brain, and as more DA terminals are lost over the course of the disease,
the stimulation of DA receptors becomes increasingly inconsistent (Vijayakumar & Jankovic,
2016a, 2016b).

7

The nonmotor symptoms of Parkinson’s disease can be manifested long before the motor
symptoms begin and may represent a prodromal stage. By the time the telltale motor symptoms
emerge, as many as 50-70% of dopaminergic neurons in the SN are already lost (Damier et al.,
1999; Kordower et al., 2013; Marsden, 1990), and, therefore, diagnosing PD early is crucial to
maintaining a patient’s quality of life. This prodromal phase is estimated to be 20 years for patients
who present with PD in the sixth decade of life (Hawkes et al., 2010). Nonmotor symptoms include
olfactory impairments, rapid eye movement sleep behavior disorder (RBD), gastrointestinal
dysfunction, dysphagia, and orthostatic hypotension (Adler & Beach, 2016; Postuma et al., 2012;
Siderowf et al., 2012). Olfactory impairment is a well-established premotor symptom of
Parkinson’s disease (Doty et al., 1988; Hawkes et al., 1997). The presence of Lewy aggregates in
the olfactory bulb (OB) is correlated with olfactory dysfunction in PD (Driver-Dunckley et al.,
2014; Wilson et al., 2011), and olfactory dysfunction is associated with ILBD (Ross et al., 2006).

Gastrointestinal symptoms in PD include dysphagia, gastroparesis, prolonged GI transit time, and
constipation (Natale et al., 2008). One study of 245 autopsied men found that those with less than
one bowel movement per day were 4.3-fold more likely to have ILBD compared to those with
more than one bowel movement per day (Abbott et al., 2007), but the SN and locus coeruleus were
the only brain regions analyzed. Other studies have found that only 25% of ILBD subjects have
Lewy aggregates in the colon (Annerino et al., 2012), and that constipation may be more associated
with Lewy pathology in the spinal cord than the G.I. tract (Beach et al., 2010; Tamura et al., 2012;
VanderHorst et al., 2015). Loss of neurons in the dorsal motor nucleus of the vagus nerve, which
occurs early in PD, could also be the cause of constipation (Del Tredici et al., 2002).

8

Immunoreactive α-synuclein aggregations have also been reported in neurons of the submucosal
tissue of the intestines and stomach (Braak, de Vos, et al., 2006).

Rapid eye movement sleep behavior disorder is a common prodromal symptom of Lewy body
disorders and is characterized by the loss of paralysis that normally occurs during sleep.
Degeneration of the locus coeruleus could result in less noradrenergic (excitatory) signaling to the
magnocellular reticular formation, which is involved with inhibitory signaling to spinal motor
neurons during sleep (Boeve, 2010). One study found that 79% of autopsied cases with RBD had
pathologically defined DLB or PD (Boeve et al., 2013). This symptom is reported in up to 65% of
PD patients (Adler et al., 2011; Boeve et al., 2001; Postuma et al., 2006; Schenck et al., 1996).
RBD also increases the likelihood of developing PD, and patients with RBD often present with
additional nonmotor symptoms of PD such as olfactory dysfunction (Postuma et al., 2006).
Patients with both RBD and olfactory dysfunction may also progress to clinically diagnosed Lewy
body disorders at a faster rate (Mahlknecht et al., 2015; Postuma, Gagnon, et al., 2015; Postuma,
Iranzo, et al., 2015). Cases of concurrent PD and RBD were also found to have increased αsynuclein deposition in 9 out of 10 brain regions analyzed (Postuma, Adler, et al., 2015).

Dysphagia and orthostatic hypotension are less common nonmotor early symptoms and their
pathological underpinnings are not as well understood. It has been reported that there is a higher
density of Lewy aggregates in the pharyngeal nerves in PD cases, which may be responsible for
dysphagia (Mu et al., 2013). Orthostatic hypotension can occur early in PD but is more often
present in advanced stages of the disease and may be related to Lewy aggregates in cardiac tissue
or the sympathetic ganglia (Beach et al., 2010; Fumimura et al., 2007; Gelpi et al., 2014).
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The most common cognitive and behavioral/psychiatric symptoms are cognitive impairment,
anxiety, and depression. Cognitive impairment is indeed a premotor symptom of PD, as
approximately 15% of PD patients present with mild cognitive impairments before the onset of
motor symptoms (Aarsland, 2016). Cognitive impairment differs from dementia, as the latter is
diagnosed when cognitive impairments are so severe that one can no longer function independently
and perform activities of daily living. When dementia symptoms emerge within a year prior to or
simultaneously with parkinsonism, patients are diagnosed with DLB (McKeith et al., 2005). When
the motor symptoms of PD are well established before dementia symptoms emerge, patients are
diagnosed with PDD (Goetz et al., 2008; McKeith et al., 2005). PD patients have a much greater
risk of developing dementia than healthy elderly controls (Aarsland et al., 2017), and 75-90% of
PD patients will eventually develop dementia (Aarsland et al., 2003; Aarsland & Kurz, 2010a;
Gratwicke et al., 2015).

While there are some conflicting reports, most studies agree that the primary cause of cognitive
decline in Lewy body disorders is limbic and cortical Lewy pathology (Aarsland, 2016; Aarsland
et al., 2017; Kalaitzakis & Pearce, 2009). Neocortical Lewy bodies are associated with cognitive
impairment (Aarsland et al., 2005) and dementia (Hurtig et al., 2000). Some have found that
cortical Lewy bodies do not always predict dementia (Colosimo et al., 2003), but one study
reported a 10-fold increase in neocortical and limbic Lewy aggregates in the brains of PDD patients
compared to PD patients without dementia (Apaydin et al., 2002) suggesting the density of Lewy
pathology in these regions is key to cognitive impairment. Atrophy of the hippocampus has also
been associated with cognitive decline (Nagano-Saito et al., 2005), and DLB patients with
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hippocampal atrophy are at greater risk of mortality (Graff-Radford et al., 2016; Lemstra et al.,
2017).

The link between Lewy pathology and the symptoms of anxiety and depression is less well
understood. Anxiety may be linked to pathology in the amygdala, which often presents with the
most Lewy aggregates of any brain region (Beach, Adler, et al., 2009). The amygdala is also known
to atrophy significantly in both DLB and PD (Cordato et al., 2000). Pathology is the coeruleussubcoeruleus complex may be responsible for symptoms of depression. This region has strong
serotonergic inputs from the caudal raphe nuclei and a reduction in norepinephrine activity at the
synapse in this region has been linked to depression (Klimek et al., 1997). PD patients can also
experience significant neuron loss in this area (Kalaitzakis & Pearce, 2009).
PD and DLB staging
It is important to understand the progression of PD because there is never a case where Lewy
pathology is only present in the SN (Adler & Beach, 2016), suggesting that this area is not where
Lewy aggregates first develop. In 2003, Heiko Braak and colleagues proposed a six-stage pattern
of Lewy body development in Parkinson’s disease (Braak et al., 2003) that was based on autopsies
of 168 brains (69 incidental cases, 41 clinically diagnosed PD patients, and 58 age and gender
matched controls) (Braak, Bohl, et al., 2006). The first three stages are the presymptomatic stages,
in which Lewy aggregates appear within the brain but do not cause overt motor symptoms. In the
first stage, Lewy aggregates are found in the OB, anterior olfactory nucleus (AON), dorsal IX/X
motor nucleus, and enteric nervous system (Braak et al., 2003; Hawkes et al., 2010). In Stage 2,
aggregates are found in the magnocellular portions of the reticular formation, the caudal raphe
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nuclei, and the coeruleus-subcoerulus complex. In Stage 3, the midbrain begins to develop Lewy
aggregates. At this stage, degeneration in the SN pars compacta begins. In Stage 4, the Lewy
aggregates can be identified in the cortex, but it is typically constrained to the temporal mesocortex
and allocortex. The accessory cortical and basolateral nuclei of the amygdala and interstitial
nucleus of the stria terminalis are also affected at this stage (Hawkes et al., 2010). In Braak Stages
3 and 4, Lewy pathology appears in the entorhinal cortex and hippocampus, which may lead to
cognitive decline. In Stage 5, the pathology progresses to higher order sensory association areas
of the neocortex and prefrontal cortex. Stage 6, the final stage, is reached when the entire neocortex
succumbs to Lewy pathology. Stages 5 and 6 typically have extensive cortical damage.

One of the limitations of Braak’s work is that he did not analyze the brain tissue of patients
diagnosed with DLB or investigate pathology in the spinal cord or peripheral nervous system,
where α-synuclein pathology also presents in Lewy body disorders (Gelpi et al., 2014). After
autopsying 417 brains of patients with PD, DLB, ILBD, and Alzheimer’s disease with Lewy
Bodies (ADLB), Beach and colleagues found that 42% with Lewy pathology could not be
classified by the Braak staging system, and 50% could not be classified by the DLB consortium
system (Beach, Adler, et al., 2009). According to both staging systems, approximately one-third
of the unclassifiable patients had pathology only in the OB, and two-thirds had pathology in the
limbic system in the absence of pathology in the brainstem (Beach, Adler, et al., 2009). Beach and
colleagues also found that there was not a single case of pathology in the periphery when it was
absent from the central nervous system (CNS), suggesting the enteric nervous system is not the
site of induction (Adler & Beach, 2016). Indeed, others have found that the dorsal motor nucleus
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of the vagus nerve, a connection to the enteric nervous system, does not always present with Lewy
pathology when pathology is present within the SN (Kalaitzakis et al., 2008).

Given these caveats of prior staging systems, Beach and colleagues proposed a new staging system
that could include all cases of Lewy pathology they observed. In this system, Stage I is when the
OB alone develops Lewy pathology, but as the OB is occasionally unaffected, it may be skipped
and subjects can be classified to higher stages. From the OB, Stage II is divided into 2 substages
as pathology may progress through two different pathways. Stage IIa has brainstem-predominant
Lewy pathology and Stage IIb has limbic-predominant Lewy pathology. In Stage III, both the
brainstem and limbic system are affected, and in Stage IV, the pathology emerges in the neocortex.
Most ILBD subjects are classified as Stage IIa and most ADLB subjects are Stage I or Stage IIb.
Most PD and DLB patients are Stage III or IV. This staging system is based on probability of
where pathology develops and not deterministic factors. There were not any cases of DLB or PD
where only a single brain region was affected, but in ADLB and ILBD cases, some had only a
single brain region affected, and it was most often the OB (Beach, Adler, et al., 2009). There are
several limitations in attempting identify and stage pathology including differences between
researchers in tissue processing, immunohistochemical methods, tissue sample collection, and
inter-observer assessment of the pathology (Alafuzoff et al., 2008; Croisier et al., 2006; Muller et
al., 2005).

Alzheimer’s disease and Lewy body disorders are not mutually exclusive. Patients often present
with the hallmark inclusions of both pathologies and some have observed that the occurrence of
neocortical Lewy pathology often coincides with β-amyloid deposits and neurofibrillary tangles
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(Apaydin et al., 2002). Indeed, diffuse β-amyloid plaques have been observed in PDD and DLB
patients (Aarsland, 2016), and Lewy pathology has been frequently observed in Alzheimer’s
patients, most often confined to the limbic system (Beach, Adler, et al., 2009; Toledo et al., 2016).
The reasons for these overlaps are unclear, but it has been observed that phosphorylated αsynuclein can promote the phosphorylation of tau and disrupt its normal functioning (Guo et al.,
2013). Mice over expressing both α-synuclein and β-amyloid have been reported to exhibit more
robust Lewy-like pathology than mice overexpressing α-synuclein alone (Irwin et al., 2013),
suggesting that there may be cumulative effects.

Transmission of α-synucleinopathy

The first evidence of Lewy pathology transmission in humans was observed after embryonic
mesencephalic neurons were transplanted into the striatum of patients with PD. Years later, the
transplanted neurons exhibited Lewy bodies, which indicated a host-to-graft transmission of
pathology (Kordower et al., 2008; Li et al., 2008). A host-to-graft transmission of α-synuclein from
host cells to grafted dopaminergic neurons was then confirmed in an in vivo mouse model (Hansen
et al., 2011). Since then, much has been learned about the cell-to-cell spread of misfolded αsynuclein. In animal models, transmission of pathology has been observed after injections of
recombinant α-synuclein fibrils (Luk, Kehm, Carroll, et al., 2012) and brain homogenates from
both transgenic α-synuclein mice (Luk, Kehm, Zhang, et al., 2012; Mougenot et al., 2011) and
patients with Lewy body disorders (Prusiner et al., 2015; Recasens et al., 2014). These
observations support the theory that misfolded α-synuclein can be transmitted between neurons
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across anatomically connected brain regions (Jucker & Walker, 2013; Luk, Kehm, Zhang, et al.,
2012).

It is not known for certain how misfolded α-synuclein enters a neuron, but it has been demonstrated
that α-synuclein can enter the central nervous system by crossing the blood brain barrier after
intravenous injection of α-synuclein assemblies (Peelaerts et al., 2015). Exogenous α-synuclein
fibrils are capable of interacting with 178 neuron and 108 astrocyte membrane proteins, 58 of
which are common to both (Shrivastava et al., 2015). The lymphocyte-activation gene 3 (LAG3)
receptor is a likely candidate involved with misfolded α-synuclein internalization as it had the high
binding affinity for biotin-tagged preformed α-synuclein fibrils in a streptavidin-alkaline
phosphatase assay and did not bind biotin-tagged α-synuclein monomers, tau or β-amyloid (Mao
et al., 2016). Free intercellular oligomeric α-synuclein is not internalized as efficiently as
oligomers associated with exosomes (Danzer et al., 2012), and neuronal uptake of α-synuclein
aggregates can be reduced by pretreatment with endocytosis inhibitors monodansylcadaverine and
dynasore (Hansen et al., 2011), suggesting endocytosis rather than passive diffusion is the primary
means of entry.

Once inside the cell, α-synuclein aggregates can escape into the cytoplasm from
endosome/lysosome compartments and evade degradation (Flavin et al., 2017). The misfolded αsynuclein can then act as a template and induce the misfolding and aggregation of endogenous αsynuclein (Luk et al., 2009; Volpicelli-Daley et al., 2011). While α-synuclein aggregates have been
observed to move in neurons in both anterograde and retrograde directions in vitro (Freundt et al.,
2012), the spread of α-synuclein aggregates is primarily in a retrograde direction in vivo (Luna &
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Luk, 2015; Uchihara et al., 2016). This agrees with the reports that Lewy bodies are enriched with
dynein, a protein associated with retrograde transport (Volpicelli-Daley, 2017).

For the pathology to transmit to neighboring cells the aggregates must exit the neuron. Failure to
degrade aggregated α-synuclein can result in exocytosis that is not mediated by the endoplasmic
reticulum and Golgi apparatus (Alvarez-Erviti et al., 2011). The release is related to neuronal
activity (Yamada & Iwatsubo, 2018) and can be increased by proteotoxic and mitochondrial stress
(Jang et al., 2010; H. J. Lee et al., 2005). As astrocytes can engulf and degrade misfolded αsynuclein assemblies (Loria et al., 2017), exocytosis by neurons may be an attempt to share the
proteotoxic stress burden with support cells.

Risk Factors

There are many risk factors than can increase the likelihood of developing Lewy body disorders.
In PD, 5-10% of cases are linked to a genetic mutation (Poewe et al., 2017). The most significant
mutations related to familial PD are the genes for α-synuclein, PINK1, parkin, DJ-1, GBA, and
LRRK2 (Bonifati et al., 2003; L. N. Clark et al., 2009; Kitada et al., 1998; Paisan-Ruiz et al., 2004;
Polymeropoulos et al., 1997; Sidransky et al., 2009; Valente et al., 2004). With regard to αsynuclein, A53T, H50Q, E43K, and A30K mutations all have been reported to increase the
aggregation of α-synuclein in vitro (Conway et al., 2000; Ghosh et al., 2013; Greenbaum et al.,
2005). Changes in charged amino acid residues can influence the conformation of α-synuclein and
increase its likelihood to form into an insoluble aggregate. Duplication of triplication of the gene
encoding for α-synuclein also increases the likelihood of developing PD (Singleton et al., 2003).
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The environmental risk factors of Lewy body disorders are less well understood, but in a casecontrol study in China, exposure to industrial chemicals increased the likelihood of developing PD
(Tanner et al., 1989). Indeed, chronic exposure to certain herbicides and pesticides, particularly
paraquat and rotenone can increase the risk of developing PD (Gorell et al., 1998; Gorell et al.,
2004; Hertzman et al., 1990; Liou et al., 1996; Semchuk et al., 1993; Tanner et al., 2011). Exposure
to heavy metals including lead, copper, iron, and mercury also increase the risk of developing PD
(Gorell et al., 2004; Ngim & Devathasan, 1989). PD patients often have elevated levels of these
metals in the SN (Dexter et al., 1989; Gerlach et al., 2008; Sofic et al., 1988).

The reason for a PD-specific phenotype after exposure to these agents is only partially understood.
It has been reported that paraquat kills neurons within the SN (Liou et al., 1996), and that iron and
paraquat can synergistically increase the age-related loss of dopaminergic neurons within the SN
(Peng et al., 2007). Paraquat inhibits complex 1 of the mitochondria, which increases ROS within
the cell (Castello et al., 2007; Jenner, 2003). It has also been reported that heavy metals and
pesticides promote the aggregation of α-synuclein (Uversky et al., 2001). Treatment with charged
metal ions are reported to increase the rate of α-synuclein fibril formation (Uversky et al., 2001),
possibly by inducing a conformation change in the protein that favors aggregation. Heavy metals
like mercury and lead inhibit glutamine synthetase, which is responsible for converting glutamate
into less toxic glutamine (Sierra & Tiffany-Castiglioni, 1991).

Lifestyle risk factors favoring PD include a history of head trauma (Semchuk et al., 1993) and
circadian disruption (Lauretti et al., 2017). Additionally, a high fat and high calorie diet
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(Logroscino et al., 1996), diabetes (Hu et al., 2007), and obesity (Abbott et al., 2002; Hu et al.,
2006) may also be risk factors for developing Lewy body disorders. These risk factors may be
related to increased glycation of Lewy bodies with chronic high blood sugar levels (Vicente
Miranda et al., 2016). Glycation of α-synuclein is reported to increase its propensity to aggregate
(Vicente Miranda et al., 2017), and advanced glycation end products are reportedly increased in
the SN, amygdala, and frontal cortex of ILBD patients compared to age-matched controls (Dalfo
et al., 2005), or the observations that cholesterol metabolites can increase α-synuclein fibrilization
(Eriksson et al., 2017), and that obese patients typically have lower levels of the dopamine D2
receptor in the striatum (H. Chen et al., 2004).

Gender and aging

Two often reported and particularly important risk factors in the context of this dissertation are age
and male gender. Age is the strongest risk factor for developing PD (Bennett et al., 1996; Morens
et al., 1996; Tanner & Goldman, 1996). Rapid Eye Movement (REM) sleep disorders, a common
prodromal symptom of Lewy body disorders and risk factor discussed earlier, is more prevalent
with age (Sixel-Doring et al., 2011). The increased risk of PD with age is likely related to increased
susceptibility to α-synucleinopathy, as normal aging does not result in significant loss of
dopaminergic neurons within the SN (Alladi et al., 2009). This effect was confirmed in non-human
primates as aging failed to cause a significant loss DA neurons, but did lower phenotypic
expression of tyrosine hydroxylase (McCormack et al., 2004). Normal aging does lead to a
progressive accumulation of α-synuclein within dopaminergic neurons of the SN in rhesus
monkeys, but it is the soluble, non-pathogenic form (Chu & Kordower, 2007). In addition to the
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patient’s age, the age of onset of PD is also associated with a greater risk of developing dementia
(Aarsland & Kurz, 2010b), suggesting the effects of age are not limited to the nigrostriatal
pathway. In PD patients, age, severity of motor symptoms, cognitive impairment, but also male
gender are associated with an increased risk of death (Forsaa et al., 2010).

While the reasons are not well understood, many studies have reported that females develop Lewy
body disorders less often than males (Beach, Adler, et al., 2009; Savica et al., 2017; Savica et al.,
2013; K. M. Smith & Dahodwala, 2014; Twelves et al., 2003). Females are also diagnosed with
PD on average two years later than men (Haaxma et al., 2007) suggesting that clinical symptoms
manifest later in women. Only in men but not women was plasma α-synuclein concentration
associated with sleep disorders, hallucinations, and cognitive impairment (Caranci et al., 2013).
Neocortical Lewy pathology appears in the advanced stages of PD, is related to cognitive decline,
and is more prevalent in men (Nelson et al., 2010), suggesting that gender can affect the
development and spread of α-synuclein pathology.

The symptoms and risk factors of Lewy body disorders can also differ amongst the genders. In
PD, males are more likely to experience hyposmia, urinary symptoms, sexual dysfunction, gait
disturbances, and rigidity, while females are more likely to experience depression, dyskinesia,
anxiety, postural instability, more pain symptoms, and a tremor-dominant phenotype (Farhadi et
al., 2017; Georgiev et al., 2017). Risk factors more associated with male gender are head trauma
and exposure to pesticides while anemia is more associated with females (Georgiev et al., 2017).
In terms of treatment, male PD patients are more likely to be prescribed antipsychotics while

19

female PD patients are more likely to be prescribed antidepressants (Fernandez et al., 2000),
possibly as a consequence of the differing symptoms between genders.

The differences in PD etiology may be a result of natural underlying differences between males
and females. Female brains also have a greater percentage composition of gray matter
(Geevarghese et al., 2015), and females below 60 years of age have 8.4% higher DAT binding
compared to men (Wong et al., 2012). It has been reported that males typically have a higher
baseline oxidative stress level than women (Ide et al., 2002), which may contribute to their greater
vulnerability. From a genetic standpoint, the MAO-A gene, involved with neurotransmitter
metabolism is on the X chromosome and so with only one copy, males might express lower levels.
To compensate for this insufficiency, the SRY gene on the Y chromosome can become activated.
The SRY gene produces the SRY protein, and the expression of this protein is associated with
increased levels of tyrosine hydroxylase (TH), dopamine β-hydroxylase, DOPA decarboxylase,
the D2 receptor, and monoamine oxidases (Tao et al., 2012; Wu et al., 2009). The MAO-A gene
has a SRY binding site on the core promoter. The SRY gene is expressed in the SN and the SRY
protein specifically localizes with TH positive neurons (Dewing et al., 2006). The SRY gene may
therefore have evolved on the Y chromosome to compensate for the increased oxidative stress and
reduced estrogen levels in the male brain.

Estrogens are neuroprotective and in a cross-sectional study of female PD patients, increased
duration of estrogen exposure was associated with a later age of diagnosis and less severe motor
impairment (Cereda et al., 2013; Haaxma et al., 2007). Females who develop PD also experience
menopause earlier than age-matched controls (Benedetti et al., 2001; Nitkowska et al., 2014).
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Estrogen replacement therapy at the onset of menopause reduces the risk of developing dementia
in female patients (Marder et al., 1998), which suggests that estrogens may reduce the spread of
α-synucleinopathy to regions where Lewy pathology is associated with cognitive decline. This
agrees with reports men are more than twice as likely to develop both the limbic predominant and
diffuse neocortical subsets of DLB as women (Nelson et al., 2010), and is consistent with
observations that estrogens can disaggregate aggregated forms of α-synuclein (Hirohata et al.,
2009).
Olfactory dysfunction

As discussed previously, olfactory dysfunction is a well-established premotor symptom of
Parkinson’s disease (Doty et al., 1988; Hawkes et al., 1997), but it is somewhat nonspecific, as
other neurodegenerative diseases can also reduce olfactory capability. Olfactory impairment is also
age-related, as approximately 75% of people report a reduction in their sense of smell after the
seventh decade of life (Doty, 2009). This age-related loss of olfaction is more severe for men than
women (Godoy et al., 2015), possibly because females have significantly more neuronal and nonneuronal cells in their OBs (Oliveira-Pinto et al., 2014) or have a larger orbitofrontal cortex, a part
of the olfactory system (Gur et al., 1999). Females typically perform better on olfactory exams
(Doty et al., 1984), and female PD patients also often perform better than male PD patients on
smell tests (Stern et al., 1994).

Loss of olfaction is associated with ILBD (Ross et al., 2006), and is often reported years before
the motor symptoms of PD emerge (Hawkes et al., 1997). The presence of Lewy aggregates in the
OB is correlated with olfactory dysfunction in PD (Driver-Dunckley et al., 2014; Wilson et al.,
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2011). In the OB, Lewy pathology is most often observed in the mitral and tufted cells, but also in
the granule and periglomular cells (Sengoku et al., 2008). PD patients often show reduced volume
and sulcus depth (Palatini et al., 1992), and loss of mitral and substance P containing cells in the
OB (Ferrer et al., 2012).

Mechanisms of neurodegeneration

Lewy aggregates can be toxic to neurons through several related mechanisms. As mentioned
earlier, misfolded α-synuclein molecules can bind to many different proteins on the cell surface.
In doing so, they can cause a deleterious protein clustering effect, in which many membrane
proteins bind to an aggregate of misfolded α-synuclein, leaving some areas with reduced density
of vital cell-surface receptors such as ion channels (Shrivastava et al., 2017; Shrivastava et al.,
2015). If the misfolded α-synuclein is endocytosed, the aggregates can sequester synaptic proteins
such as VAMP2 and SNAP25 (Choi et al., 2018), which can inhibit synaptic vesicle recycling and
reduce neurotransmitter release (Nemani et al., 2010; Volpicelli-Daley et al., 2011). Inside the cell,
the aggregates can induce vesicle rupture (Danzer et al., 2007; Samuel et al., 2016) and impair
intracellular transport (Volpicelli-Daley, Gamble, et al., 2014).

Under normal conditions, misfolded proteins can be degraded by the ubiquitin-proteasome system
(UPS) or the lysosome autophagy system (LAS). Aggregated α-synuclein is difficult to degrade
by these systems and can inhibit the proteasome (Lindersson et al., 2004; Rideout et al., 2001; W.
W. Smith et al., 2005; Y. Tanaka et al., 2001) as well as the lysosome (Cuervo et al., 2004).
Oligomeric α-synuclein has also been detected in mitochondria (Nakamura et al., 2008) where it
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can inhibit complex 1 (Luth et al., 2014; Reeve et al., 2015), and lead to the generation of ROS
and induce apoptosis (Eschbach et al., 2015; W. W. Smith et al., 2005). Aggregated α-synuclein
can also form pores in the cell membrane that cause loss of calcium ion homeostasis and lead to
apoptosis (Danzer et al., 2007). Neurons that express calcium binding proteins and are able to
buffer calcium ion levels are reported to be resistant to developing Lewy aggregates (GomezTortosa et al., 2001). While there are many downstream negative effects of misfolded α-synuclein,
the toxicity of the α-synucleinopathy is ultimately a function of the accumulation of misfolded or
deleteriously modified proteins and the generation of oxidative stress.

Accumulation of misfolded proteins

The accumulation of misfolded proteins into large insoluble aggregates causes proteotoxic stress
within neurons and is a key feature of neurodegenerative diseases (Morimoto, 2008). The primary
mechanisms used by cells to mitigate proteotoxic stress are the UPS and LAS. Depending on the
conformation, misfolded α-synuclein can be targeted to either the UPS or LAS (Shin et al., 2005)
and cleared by both systems (Cuervo et al., 2004; Emmanouilidou et al., 2010; Rideout et al.,
2004). In order to target large misfolded proteins to the proteosome, they must first be tagged with
ubiquitin proteins, which requires multiple enzymes. Phosphorylation of serine 129 may direct
misfolded α-synuclein to the UPS when the LAS in not adequately preventing α-synuclein
accumulation (Arawaka et al., 2017).

In the first step of ubiquitination, E1, an ubiquitin-activating enzyme hydrolyzes ATP and prepares
the C terminus of ubiquitin for nucleophilic attack (Pickart, 2001). E2, an ubiquitin-conjugating
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enzyme binds to the activated ubiquitin and carries it to E3, an ubiquitin-ligase. E3 binds both E2
and ubiquitin and can then transfer the ubiquitin to a lysine residue on the protein targeted for
degradation (Richly et al., 2005). The Parkin protein, commonly mutated in familial early onset
PD, is an E3 ubiquitin ligase involved with protein degradation (Baptista et al., 2004), and
proteasome dysfunction has been reported in the SN of PD patients (McNaught et al., 2003;
McNaught & Jenner, 2001), confirming the crucial role of the UPS. Oligomeric α-synuclein can
also induce the S-nitrosylation of Parkin, enhancing its degradation and reducing the functionality
of the UPS (Wilkaniec et al., 2018). Activity of the UPS also decreases normally as a consequence
of aging in nearly every tissue (Martinez-Vicente et al., 2005), but this natural process may be
exacerbated by misfolded α-synuclein, as it can bind the proteasome and reduce its activity
(Cuervo et al., 2004; Lindersson et al., 2004).

While both the UPS and LAS can degrade misfolded α-synuclein, the LAS has been reported to
be more important for degrading oligomeric α-synuclein (Xilouri et al., 2013). Autophagy can be
subdivided into at least three distinct forms: microautophagy, macroautophagy, and chaperonemediated autophagy. Microautophagy involves the lysosome directly engulfing cytosolic material.
Macroautophagy involves the engulfment of substrates by a double membrane and the formation
of an intermediate structure called the autophagosome, which then fuses with the lysosome (Lopez
Meza et al., 2010). Chaperone-mediated autophagy involves the delivery of targeted proteins to
the lysosome by chaperones, followed by transport across the membrane by the LAMP2A receptor
(Kaushik & Cuervo, 2012; Yang & Klionsky, 2010).
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The large misfolded α-synuclein aggregates that are the hallmarks of Lewy body disorders are
most likely degraded through the macroautophagy and chaperone-mediated autophagy systems.
Overexpression of α-synuclein is reported to impair autophagosome formation both in vitro and in
vivo (Winslow et al., 2010). The A53T and A30P mutant forms of α-synuclein may also inhibit
the LAMP2A receptor and block the translocation of materials into the lysosome (Cuervo et al.,
2004; Martinez-Vicente et al., 2008). Furthermore, chloroquine, a lysosome inhibitor, increases
the formation of α-synuclein aggregates (Sacino et al., 2017). Impairment of the LAS can also
increase secretion of aggregated α-synuclein by exosomes into the extracellular space (AlvarezErviti et al., 2011).

There is growing evidence to support the theory that Lewy bodies may be a form of failed
aggresome. An aggresome is a protein-filled insoluble inclusion that forms at the centrosome in
response to proteotoxic stress (Bence et al., 2001; Kopito, 2000). Centrosomes can serve as a
scaffold to direct the degradation of misfolded proteins (Kopito, 2000), and misfolded proteins are
actively transported to the centrosome (Johnston et al., 2002; Johnston et al., 1998; Kawaguchi et
al., 2003; Wigley et al., 1999; Wojcik, 1997; Wojcik et al., 1996). Many of the same proteins
trafficked to the centrosome (chaperone proteins, components of the UPS, substrates for
proteolysis) are also found in Lewy bodies, suggesting that Lewy bodies are not formed though a
chaotic process of protein accretion, but rather through a regulated attempt to degrade misfolded
proteins (McNaught et al., 2002; Olanow et al., 2004). In cells that are stressed with proteasome
inhibitors, inhibiting microtubule transport impedes the development of the aggresome and
increases toxicity (Bence et al., 2001; Johnston et al., 1998; Junn et al., 2002; H. J. Lee & Lee,
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2002). Furthermore, Lewy neurites may be protein aggregates en route to the centrosome (Olanow
et al., 2004).

After formation, the aggresome can recede or persist as an insoluble mass (Bence et al., 2001),
quite similar to the prototypical Lewy body. Aggresomes are believed to be neuroprotective, as
aggresomes appear in 60% of non-apoptotic cells but only 10% of apoptotic cells (M. Tanaka et
al., 2004). Similarly, some authors report that Lewy bodies do not deleteriously affect neuron
structure or function (Gertz et al., 1994). Furthermore, it has been reported that neurons with Lewy
bodies in the SN appear more resistant to apoptosis than neurons without Lewy bodies (Tompkins
& Hill, 1997).

Oxidative stress

Oxidative stress is defined as the imbalance between the cellular mechanisms responsible for
mitigating ROS and those responsible for their generation (Sies, 2015). Neurons are particularly
susceptible to oxidative stress as they contain a relatively large amount of unsaturated lipids that
can be deleteriously modified by oxidative stress (Uttara et al., 2009). The components of the UPS
are also particularly vulnerable to damage from ROS (Bulteau et al., 2001; Sitte et al., 2000).
Oxidative stress in neurons can be caused by dysregulation of the UPS as well as mitochondrial
dysfunction (Double et al., 2010). Defective mitochondria are typically removed from the cell by
the LAS (Brunk & Terman, 2002a, 2002b), but as discussed earlier, this system can be inhibited
by α-synuclein aggregates. The increased oxidative stress levels caused by dysfunctional
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mitochondria can also reduce the effectiveness of the LAS (Dehay et al., 2010), further reducing
the ability of the cell to mitigate oxidative stress.

Oligomeric forms of α-synuclein can interact with metal ions to induce the generation of
superoxide and hydrogen peroxide (Deas et al., 2016), and oxidative stress has been reported to
increase the accumulation of α-synuclein aggregates in vitro (Hashimoto et al., 1999; Souza et al.,
2000). Dopaminergic neurons contain relatively high levels of iron (Halliwell, 1992), and iron can
generate ROS through the Fenton reaction (Rhodes & Ritz, 2008). DA can also be metabolized
into cytotoxic free radicals, including hydrogen peroxide and dopamine quinones (Greenamyre &
Hastings, 2004; Halliwell, 1992), and dopaminergic neurons are also particularly susceptible to
damage from oxidative stress (Fahn & Cohen, 1992; Olanow, 1990). The enhanced vulnerability
of dopaminergic cells to ROS may contribute to the neurodegeneration of the nigrostriatal pathway
in PD. Indeed, there is an upregulation in ROS production (Dias et al., 2013) and high levels of
oxidatively damaged proteins within the SN of PD patients (Alam et al., 1997; Good et al., 1998;
Yoritaka et al., 1996). In addition, DA neurons exposed to α-synuclein fibrils exhibit an increase
in mitochondrial and cytoplasmic oxidative stress markers (Dryanovski et al., 2013).

Importance of glutathione/N-acetyl cysteine

Glutathione (GSH) is the most abundant antioxidant in the central nervous system and is found in
millimolar concentrations in most cell types (Pocernich & Butterfield, 2012). GSH is produced by
both neurons and glia (Dickinson & Forman, 2002) and efficiently detoxifies ROS (Dringen,
2000; Griffith, 1999). The GSH concentration is neurons (~2.5 mM) is lower than that of astrocytes
(~3.8 mM) (Bolanos et al., 1995; Rice & Russo-Menna, 1998), but astrocytes can release GSH
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into the extracellular space to supply it to nearby neurons (Rice & Russo-Menna, 1998). GSH can
be conjugated to compounds to target them for efflux though multidrug resistance efflux
transporters (Marchan et al., 2008), and thereby help rid the cell of potentially toxic substances.
GSH is particularly important in the brain as the brain consumes 20% of the oxygen but only
weighs 2% of total bodyweight. Of the 20% of oxygen consumed by the brain, approximately 90%
is used by the mitochondria to produce ATP to fuel the energy intensive process of
neurotransmission (Ballatori et al., 2009).

The rate of synthesis of GSH is determined by the activity of the enzyme gamma-glutamylcysteine
ligase and by the availability of the amino acid cysteine (Dickinson et al., 2004; Stringer et al.,
2004). N-Acetyl cysteine (NAC) is metabolized into cysteine, which provides the rate-limiting
substrate necessary to increase the production of GSH (Aldini et al., 2018). While NAC is indeed
neuroprotective by enhancing GSH production (Unnithan et al., 2014), it has also been reported to
have beneficial GSH-independent effects (Jiang et al., 2013; Unnithan et al., 2014), which are less
well understood.

NAC supplementation has proven beneficial in a variety of neurological disorders. NAC is
reported improve symptoms of akathisia in schizophrenia patients (Berk, Copolov, Dean, Lu,
Jeavons, Schapkaitz, Anderson-Hunt, Judd, et al., 2008), some cognitive impairments in
Alzheimer’s patients (Adair et al., 2001), and the depressive symptoms in bipolar patients (Berk,
Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt, & Bush, 2008). In patients with
traumatic brain injury, NAC supplementation doubled the chance of symptom resolution (Hoffer
et al., 2013).
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A decrease in GSH levels is one of the earliest reported pathologies in PD (Martin & Teismann,
2009). GSH depletion occurs before neurodegeneration of the SN (Chinta & Andersen, 2006) and
there are reports of a 40-90% loss of GSH in this brain region (Dexter et al., 1994; Perry et al.,
1982; Sian, Dexter, Lees, Daniel, Agid, et al., 1994; Sian, Dexter, Lees, Daniel, Jenner, et al.,
1994). The severity of PD symptoms has been correlated to the degree of GSH loss (Jenner, 1998;
Riederer et al., 1989). DA injection into the striatum of rats causes a significant depletion of GSH
(Rabinovic & Hastings, 1998), suggesting that GSH may mitigate the toxicity associated with DA
metabolism. Baseline GSH levels decrease with age, and male mice experience a greater ageassociated decline in GSH (Liu et al., 2004), possibly contributing the increased risks of PD in
males and with aging discussed earlier.

There is mounting evidence that NAC therapy could be beneficial to PD patients. In cell lines,
NAC is reported to decrease DOPAL-quinone formation and reduce the formation of α-synuclein
oligomers (D. G. Anderson et al., 2016; Goldstein et al., 2017; Jinsmaa et al., 2018). In α-synuclein
overexpressing mice, oral NAC administration reduced α-synuclein aggregate formation and
preserved striatal dopaminergic terminals (J. Clark et al., 2010). NAC has also shown to mitigate
the toxicity of the dopaminergic neurotoxins MPTP and 6-OHDA (Aluf et al., 2010; K. W. Lee et
al., 2004; Perry et al., 1985; Sharma et al., 2007). In PD patients, NAC administration increases
GSH levels in the CNS (Holmay et al., 2013; Katz et al., 2015) and increases dopamine transporter
binding in the striatum by 4.4 to 7.8% (Monti et al., 2016).

Preformed fibril model
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The development of exogenous recombinant α-synuclein fibrils was an important innovation for
modeling Lewy body disorders. In 2012, Luk et al. demonstrated that striatal injections of these
fibrils could seed Lewy-like pathology that spreads to neuroanatomically connected brain regions
and causes nigral cell loss and motor impairments in non-transgenic animals (Luk, Kehm, Carroll,
et al., 2012; Luk, Kehm, Zhang, et al., 2012). A few years earlier, the prevailing theory had been
that transgenic animals are essential to study α-synucleinopathy (Dawson et al., 2010). Upon
injection, the preformed fibrils induce the accumulation of the endogenous mouse α-synuclein into
an aggregated and pathogenic form that decreases synaptic proteins, impairs neuronal excitability,
reduces neuronal connectivity, and eventually leads to apoptosis (Volpicelli-Daley et al., 2011).
The endogenous α-synuclein misfolds into an insoluble, hyperphosphorylated and ubiquitinated
form (Luk, Kehm, Carroll, et al., 2012; Luk, Kehm, Zhang, et al., 2012). As little as 0.1 μg of
preformed fibrils is enough to induce Lewy-like pathology in wild-type mice (Tarutani et al.,
2018), and fibrils 50 nm or less in length are the most efficient at inducing pathology (Tarutani et
al., 2016). While uptake of the preformed fibrils can occur at either the soma or dendrites (Bieri et
al., 2018), the aggregates are typically first detected in axons and then travel to the cell soma where
Lewy body-like aggregates form (Volpicelli-Daley et al., 2011). It has also been reported that there
are different strains of α-synuclein fibrils that can induce distinct α-synucleinopathies in vivo
(Bousset et al., 2013; Pieri et al., 2016; Yonetani et al., 2009). Bousset et al. demonstrated that αsynuclein could assemble into structurally distinct aggregates he differentiated as “fibrils” or
“ribbons,” which induce endogenous α-synuclein to form aggregates of the same architecture. The
fibril form was found to be more toxic to cells and the A30P α-synuclein mutation made αsynuclein incapable of forming ribbons, possibly contributing to increased toxicity (Bousset et al.,
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2013). The PFF model is the first reproducible and progressive model to recapitulate many key
features of human Lewy body disorders, such as nigrostriatal pathway degeneration.

Materials and Methods
Animals and surgeries
All treatments and procedures were approved by the Duquesne University Institutional Animal
Care and Use Committee (protocol nos. 1403-04 and 1604-05), and performed in accordance with
NIH regulations. Male and female CD-1 mice were purchased from Charles River (Horsham, PA)
and housed and bred in the Duquesne University animal care facility. All animals were housed in
a 12:12 photoperiod with ad libitum access to UV-disinfected water and food. Sprague Dawley
rats were purchased from Hilltop Lab Animals (Scottsdale, Pennsylvania). Female Sprague
Dawley rats were singly housed and part of an in-house breeding colony maintained to generate
rat pup tissue for postnatal cultures.

Every effort was made to reduce pain and suffering related to experimental procedures. Prior to
surgeries, the animals were anesthetized with 3% isoflurane. A stereotaxic frame was used to
stabilize the animals for surgeries. Paxinos and Franklin’s “The Mouse Brain in Stereotaxic
Coordinates” (Franklin and Paxinos, 2013), was used to determine coordinates for injection. The
stereotaxic coordinates were confirmed with injections of blue food dye into the target structure.
Unilateral injections were made to the right OB/AON region of mice defined stereotaxically as AP
+4.0, ML -1.0, DV -2.5 mm from Bregma at the top of the skull. The AP coordinate was increased
to +4.1 in the 11-month-old mice to account for the slightly larger skull size. Injections into the
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hippocampus were defined as AP -2.5, ML -2.8, DV -3.6 mm from Bregma. The infusion occurred
at a rate of 0.25 µL/min followed by a 4-minute rest period before the needle was withdrawn.
Following the surgery, the animals received 0.015 mg/kg buprenorphine subcutaneously and were
placed on a heating pad. Lidocaine and antibiotic ointment were applied to the wound for three
days after the surgery. At the end of the experiment, the animals were anesthetized with isoflurane
and perfused through the left ventricle with 50 mL of saline followed by 100 mL of 4%
paraformaldehyde in 0.1 M phosphate buffer.

Alpha-synuclein
Kelvin Luk (University of Pennsylvania Perelman School of Medicine) generously provided the
α-synuclein fibrils. The stock solution of the fibrils was kept frozen at -80 o C until thawed prior to
sonication. Approximately 10 µL of fibrils were sonicated either with a probe sonicator (Misonix
XL2020, Misonix incorporated, Farmingdale NY) for 60 pulses of approximately 0.2 seconds or
with a waterbath sonicator (Bransonic series model M1800, Branson Ultrasonics Corporation,
Danbury CT) for either 1 or 24 hours. After sonication, the fibrils were kept at room temperature.
The fibrils were infused at a maximum of four hours post-sonication. Excess fibrils were discarded
and no solutions were reused.

Male mice (2, 3, 5, 11, and 17 months old) or female mice (3 months old) were infused with
sonicated preformed full-length wild-type mouse α-synuclein. The mice were infused with 5 µg in
1 µL of the preformed fibrils or 1 µL of phosphate buffered saline (PBS).

Chemicals and antibodies
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The primary and secondary antibodies used in these experiments are listed Tables 2 & 3. A noprimary control was always performed to confirm specificity of the secondary antibody. MG132
(UBPBio Aurora CO, Cat. No. F1101) was stored at -80 o C as 10 mM stock solution in dimethyl
sulfoxide (DMSO). VER155008 (R&D systems, Minneapolis, MN) was used to inhibit
Hsp70/Hsc70 activity as previously reported (Chatterjee et al., 2013; Saykally et al., 2012;
Schlecht et al., 2013). It was stored at -80 o C as a 10 mM stock solution in DMSO. MAL3-101,
an Hsp70/Hsc70 inhibitor (Braunstein et al., 2011; Huryn et al., 2011; Kilpatrick et al., 2013), was
stored as a 10 mM stock in DMSO at -80 o C until use. Lactacystin (AdipoGen Corporation, San
Diego, CA) was stored at -20 o C as 10 mM stock solution in DMSO. Paraquat (Sigma-Aldrich, St.
Louis, MO) was dissolved in PBS (100 mM) and stored at -80 o C until use. DRAQ5 (1:10000 or
0.5 µM, Biostatus, Leicestershire, UK) was stored at 4 o C until use. NAC (Acros Organics,
160280250 Lot A0333137) for in vitro studies was prepared by dissolution in PBS, sterile filtering,
and stored at a concentration of 1000 mM at -80 o C. A 0.15% NAC diet for in vivo studies was
prepared by mixing 1.5 g of NAC per kg of 5001 PMI Laboratory Diet (Envigo Teklad Diets,
Madison WI). FluoroGold (Fluorochrom LLC, Denver, CO) was stored at 4 o C as a concentration
of 1.5% in PBS until use. In the in vivo experiment, 300 nL of a 1.5% Fluorogold solution or an
equal volume of PBS was injected into the same region (OB/AON) in male CD-1 mice (2 months
old). For this experiment, the mice were sacrificed one week following injection of FluoroGold.

Behavioral testing
All testing was performed within an arena (45 cm x 60 cm x 60 cm) of black polyvinylchloride
plastic walls with a green polyvinylchloride floor. Two lamps were used to create a dim diffuse
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light that minimized shadows in the arena. The arena was sprayed with 70% isopropyl alcohol
between trials to remove olfactory cues.

Buried pellet test
To measure olfactory function, the buried pellet test was employed as described previously
(Lehmkuhl et al., 2014). On the first day of testing, the animals were placed in a cage with corncob
bedding piled in one half for three minutes. On the second day of testing, the animal was placed
in a fresh cage with the corncob bedding piled in one half of the cage and a peanut was placed on
the top of the pile. The latency of each mouse to contact the exposed peanut was recorded. On the
third day, the mice were placed in an empty cage with the corncob bedding piled in the opposite
half and a peanut was buried 0.5 cm deep in a random location. The latency to find and contact the
buried peanut was then recorded. An observer blinded to the treatment group of each animal
performed the video analysis. To account for the preference of the treat between animals, the time
the animal took to contact the exposed peanut was subtracted from the time the animal required to
find the buried peanut.

Novel object (NOR) and novel place (NPR) tests
The object and place recognition tasks were performed to measure learning and memory. For these
tests, three identical bases were used—a bare floor for the acclimation, and two other identical
floors with brackets fastened to hold the objects in place. A video camera was positioned above
the arena so that the entire arena was visible in the camera’s field of view. The camera was used
to record behavior during the later phases of the tests. The objects were made of glass or plastic
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with varying shapes and textures, including light bulbs and plastic bottles. The objects were
fastened so that the animals could not displace or hide beneath them. On the first day, the animals
were acclimated to the arena by placing them on the bare floor an allowing them to explore the
arena for 10 minutes. On the next day, the floor of the arena was changed so that the arena
contained two identical objects in fixed positions in opposite corners of the arena approximately
10 cm from the walls of the arena. The animals were allowed to explore the arena and interact with
the objects for five minutes. On the next day, a novel object was substituted for one of the familiar
objects in the arena and the animal was allowed to explore for a five-minute period. The time spent
exploring the familiar and novel objects was recorded. The animal was considered to be interacting
with the object if the head was within 4 cm and oriented within a 45-degree angle of the object.
On the final day of testing, the animals were returned to the arena with the same two identical
objects from the first familiarization phase but with one object moved to a novel location. The
exploration time was scored the same as the novel object test and the exploration ratio for both
tests was defined as the time the animal spent exploring the novel object/place divided by the time
the animal spent exploring both the novel and familiar objects. The mice that spent less than 10
seconds exploring the objects during the testing phase were classified as “non-responders” and
excluded from the data analysis (Cai et al., 2012).

Cylinder test
To measure spontaneous motor activity, the mice were placed in a clear, Plexiglass cylinder (8.9
cm diameter, 15.2 cm high) for 10 minutes. The Plexiglass cylinder placed on top of a clear base
with a mirror underneath so that the camera had an upward view of the mouse and could see turning
in all directions.
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Challenge beam test
The challenge beam test was used to measure motor coordination. On the first two days, the mice
were placed on the wide end of a trapezoid beam and trained to traverse the beam as described
previously (Fleming et al., 2004). On the third day, a mesh grid was placed over the beam and the
time to traverse the beam and the number of slips while crossing the beam was recorded. On the
test day, the mice traversed the beam three times.

Histology
After perfusion, the brains were immersed in 30% sucrose in 10 mM PBS for 48 hours and cut
into sections 40 or 50 µM thick on a freezing microtome in the sagittal place. The free-floating
sections were stored in a cryoprotectant solution at -20

o

C. To immunostain the tissue,

cryoprotectant was rinsed off with three washes of PBS and then heated to 80 o C in a 10 mM
sodium citrate tribasic dehydrate solution (pH 8.5) for 30 minutes to expose antigen binding sites
(Jiao et al., 1999). The sections were then incubated at room temperature in a 1:1 solution of
Odyssey block (LI-COR Bioscience, Lincoln, NE) in PBS for 1 hour on a shaker. Both primary
and secondary antibodies were added to a 1:1 Odyssey Block in PBS with 0.3% Triton X-100. The
primary antibodies listed in Table 2 were then applied to the sections and incubated at 4 o C for 24
hours on a shaker. The tissue sections were then washed three times and the secondary antibodies
listed in Table 3 were applied to the tissue for one hour at room temperature. Hoechst 33258
(bisBenzimide) and/or the infrared marker DRAQ5 were added at a concentration of 0.005 µM or
0.5 µM, respectively, during the secondary antibody incubation. The tissue was then washed three
times with PBS and mounted onto glass slides (Superfrost Plus, Fisher Scientific, Pittsburgh, PA)
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and coverslipped with either FluoroMount G (Southern Biotech, Birmingham AL) or Krystalon
(EMD Chemicals, Gibbstown, NJ). Sections were then scanned on an infrared Odyssey imager or
analyzed on an epifluorescent microscope (Olympus IX73, B&B Microscopes, Pittsburgh PA)
with magnification objectives ranging from 4× to 100×. Sections from control and experimental
groups were processed and analyzed in parallel. Primary antibodies were omitted from the
immunohistochemical protocol in some sections to control for secondary antibody specificity.
Loss of epifluorescent signal confirmed label of primary antibody.

Thioflavin staining
Thioflavin S staining was performed as published by Paumier and colleagues and our previous
work (Paumier et al, 2015, Mason et al., 2016, Nouraei et al., 2016), as an additional measure of
the aggregated and insoluble from of α-synuclein. The tissue was washed 3× in filtered PBS and
mounted onto Superfrost Plus glass slides and dried. The slides were dipped into several solutions:
10 mM PBS for 5 minutes, 0.05% KMnO4 in PBS for 20 minutes, 2 rinses of PBS for 2 minutes,
0.2% K2S205 and O.2% oxalic acid in PBS for 1 minute, 5 rinses of PBS for 2 minutes, freshly
filtered 0.0125% Thioflavin S in 40% EtOH and 60% PBS for 3 minutes in darkness, 50% EtOH
and 50% PBS for 10 minutes, 4 rinses of PBS for 5 minutes, 0.003 mM Hoechst 33258
bisBenzimide in 0.3% Triton X-100, a final rinse of sterile water for 5 minutes. After the
immersions, the slides were allowed to dry and then coverslipped. Thioflavin S signal was
measured in the 488 (green) channel of the Olympus IX73 microscope. Sections from control and
experimental groups were prepared and analyzed in parallel.

Image analysis
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In order to measure tyrosine hydroxylase (TH) and dopamine transporter (DAT) on the Licor
Odyssey scanner, a blinded observer traced the boundaries of the regions of interest using TH and
DAT signal as a guide. The background signal for each animal was subtracted by determining the
signal per area in a brain region (occipital cortex) that has low endogenous DA levels (Brown et
al., 1979). For counting TH+ and Hoechst+ cells, images taken with the 20× objective were stitched
on the Olympus IX83 microscope, and a blinded observer used the multichannel images to define
the TH+ cells. In cellSens software, the observer drew a shape around the various areas containing
TH+ cells. Images were captured in grayscale (12-bit depth) and pseudocolored. The images were
then saved with the shape in the Hoechst channel, so that the number of Hoechst + cells in that
region could be counted automatically with ImageJ (NIH, Bethesda MD) software. Grayscale
TIFF images were opened and a blinded observer used the “analyze particles” function to count
inclusions after setting a binary threshold for each image. All photos were captured at the same
exposure. High-resolution (100× oil objective) images were captured on the Olympus microscope
with a 12-bit grayscale camera (CS-S-CCD High End Flash 4.0 Camera). For the VTA and SN
counts in Aim 2, the TIFF images included a shape drawn around a region of interest. The threshold
value was kept the same for all the images in each experiment. Particles with areas <50 pixels
(background staining, not nuclear) or >1000 pixels (clusters of more than one cell) were excluded
a priori. For the counts in Aim 3, the region of interest was cropped out of a 40× magnified image
and counted in ImageJ using the methods described above.

Confocal microscopy
Confocal images in Aim 1 were captured with an Olympus Fluoview 1200 confocal system on an
IX83 inverted frame with a 40× silicone oil objective (NA 1.25), using a gain of 1.0. Confocal
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images in Aim 2 were captured on a Nikon A1R LU-NV confocal imaging system with a Nikon
Ti2 microscope (Nikon Instruments Inc., Melville, NY). The gain was set to 1.0 and images
captured with a 20× and 60× oil objective (NA 1.40). The Z-stacks were captured at 0.31 μm per
pixel at 1.391 μm per section in the Z plane.

Electron microscopy
Unsonicated, probe-sonicated, 1-hour waterbath sonicated, and 24-hour waterbath sonicated fibrils
were visualized with transmission electron microscopy using a JEOL JEM1210 at 60 kV (Jeol
USA Inc., Peabody MA) using whole-mount preparations. The samples were first diluted 50% in
PBS. They were then suspended on Formvar-coated 200 mesh copper grids (Electron Microscopy
Sciences, Hatfield PA), and visualized by staining with 1% uranyl acetate. The images were
captured with an ORCA-HR digital camera (Hamamatsu, Middlesex NJ). The fibrils were
negatively stained as well as positively stained with the uranyl acetate, but more fibrils stained
positively in all sonicated groups.

Blocking peptide experiments
A preadsorption control was used to confirm the specificity of the primary antibodies used to label
aggregated α-synuclein in our experiments. Specifically, the preadsorption control was employed
on polyclonal pSer129 antibodies; this type of control is not useful with monoclonal antibodies
because there is only one binding site and thus incubating with the antigen will block all binding
and not reveal unintended binding in the tissue. In our study, the rabbit polyclonal pSer129 (Abcam
Ab59264) was incubated with 10-fold excess blocking peptide (Abcam Cat no. 188826) overnight
prior to applying it to the tissue. Adjacent sections from the same animal were used to eliminate
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any confounding variations in levels of background staining between animals. The tissue was
exposed to the free polyclonal antibody or the blocked primary antibody for 24 hours at 4 o C and
then rinsed prior to application of the secondary antibodies.

Primary neuron cultures
Animal use was approved by the Duquesne University IACUC (protocol no. 1505-04), and all
experiments were performed in accordance with the guidelines described in the NIH Guide. Every
effort was made to reduce the number of animals used and to minimize animal suffering. Tissue
from the OB and hippocampus were dissected with microforceps from the brains of postnatal day
1 or 2 Sprague Dawley rat pups (Charles River, Wilmington, MA) and incubated in 10 units/mL
of papain (Sigma-Aldrich, Cat. No. P3125) for 30 minutes. The tissue was homogenized and
incubated in 10% type II-O trypsin inhibitor (Sigma-Aldrich, Cat. No. T9253). The cells were then
triturated in Basal Medium Eagle (Sigma-Aldrich, Cat. No. B1522) containing 10% bovine calf
serum (BME/BCS, HyClone Thermo Scientific, Logan, UT. Cat. No. 2151) and supplemented
with 35 mM glucose (Sigma-Aldrich, Cat. No. G8769), and 1 mM L-glutamine (Gibco, Life
Technologies, Cat. No. 25030-081). The dissociated cells were plated in Opti-MEM (Gibco, Life
Technologies, Cat. No. 51985-034) with 20 mM glucose at a plating density of 80,000-100,000
cells/well in a 96-well plate (Corning, Inc 353072). The plates were precoated with laminin (1.88
ug/mL, BD Biosciences), and lysine (1 ug/mL) washed and dried prior to plating. After two hours
in the Opti-MEM solution, a full media change was performed replacing the Opti-MEM for
Neurobasal-A media (Gibco, Life Technologies) supplemented with 2% v/v serum-free B27
(Gibco, Life Technologies) and 2 mM L-glutamine.
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Treatments
Treatments began on day-in-vitro 5 (DIV5), approximately 120 hours after plating. The cells were
treated with a 10× stock of MG132 added to Neurobasal-A media supplemented with 2% v/v
serum-free B27 and 2 mM L-glutamine. Cultures were treated with toxicants and NAC in a 2×
media exchange on DIV5. On DIV7 viability assays were performed as described below. For αsynuclein fibril treatments, cultures were treated with α-synuclein fibrils and NAC in a full media
exchange on DIV2 and then fixed on DIV9.

Viability assays
ATP levels were assessed using the luciferase-based Cell Titer Glo assay (Promega Inc, Madison,
WI). Briefly, 25 µL of reagent was added to 50 µL of media. Within 15 minutes, 60 µL of solution
was transferred to a white 96 well plate and analyzed on a microplate reader (VICTOR 1420
multilabel counter; PerkinElmer, Waltham, MA). To determine neuronal viability, cultures were
stained for the neuronal marker microtubule associated protein 2 (MAP2) using an infrared In-Cell
Western assay (Posimo et al., 2013; Posimo et al., 2014a). GSH levels were measured in the same
manner. Nuclei were stained with the infrared marker DRAQ5 (1:10,000, 700 nm; Biostatus,
Shepshed, Leicestershire, UK). MAP2, GSH, and DRAQ5 levels were then quantified on Odyssey
imager with Odyssey software (Version 3.0, LI-COR, Lincoln, NE).

α-synuclein+ protein inclusions were visualized by immunostaining for the aggregated form of αsynuclein (phosphorylated at serine 129 or pSer129) (J. P. Anderson et al., 2006; Fujiwara et al.,
2002; Hasegawa et al., 2002; Saito et al., 2003). For this experiment, nuclei were stained with
Hoechst (10 μg/ml Hoechst 33258, bisBenzimide) in phosphate-buffered saline with 0.3% Triton-
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X (ACROS, Cat. no. 21568-0010, Geel, Belgium) for one hour. Phospho-Ser129 and Hoechst
staining was visualized on an epifluorescent microscope (EVOS, Life Technologies) at 200×
magnification (0.213 mm2 field of view, three fields per well). ImageJ software was used to
quantify Hoechst-stained nuclear counts and α-synuclein + inclusions. The software displayed the
following measurements: particle count, average particle size, and area fraction. The area fraction
signifies the percentage of pixels in the image that have been segmented over background.
“Background” was expressed at the same level for all microphotographs.

Statistical analyses
For In-Cell Westerns, wells with fluorescent lint or air bubbles were excluded from analysis.
Statistical significance for the concentration-response curves was determined by one-way
ANOVA followed by the Bonferonni post-hoc correction (IBM SPSS Statistics, Version 20,
Armonk, NY). The data from the treatments were analyzed by two or three-way ANOVA followed
by the Bonferroni post hoc correction. All in vitro experiments were performed in triplicate wells,
and the data from the three wells was averaged to generate an “n” of 1. Each in vitro experiment
was repeated on at least three independent occasions. The Grubb’s outlier test was performed once
on all the data.

For in vivo experiments, the data were analyzed by the appropriate ANOVA given the number of
independent variables and followed by the Bonferroni post hoc correction (SPSS Version 20,
Armonk, NY). The log-rank survival analysis was performed with GraphPad Prism software
(Version 6.0h). In cases where there were only two groups, the two-tailed, unpaired Student’s t
test was performed. The threshold of p ≤ 0.05 was used to define significance between groups.
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Chapter 1

Rationale

Some of the first brain regions to develop Lewy aggregates in Lewy body disorders are the OB
and AON (Beach, Adler, et al., 2009; Beach, White, et al., 2009; Braak et al., 2003). Lewy
pathology in these regions contributes to the early olfactory dysfunction experienced by
approximately 90% of PD patients (Doty, 2012; Wilson et al., 2011). At autopsy, Lewy pathology
is observed in 97.1% of DLB cases, 94.8% of PD cases, 66.6% of ILBD cases, but only 7.2% of
healthy controls (Beach, White, et al., 2009). In a separate autopsy study, every patient exhibiting
a loss of pigmented neurons in the SN also displayed Lewy bodies in the OB (Sengoku et al.,
2008). Despite these findings, α-synucleinopathy has been theorized to spread from neuron to
neuron across interconnected brain regions with the brainstem as the primary starting point for αsynuclein pathology, with minimal transmission of pathology from olfactory structures (Braak et
al., 2003; Dehay et al., 2016; Jones et al., 2015). As OB sensory neurons project into the nasal
mucosa, the “olfactory vector hypothesis” proposes that an environmental insult such as bacteria,
viruses or toxins may initiate α-synucleinopathy in the olfactory structures and then spread to
additional brain regions (Dando et al., 2014; Doty, 2008). The primary goal of this Aim was to
resolve whether α-synucleinopathy could indeed spread from the OB and AON into distant brain
regions in wild-type mice that do not overexpress α-synuclein.

Before we commenced our experiments, Rey and colleagues published that human α-synuclein
monomers and oligomers, but not preformed fibrils could be transmitted to some brain regions
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including the piriform cortex within hours after injection into the OB (Rey et al., 2013).
Nevertheless, Luk and colleagues had shown that PFFs elicit the spread of Lewy-like pathology in
the dopaminergic system within three months following infusions in the striatum (Luk, Kehm,
Carroll, et al., 2012). Longer time points may have led to transneuronal transmission of pathology
in their model, but this was not confirmed with tract-tracing studies. Therefore, we decided to
infuse PFFs into the OB/AON rather than monomers or oligomers and to sacrifice the mice at three
months post-infusion to attempt to limit the spread to first-order circuitry, and to use a wellestablished tract-tracer to verify the afferent connections of the injection site.

Subsequent to our collection of the histological data, Rey published a review article with pilot data
demonstrating long-term transmission from the OB into the entorhinal cortex, amygdala and
hippocampus (Rey, George, et al., 2016). While these data were encouraging and consistent with
our findings, the pathology appeared sparse, perhaps because their injections were in the rostral
OB and they had not optimized fibril sonication parameters as we had (Rey, George, et al., 2016;
Rey et al., 2013). As the AON develops more Lewy pathology than the OB in PD (Beach, White,
et al., 2009; Braak et al., 2003; Ubeda-Banon et al., 2010), we had decided to inject the caudal OB,
closer to the AON, before we commenced the study.

Fibril sonication parameters are of paramount importance for the generation of robust pathology
as differences among sonicators and sonication protocols can affect PFF activity in vitro
(Volpicelli-Daley, Luk, et al., 2014). Therefore, we tested various protocols for sonication of the
preformed α-synuclein fibrils in vivo, as, to our knowledge, this has not been accomplished before.
In two month-old mice, we infused vehicle, 1-minute probe-sonicated, or 1-hour waterbath-
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sonicated α-synuclein fibrils into the OB/AON and sacrificed the mice three months later. To
visualize the epicenter of the injection site, we performed injections at the same stereotaxic
coordinates in a separate cohort of mice and sacrificed them after 90 minutes. This time point was
chosen because Rey and colleagues had reported the greatest spread of human α-synuclein 90
minutes post-infusion (Rey et al., 2013). We employed the retrograde tract-tracer FluoroGold to
determine if the brain regions that develop Lewy pathology are neuroanatomically connected to
the site of infusion.

After the first study revealed that waterbath sonication was far more effective at eliciting robust
Lewy-like pathology, we repeated the study comparing 1-hour waterbath sonicated fibrils to 24hour waterbath sonicated fibrils. In that study, we injected the sonicated fibrils into the CA2/CA3
fields of the hippocampus—the primary hippocampal fields to develop pathology in Lewy body
disorders (Braak et al., 2003; Dickson et al., 1994; Flores-Cuadrado et al., 2016). As age-related
changes in the expression α-synuclein may alter the development of Lewy pathology (Chu &
Kordower, 2007; Mak et al., 2009), we repeated the OB/AON infusions on 1-hour waterbath
sonicated fibrils in older animals (17 months old) to determine if the transmission of pathology
would be more extensive with aging.

Misfolded α-synuclein is typically phosphorylated at serine 129 and this post-translational
modification is implicated in α-synucleinopathies (Fujiwara et al., 2002). Greater than 90% of αsynuclein that comprises Lewy bodies and Lewy neurites is phosphorylated at serine 129 (Sato et
al., 2013) and only 4% of the soluble monomeric form has this modification (Fujiwara et al., 2002).
Phosphorylation of serine 129 is the most frequent post-translational modification of α-synuclein
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in Lewy bodies (J. P. Anderson et al., 2006; Fujiwara et al., 2002; Waxman et al., 2008). For these
reasons, we employed antibodies against phosphorylated α-synuclein at Ser129 in our studies.

Specific Aim 1: To test whether α-synucleinopathy induced in rostral olfactory structures can be
transmitted caudally into brain regions involved in Lewy body disorders. We hypothesize that
some of the limbic α-synucleinopathy that develops in LBD patients may be attributable to spread
from olfactory structures. Therefore we expect that fibril infusion in the OB/AON will result in
the appearance of misfolded α-synuclein aggregations in deeper brain regions that harbor
connections with the OB/AON, such as the amygdala and hippocampus.
Results

All images in Aim 1 are adapted from a paper published in Molecular Neurodegeneration
(Mason et al. Molecular Neurodegeneration (2016) 11(1):49; doi: 10.1186/s13024-016-01134), and we made the raw images downloadable at Gumberg library’s website:
https://dsc.duq.edu/pharmacology/

Waterbath sonication increases the density of pSer129+ inclusions in vivo
Mice infused in the right OB/AON region with fibrils sonicated for 1 hour in a waterbath exhibited
more robust pSer129+ pathology than mice infused with fibrils sonicated for 1 minute with a probe
sonicator (Figure 3, Table 1). Longer sonication of the preformed α-synuclein fibrils reduced their
size (Figure 4). Probe sonication is inherently less consistent than waterbath sonication, as the
duration of each pulse is not easily controlled. Furthermore, probe sonication involves pausing to
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prevent overheating the solution and may aerosolize toxic fibrils. Waterbath sonication is feasible
even with smaller solution volumes, and the sonication occurs under water, which prevents the
solution from overheating as rapidly as with a probe. The ability to sonicate closed containers also
reduces the risk of human exposure.
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Figure 3. Waterbath sonication dramatically increases the amount of pSer129+ inclusions in
olfactory structures 3 months after infusion of preformed fibrils. Mice were infused in the
OB/AON with either PBS or 5 μg of preformed α-synuclein fibrils (1-minute probe sonicated of 1hour waterbath sonicated). Sagittal brain sections were collected 3 months later and labeled with
pSer129 (red) and Hoechst (blue). Shown is the tenia tecta, an olfactory structure caudal to the OB.
Few inclusions were present in the main olfactory bulb.
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Figure 4. Preformed α-synuclein fibrils become smaller with waterbath sonication. Electron
micrographs of α-synuclein fibrils before and after sonication (1 min probe sonication and 1 h or 24 h
waterbath sonication). Most sonicated fibrils were positively, not negatively stained with uranyl
acetate.

Unilateral injections of α-synuclein fibrils in the OB/AON lead to formation of pSer129 + inclusions
in neuroanatomically connected brain regions within three months post-infusion

Three months after fibril infusion into the OB/AON, the pSer129 + inclusions formed most often
in anatomically connected structures, such as the piriform cortex, the amygdala, the nucleus of the
lateral olfactory tract, the subiculum, hippocampal CA1, and the entorhinal cortex. These
structures are all key components of the limbic temporal lobe. A blinded analysis of the density of
pSer129+ protein aggregates revealed dramatically more pSer129 immunoreactivity in fibrilinfused animals than PBS-infused animals in the olfactory peduncle (defined as the tenia tecta and
AON complex), the piriform and entorhinal cortices, the amygdala, and hippocampal formation
(CA1 and subiculum) (Figure 5). Additional pathology was also observed in some cases in
hippocampal CA2/CA3, the dentate gyrus, and the ectorhinal cortex, consistent with the possibility
of transynaptic spread, but pathology in these regions was sparse and not consistently observed
(Table 1).
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Figure 5: α-synucleinopathy is transmissible from the OB/AON to deeper brain regions. Two
month-old CD1 mice were infused in the right OB/AON with α-synuclein fibrils (5 μg) or an
equivalent volume of phosphate-buffered saline (1 μL). The α-synuclein fibrils were sonicated for 1
hour in a waterbath prior to infusion. After three months, sagittal brain sections were collected and
immunostained for a marker of aggregated α-synuclein (pSer129; red). The Hoechst reagent (blue)
was also applied to visualize nuclei. Shown are 40× images of the olfactory peduncle (A-B), the
piriform cortex (C-D) and the hippocampus and amygdala (E-F) in PBS and fibril infused animals.
pSer129+ inclusions were counted in ImageJ software by a blinded observer and the same threshold
values were applied across all images. *p ≤ 0.05, **p ≤ 0.01, ***p ≤0.001 vs PBS, Student’s t test (n
= 4–5 mice/group). All abbreviations are listed in Table 4.
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Preadsorption of polyclonal anti-pSer129 antibody with pSer129 blocking peptide leads to a loss
of immunoreactivity

To examine the specificity of pSer129 antibodies, we pre-incubated the polyclonal pSer129
antibody with pSer129 antigen and applied the “blocked” solution to the tissue. As expected, when
the antigen site was already bound to a peptide, the primary antibody was unable to bind to the
antigens in the tissue, leading to a loss of signal (Figure 6). We did not perform this test with the
monoclonal mouse antibody, because preadsorption controls with monoclonal antibodies will

Figure 6: Polyclonal pSer129 antibody is specific for aggregated α-synuclein inclusions as
demonstrated by preadsorption control. Phosphoserine129 blocking peptide was incubated
with a rabbit polyclonal pSer129 antibody (Ab59264; see Table 2) for 24 hours prior to applying
the antibody to the tissue. Shown are adjacent sagittal sections of the AON from the same animal
infused with 1-hour waterbath sonicated preformed α-synuclein fibrils.
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always result in a loss of labeling regardless of the presence of proteins they may bind
nonspecifically in tissue (Saper, 2005). We also observed a loss of signal when primary antibodies
were omitted, supporting the specificity of the fluorescent secondary antibodies used in our studies.

Immunostaining with monoclonal and polyclonal anti-pSer129 antibodies shows colocalization
We sought to test whether the monoclonal mouse and polyclonal rabbit anti-pSer129 antibodies

Figure 7: Monoclonal and Polyclonal antibodies show a high degree of overlap. Monoclonal
pSer129 antibody (green) and polycloncal pSer129 antibody (red) (see Table 2) were applied
simultaneously and visualized with distinct secondary antibodies. DRAQ5, an infrared nuclear stain
(purple) was applied to reveal cytoarchitectonic boundaries. A few immunoreactive structures showed
more staining with one antibody or the other.

are equally effective at labeling Lewy-like aggregates. In this study, we applied both antibodies
simultaneously and employed different fluorescent secondary antibodies so that we could visualize
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both antibodies in the same tissue. Here, we saw that both antibodies are indeed effective at
labeling the aggregates and that there was considerable but imperfect colocalization of both
antibodies (Figure 7), likely due to competition between clones with varying binding affinities
(Saper, 2009).
Perinuclear pSer129+ aggregations form in neurons

Figure 8: High resolutions images of pSer129+ protein aggregates display perinuclear and
neuritic forms. Images of pSer129+ inclusions (red) (monoclonal 81A pSer129 antibody; see Table
2) and Hoechst-stained nuclei (blue) were captured using a 100× oil objective. The pSer129+
inclusions were perinuclear or found in processes. The pSer129+ cell in the OB (uppermost row) was
in the mitral cell layer, which is known to house large somata.
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In each of the primary regions of pSer129+ inclusion formation (OB, AON, piriform cortex,
amygdala, hippocampal CA1, and entorhinal cortex), both perinuclear inclusions and neuritic,
perhaps axonal inclusions were observed (Figure 8). Perinuclear α-synuclein inclusions were most
frequently observed within cells expressing the neuronal nuclear marker NeuN, as confirmed with
a 100× oil objective (Figure 9). This is in agreement with human Lewy body disorders, in which
Lewy aggregates are most often found within neurons, likely because α-synuclein is expressed
predominantly at synaptic terminals in neurons (Iwai et al., 1995). Confocal analyses revealed that
the perinuclear inclusions wrap themselves around the nuclei of NeuN + neurons (Figure 9, right).
This dense perinuclear conformation is similar to the aggregates seen in the work of Osterberg and
colleagues, who argued that these structures are the most mature form of aggregate and display

Figure 9: pSer129+ protein aggregates are largely found within NeuN+ cells. Two-month old mice
were unilaterally infused with α-synuclein fibrils (5 μg) or an equal volume of phosphate-buffered
saline (PBS) into the OB/AON. Fibrils were sonicated for 1 hour in a waterbath prior to infusion.
Three months post-infusion, sagittal brain sections stained with antibodies against pSer129 (red)
(monoclonal 81A pSer129 antibody; see Table 2) and the neuronal nuclear marker NeuN (green).
Hoechst-labeled nuclei are shown in blue. (Left) epifluorescent microscopy. (Right) Confocal
microscopy. Arrows point to some examples of the many triple-labeled cells in the AON. Arrowhead:
Hoechst+/NeuN−/pSer129+ profile.

post-translational hallmarks of human Lewy aggregates (Osterberg et al., 2015).
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Some but not all pSer129+ inclusions harbor the proteasomeal degradation tag ubiquitin

To further examine the pSer129+ inclusions, we also stained the tissue for ubiquitin, an established
marker of protein aggregations and Lewy pathology. Here, we observed that some, but not all of
the perinuclear inclusions were also labeled by ubiquitin (Figure 10). The ubiquitin staining in the
PBS group was diffuse and low in intensity, while the ubiquitin staining in the fibril-infused
animals was compact and intense. The Thioflavin S stain for amyloid protein aggregates was also

Figure 10: α-synucleinopathy is found within neuronal somata and some of it colocalizes with
the ubiquitin marker of protein aggregates. Mice were infused in the OB/AON with 5 μg of 1-hour
waterbath sonicated preformed α-synuclein fibrils and sacrificed three months later. Some but not all
of the pSer129+ (red) protein aggregates colocalized with ubiquitin (green) in NeuN+ (purple) neurons.
Antibodies are listed in Table 2. Photos from fibril and PBS treated animals were captured at the
same exposure and intensity scaling.
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applied to the tissue. With this stain, densely labeled structures were visible at the site of infusion
and some diffuse labeling was present in the rostral OB (Figure 11). Few to no Thioflavin S+

Figure 11: Amyloid stain Thioflavin S is only apparent at or very near the site of fibril
injection. Mice were infused in the OB/AON with α-synuclein fibrils that were sonicated for 1 hour
or PBS. Sagittal brain sections were labeled with Thioflavin S stain for amyloid (green) and Hoechst
(blue). (A) Faint Thioflavin S stain is visible in the olfactory bulb rostral to the site of injection. (B)
Dense Thioflavin S stain is visible at the site of injection in the dorsal OB. All abbreviations are listed
in Table 4.

structures were visible in brain regions distant from the site of injection.
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pSer129+ aggregations are likely formed from endogenous and not exogenous α-synuclein
molecules

In order to define the site of injection, we injected 1-hour waterbath sonicated preformed αsynuclein fibrils into the OB/AON and sacrificed the mice 90 minutes later. This tissue was
immunostained for pSer129 and total α-synuclein. Previous work has demonstrated that the
preformed α-synuclein fibrils are not phosphorylated (Luk et al., 2009). In agreement with these
findings, we did not observe any pSer129 immunoreaction 90 minutes after injection of the fibrils

Figure 12: pSer129+ aggregates are absent from tissue 90 minutes after infusion. Mice were
infused in the OB/AON with 5 μg α-synuclein fibrils (1 h waterbath-sonicated) or PBS and perfused
90 minutes later. Brain sections were stained with rabbit antibodies against phosphorylated or total
α-synuclein (red) (see Table 2). The needle track is still apparent in the caudal OB at this early time
point (white arrows. Images from PBS and fibril groups were captured at the same intensity scaling
and exposure times. Differences in background staining are not the result of differential image
processing.
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into the OB/AON (Figure 12). Instead, these animals exhibited dense signal for total α-synuclein
protein (non-phosphorylated) at the site of injection, in the caudal OB, which suggests that the
preformed α-synuclein fibrils may encourage endogenous mouse α-synuclein molecules to misfold
and adopt a pathogenic conformation.

Figure 13: α-synucleinopathy is transmitted from the OB/AON to deeper limbic structures. Twomonth old CD1 mice were infused unilaterally on the right side in the OB/AON with α-synuclein
fibrils (5 μg) or an equivalent volume of phosphate buffered saline (PBS). Sagittal schematics of
clearly visible brain cytoarchitectonics (solid lines), myelinated fiber bundles (gray shading), and
pSer129+ neurites (red flourishes), and pSer129+ somal inclusions (red dots) are provided. The sections
go from medial to lateral (A-D). All abbreviations are listed in Table 4.
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α-synucleinopathy develops throughout the limbic system after induction at olfactory sites

Figure 14: α-synucleinopathy is transmitted to limbic structures three months post-infusion.
Two-month old mice were infused unilaterally in the OB/AON with α-synuclein fibrils that had been
sonicated for 1 hour. After three months, sections were collected and stained for DRAQ5 (A,C,E) and
pSer129 (B,D,F) (monoclonal 81A pSer129 antibody; see Table 2). The sections go from medial to
lateral. Abbreviations are available in Table 4.
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Sagittal schematics were generated to display the typical pattern of pSer129 + α-synucleinopathy
in the ipsilateral hemisphere three months after infusion of 1-hour waterbath sonicated preformed
α-synuclein fibrils (Figure 13). The most densely labeled region at this time point is the AON
(Figure 13A). In more lateral sections, the rostral piriform cortex, nucleus of the lateral olfactory
tract, posteromedial cortical amygdala, and ventral hippocampus exhibit pSer129 + pathology
(Figure 13B). In lateral sections, pathology is also apparent throughout the piriform cortex and
most of the amygdala. At this mediolateral level, the hippocampal CA1 and subiculum are the
most densely affected regions of the hippocampus (Figure 13C). More laterally, the entorhinal
cortex also exhibits dense pathology (Figure 13D). Overall, the pathology remains centered in the
limbic system.
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Figure 15: No pSer129+ structures are visible in PBS infused animals. Mice were infused with
phosphate buffered saline (PBS) in the OB/AON. Three months post-infusion, sagittal brain sections
were stained for pSer129 (B,D,F,H,J,L,N) (monoclonal 81A pSer129 antibody; see Table 2) and
Draq5 (A,C,E,G,I,K,N). All abbreviations are listed in Table 4.

The sagittal schematics were generated based on the pSer129 + pathology visible in stitched images
of the entire brain section. Examples of the stitched images used to generate these schematics are
provided in Figure 14. PBS-infused sections are also provided to display the lack of pSer129 +
inclusions in animals that were not infused with the preformed α-synuclein fibrils and to show the
degree of background staining (Figure 15).
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Examining first-order connections between brain regions with the tract-tracer FluoroGold

In order to label first-order afferent neurons that project directly to the injection site, the retrograde
tracer FluoroGold was employed. Robust FluoroGold labeling of neurons was evident at all sites
where inclusions were present, with the exception of occasional, sparse pSer129 inclusions in the
nucleus accumbens, caudoputamen, CA2/CA3, dentate gyrus, and ectorhinal cortex (Figure 16,
Table 1). Fluorogold+ neurons were also present at the horizontal limb of the diagonal band of
Broca, which is known to project to the AON, but did not exhibit any pSer129 + inclusions. The
olfactory tubercle, which does not project to the OB/AON, remained free of FluoroGold label as

Figure 16: Areas that develop α-synuclein aggregates send first-order projections to the site of
infusion in the OB/AON. The animals were infused at the same coordinates as the α-synuclein fibrils
with the retrograde tract-tracer FluoroGold and perfused after seven days. The nuclear marker DRAQ5
(purple) was used to visualize cytoarchitecture and FluoroGold (blue) was visualized in the UV
channel. The dual stained brain regions in (A) appear red. Dense FluoroGold label at multiple afferent
sites is displayed at higher magnification in panels C, E, G, I, K, and M. Nuclear DRAQ5 label on the
same sections is shown in panels B, D, F, H, J, and L. Abbreviations are available in Table 4.
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well as pSer129+ inclusions, suggesting perhaps that the pathology travels most frequently in a
retrograde direction.

α-synucleinopathy is primarily confined to first-order neuroanatomic connections in the limbic
system three months after infusion of α-synuclein fibrils into the OB/AON

To display the variability of the pSer129 and FluoroGold staining among all animals in the study,
a blinded observer semi-quantitatively rated the pathology after observing all of the tissue. The
observer rated the pathology on a scale of 1-5 (1 = very sparse, 5 = very dense) (Figure 17), so
that the pathology could accurately be displayed in tabular format (Table 1). It was evident that
waterbath sonication led to a much more robust pattern of inclusion formation than probe
sonication. In the waterbath sonicated fibril-infused animals, the pattern of aggregation

Figure 17: A blinded observer scored the inclusion density semi-quantitatively. Phosphoserine129 and FluoroGold labeling was semi-quantitatively described in both the ipsilateral and
contralateral hemispheres. Shown is the range of inclusion density from “1 dot” (low density) to “5
dots” high density in the anterior olfactory nucleus three months after fibril infusion. All abbreviations
are listed in Table 4.
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development was similar among the different age groups, except that more inclusions developed
in the nucleus accumbens of the 17-month-old animals (Table 1).

Generalizability of the model: Waterbath-sonicated α-synuclein fibrils also generate robust
pathology upon injection into the hippocampus

Table 1: Schematic of pSer129+ inclusions from probe and waterbath sonicated fibrils three
months after infusion and FluoroGold seven days after infusion. CD-1 mice were infused in the
OB/AON with α-synuclein fibrils and sacrificed three months later. Separate mice were infused in the
same region with FluoroGold and sacrificed seven days later. Animal IDs, are shown in the 4th row.
Semi-quantitative density of label in the ipsilateral (red) and contralateral (black) hemispheres from *
to ***** (sparsest to densest) of pSer129 (monoclonal 81A pSer129 antibody; see Table 2) or
Fluorogold label is shown for individual mice. The animal age at the time of infusion is also provided.
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To ensure that our fibril sonication protocol was reproducible in a separate set of neuroanatomical
circuits, we prepared the fibrils in the exact same manner and injected them into the CA2/CA3
region of the hippocampus. To see if additional sonication in the waterbath would change the
pathogenic characteristics of the fibrils, we also included a cohort of mice that were infused with
fibrils sonicated for 24 hours. For this study, the perfused brains were cut coronally so that we
could view the bilateral hippocampal formation. In the PBS-infused animals, little pSer129 +
pathology was observed in the hippocampus (Figure 18A). Fibril-infused animals exhibited dense
pSer129+ inclusions throughout the hippocampus and in the entorhinal cortex, which is suggestive
of transmission of α-synuclein pathology through the perforant path (Figure 18B). The
hippocampal pathology was more robust in the 1-hour sonicated fibril group than the 24-hour
sonicated fibril group, perhaps because the fibrils became so small that there were easily degraded
and could not serve as a template for seeding pathology.

Figure 18: Waterbath sonicated α-synuclein fibrils also elicit robust pathology after infusion into
the hippocampus. Two month-old mice were unilaterally infused with PBS (A) or α-synuclein fibrils
(5 μg) (B) into CA2/CA3 of the hippocampus. Fibrils were sonicated for one hour in a waterbath prior
to infusion. Three months later, coronal brain sections were collected. Shown are stitched montages of
pSer129 (monoclonal 81A pSer129 antibody; see Table 2) and Hoechst staining in the hippocampus
and entorhinal cortex in PBS and fibril-infused animals—both groups were stained in parallel and
captured at the same exposure and intensity scaling. The fibril injection in this animal extended from
CA2/CA3 into CA1. All abbreviations are listed in Table 4.
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Discussion

We have demonstrated that α-synucleinopathy initiated in the OB/AON region can be transmitted
to regions as distant as the hippocampus and entorhinal cortex within three months. Many of these
regions are most often affected at the mid to end stages of PD, and pathology in these regions is
commonly associated with cognitive dysfunction (Gomperts, 2016; Russell et al., 2014). This
suggests that some of the pathology at the later stages of PD may be attributable to spread from
olfactory structures. While the pattern of transmission outlined in this aim is not completely
representative of PD, it concurs with Beach’s Stage IIB limbic-predominant subset of Lewy body
disorders (Beach, Adler, et al., 2009). There are indeed cases of DLB where pathology is primarily
present in the limbic system (Nelson et al., 2010), and Lewy pathology in Alzheimer’s disease is
also largely confined to the limbic system (Beach, Adler, et al., 2009; Toledo et al., 2016). As
discussed in the Introduction, according to Braak staging and the DLB consortium staging,
approximately two-thirds of unclassifiable patients had pathology in the limbic system in the
absence of pathology in the brainstem (Beach, Adler, et al., 2009). Therefore, our model may
mimic the neuroanatomical features of a distinct subset of Lewy body disorders.

The limbic system is most commonly associated with maintaining emotional equilibrium, but it is
also critical to learning and memory functions (Hyman et al., 1990; Zola-Morgan & Squire, 1993),
and is involved with regulating endocrine and autonomic functions (Braak et al., 1994). Among
other regions, the limbic system includes the amygdala, hippocampal formation, and entorhinal
allocortex. These three regions are highly interconnected and project to the nucleus accumbens
and some subdivisions of the caudoputamen (Del Tredici K, 2000-2013). While the
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histopathological pattern of α-synucleinopathy in our model is not typically observed in PD,
regions of the limbic system are often the most affected by Lewy-related lesions (Braak & Braak,
2000; Braak et al., 1994). Damage to higher order centers of the limbic system may contribute to
affect-related dysfunction of emotional and voluntary motor systems, which are commonplace in
the end stages of PD (Del Tredici K, 2000-2013). Our model most closely resembles the
prototypical spread of α-synucleinopathy observed in what used to be defined as the Lewy body
variant of Alzheimer’s disease and is now known as ADLB. These observations suggest that some
of the cognitive impairments of ADLB may be related to limbic α-synucleinopathy.

Within the hippocampus, FluoroGold+ cells as well as the majority of pSer129+ inclusions were
present in the CA1 and subiculum regions. In PD and DLB, the CA2 field of the hippocampus
develops the densest Lewy pathology (Adamowicz et al., 2017; Del Tredici K, 2000-2013), which
suggests that pathology in CA2 is not transmitted from olfactory structures. In Alzheimer’s
disease, tau pathology is frequently highest in CA1 and the subiculum (Lace et al., 2009; Masurkar,
2018), suggesting that tau pathology may transmit along the olfactory/limbic route in humans.

The results of the FluoroGold tract-tracer experiments are consistent with the view that the spread
of pathology in our model might be largely in a retrograde direction. Almost every brain region
with FluoroGold+ signal also developed Lewy-like inclusions, suggesting that the majority of the
pSer129+ inclusions may develop in the axon and travel to the cell body. One exception was the
horizontal diagonal band of Broca, which appears to be resistant to the development of pSer129 +
protein aggregates despite sending dense projections to the OB/AON. The horizontal limb of the
diagonal band of Broca is the primary source of cholinergic projections to the OB (Godfrey et al.,
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1980), and perhaps cholinergic neurons are more resistant to developing pSer129 + inclusions.
High-resolution microscopy demonstrated that the perinuclear inclusions are often wrapped
around the nucleus in the cell body, and it may not be energetically favorable for a large
aggregation to disengage from the nucleus and travel through an axon in an anterograde direction.
This view is also supported by the observation that no inclusions developed in the olfactory
tubercle at three months post infusion. The AON, which exhibited robust pSer129 + pathology, has
many synapses at the olfactory tubercle, but the olfactory tubercle does not project back to the
AON. Therefore, the lack of inclusions in the olfactory tubercle supports the speculation that αsynucleinopathy in this model may travel from the synapse to the cell body.

We have demonstrated that this model generates a consistent pattern of pathology in cohorts of
various ages and that 1-hour waterbath sonicated PFFs can generate robust pathology after
injection into a separate set of neuroanatomical circuits (i.e., the CA2/CA3 fields of the
hippocampus). This is important because Lewy body disorders are heterogeneous diseases and
Lewy pathology is rarely confined to a single brain region in patients. The ability to induce robust
pathology in a variety of brain regions is important to further our understanding of the implications
of regional Lewy pathology on symptom development and transmissibility. Robust Lewy-like
pathology is also essential to adequately assess the efficacy of therapies against the development
and spread of Lewy pathology.

The experiments in this aim clearly demonstrate that it is possible to generate robust α-synuclein
pathology in wild-type mice. It was worth optimizing our sonication parameters in vivo as we
demonstrated that an inexpensive waterbath sonicator (~300$) was more effective at generating
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robust pathology than is evident in the literature, even when powerful probe sonicators costing
thousands of dollars are employed. The pathology generated from waterbath-sonicated preformed
α-synuclein fibrils is so dense that it is visible even at low magnification. Other groups in the field
typically present pathology in images that are highly magnified and without the context of the
entire brain section. Here, we have pioneered publishing large, high-resolution images of entire
brain sections so that readers may zoom in and out as with a street map to determine the location
and scale of the Lewy-like pathology. As computational power and image data storage
methodologies improve, it is likely that scientific journals will transition to requiring such images
for the independent verification of the topographical distribution of pathology.

It is unlikely that we misidentified α-synuclein pathology, as we confirmed the efficacy of our
methodology in several ways. The preadsorption control, the co-application of both antibodies to
the same tissue, and the overlap with ubiquitin support the conclusion that the immunolabeled
structures are genuine inclusions. However, there are several limitations that must be
acknowledged. First, there are obvious differences between rodent olfactory structures and human
olfactory structures. Rodents rely heavily on olfaction and, consequently, the olfactory structures
make up a relatively large portion of the rodent brain. It is therefore possible that the development
of Lewy-like pathology in rodent olfactory structures is more aggressive than it would be in
humans. Furthermore, the preformed α-synuclein fibrils are made from wild-type mouse αsynuclein, which harbors the A53T mutation that is reported to increase susceptibility of humans
to developing Lewy body disorders. The endogenous α-synuclein in CD-1 mice also has this
mutation, which suggests that the development and spread of aggregates in this model may be
more aggressive than it is in the majority of human Lewy body disorders. As mice have a typical
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lifespan of approximately two years, a more aggressive form of α-synucleinopathy is likely
necessary to generate significant pathology within their lifespan. While we are confident in our
identification and characterization of pSer129+ inclusions, a recent study indicated that even the
most sensitive and specific commercially available anti-pSer129 antibodies also display nonspecific bands in Western blots (Delic et al., 2018), which is discussed further in Aim 2.

Chapter 2
Rationale
In Aim 1, we developed a novel model of early stage Lewy body disorders. After infusion into the
OB/AON, dense α-synucleinopathy emerges in olfactory/limbic structures within three months.
This pattern of olfactory-initiated limbic pathology is similar to the Stage IIb pathology described
by Beach and colleagues. This unified staging system proposes that after appearance in the
pathology in the olfactory structures (Stage I), pathology then emerges in either brainstem
predominant (Stage IIa) or limbic predominant (Stage IIb) patterns (Beach, Adler, et al., 2009).
The Stage IIb pattern is observed in cases of ILBD and DLB, but most often in ADLB. Indeed,
Toledo and colleagues observed that coincident α-synucleinopathy in demented subjects with AD
most frequently begins in the OB and progresses through the limbic system while sparing the
brainstem (Toledo et al., 2016).

As the pathological distribution of α-synucleinopathy in our model corresponds to a distinct subset
of human patients (Beach’s Stage IIb), the goal of this Aim is to examine this model in the context
of two major risk factors for developing Lewy body disorders, age and gender. As discussed in the
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introduction, age is the strongest risk factor for developing PD (Bennett et al., 1996; Morens et al.,
1996; Tanner & Goldman, 1996), the most commonly clinically diagnosed Lewy body disorder.
In Aim 1, aged mice did not exhibit greater α-synucleinopathy than young males at three months
post-surgery. Therefore, we sought to examine the impact of aging at longer survival periods by
performing the same OB/AON infusions in mice that were 11 months old at the time of fibril
infusion and sacrificing half of the mice at six months and half at 12 months post-surgery.

Gender is another prominent risk factor in Lewy body disorders, as men are approximately twice
as likely to develop Lewy body disorders are women (Baldereschi et al., 2000; Savica et al., 2013).
When developing the unified staging theory, Beach et al. observed that ~61-69% of all subjects
with ILBD, PD, or DLB were men (Beach, Adler, et al., 2009). DLB cases can be subdivided
based on the distribution of α-synuclein pathology, and men are more than twice as likely to
develop the limbic-predominant subtype of DLB (Nelson et al., 2010). In addition to prevalence,
gender may affect the rate of progression of α-synucleinopathy as it was recently reported that
greatest risk factor for cognitive decline in PD is the male gender (Cholerton et al., 2018). The
relatively lower rates of Lewy body disorders in females may be related to the neuroprotective
effects of estrogen. Estrogen replacement therapy started early in menopause reduces the risk of
developing dementia in female PD patients (Marder et al., 1998), and bilateral oophorectomy
increases the risk of females developing PD (Benedetti et al., 2001; Rocca et al., 2008). These
observations may be related to the finding that estrogens can destabilize α-synuclein fibrils, leading
to their disaggregation (Hirohata et al., 2009).

71

Gender differences have also been reported in older models of Parkinson’s disease. In
dopaminergic neurotoxicant models, several groups have reported that female rodents are more
resistant than males to the loss of nigrostratal cells and subsequent motor deficits (Dluzen et al.,
1996; Miller et al., 1998; Murray et al., 2003). Indeed, estrogen, estrogen receptor-α agonist
propyl-pyrazome-triol, and some selective estrogen receptor modifiers are reported to protect
dopaminergic neurons against MPTP toxicity in vivo (Litim et al., 2016). In α-synuclein transgenic
mouse models, females often outperform males on sensorimotor tests (Dirr et al., 2018;
Gerstenberger et al., 2016), and display more changes in gene expression than transgenic males
(Yacoubian et al., 2008). However, little is known about how gender may affect the development
and spread of α-synuclein aggregations throughout the brain. Therefore, the second goal of this
Aim was to examine the impact of gender on the regional distribution and density of pSer129 +
aggregations as well as any accompanying cell loss. To this end, we infused either pre-formed αsynuclein fibrils or PBS into the OB/AON of three-month-old male and female mice and sacrificed
them six months after surgery.

Specific Aim 2: To examine the effects of age, gender, and disease duration in our model of early
stage Lewy body disorders. We hypothesize that α-synuclein aggregation, neuron loss, and the
spread of Lewy-like pathology through limbic circuitry is higher in male mice than females and
exacerbated with aging in male mice.
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Results

Aged animals exhibit greater mortality from OB/AON infusions of preformed α-synuclein fibrils
and mortality is not related to changes in weight

At the beginning of this study, 64 CD-1 mice were infused with either preformed α-synuclein
fibrils (n = 32) or an equivalent volume of PBS (n = 32). Of those 64 mice, half were 11 months
old and half were three months old. To assess the effects of gender, age at infusion, and postinfusion interval, 8 three-month old male, 8 three-month-old female, and sixteen 11-month-old
males received preformed α-synuclein fibril infusions into the OB/AON. An equal number of age
and gender matched mice received PBS infusions. At six months post-infusion, there was no
significant mortality observed when comparing all treatment groups (Figure 19A). When
comparing only the 11-month-old mice, a trend towards increased mortality was observed at six
months post-infusion (Figure 19B). As five of the fibril-infused animals had died compared to
only one of the PBS-infused animals, we modified our experimental design by sacrificing five of
the fibril infused animals and six of the PBS infused animals, instead of the originally planned
design of sacrificing eight per group. Therefore, 10 PBS-infused and 11-fibril-infused mice were
left to continue to the 12-month time point. However, by 10.5 months post-infusion, significant
differences in mortality were observed between the PBS and fibril infused groups (Figure 19C),
and only 3 of the 11 fibril-infused mice remained alive, compared to 8 of 10 age-matched PBS
controls. We therefore ended the study at 10.5 months post-infusion and perfused the mice at 21.5
months of age.
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Figure 19: Preformed α-synuclein fibril injections in the mouse olfactory peduncle accelerate
mortality in older mice without eliciting significant changes in body weight. Sixty-four mice were
infused in the right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an
equivalent volume of PBS (1 μL) at the indicated ages. Logrank survival analyses were performed for
all animals at 6 months post-infusion (A) and for the older males at 6 months (B) or 10.5 months (C)
post-infusion. Note the broken Y axis in panel A. The two-tailed p values of the logrank survival
analyses are shown. (D) The body weights of the older males at surgery (11 months old), 6 months
post-surgery (17 months old), and 10.5 months post-surgery (21.5 months old) are displayed as scatter
dot plots with mean and SEM bars. In panel D, crosses are placed next to mice that died before the
planned time of assay. (E-F) Weight gained in both raw numbers (E) and percentage weight gain (F)
six months after surgery in all experimental groups. For panels D-F, two-way ANOVAs were
followed by the Bonferroni post hoc correction for multiple comparisons. In panels E-F, +++ p≤0.001
versus males that were infused at 3 months of age and perfused at 9 months of age (3-9 mo males).

Given the significant mortality observed in the older mice, we examined if the cause of death was
related to any loss in body weight (Figure 19D). Crosses are placed next to the body weights of
the 8 fibril-infused older males that died before the planned date of sacrifice. Graphs of the
bodyweight gained and percent weight gained for all animals over the first 6 months of the
experiment are shown in Figures 19E-F. While the older animals gained significantly less weight
in the first six months than the younger animals, fibril infusions did not exert any significant effects
in any group (Figure 19E-F). These results suggest that the increased mortality was not related to
a loss of weight or a lack of food intake.
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Figure 20: Heat map of α-synucleinopathy following preformed α-synuclein fibril injections in
the mouse olfactory peduncle. Qualitative assessments of the density of pSer129+ inclusions in the
indicated brain regions of all fibril-infused animals that survived until the planned assay time. Each
row represents one animal. A blinded investigator systematically examined the entire 1-in-5 series of
sagittal brain sections of the ipsilateral, right hemisphere following immunostaining of pathologically
phosphorylated α-synuclein with the rabbit monoclonal EP1536Y pSer129 antibody (Table 2) as well
as staining of nuclei with the Hoechst marker to visualize cytoarchitectonic boundaries. Brain regions
with pSer129+ immunolabeling are arranged rostrocaudally and/or by anatomical/functional groupings.
Most of the midbrain pathology was confined to the ventral tegmental area and only two male animals
exhibited pSer129+ inclusions at the boundary zone between the substantia nigra, pars compacta, and
the ventral tegmental area at 6 months post-infusion.
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Fibril infusions in the OB/AON elicit α-synucleinopathy centered in the limbic connectome

The brains collected at 6 and 10.5 months post-infusion were sectioned sagittally and the ipsilateral
hemisphere was immunostained. The density of α-synucleinopathy was scored from 0 to 5, with 5
being the densest (Figure 20). As observed in Aim 1, the site of injection in the OB exhibited
minimal pSer129+ pathology compared to other olfactory structures including the AON and tenia
tecta (Table 1). The olfactory tubercle developed pathology at 6 months post-infusion in this
experiment while in Aim 1 we noted that at three months post-infusion, the olfactory tubercle
failed to develop any pSer129+ inclusions (Table 1), suggesting that additional time (3 months)
facilitates the emergence of pathology in this structure. At six months post-infusion, we also
observed pathology in the midbrain, specifically the ventral tegmental area and the most medial
sections of the SN. No pSer129+ inclusions were observed in the lateral segments of the SN pars
compacta, which is the most vulnerable nigral subregion in PD patients (Braak et al., 2003; Damier
et al., 1999; Fearnley & Lees, 1991; Jellinger, 2012). Additionally, more pSer129 + inclusions were
observed in the caudoputamen and the nucleus accumbens at 6 months post infusion than at 3
months post infusion.

Some nonspecific immunolabeling is visible in the SN, pars reticulata, and the brainstem

With both the rabbit and mouse anti-pSer129 antibodies used in this Aim (see Table 2), single or
clusters of immunopositive structures were frequently visible in the brainstem, and in some cases
the SN, pars reticulata (Figure 21A-B). A recent study found that multiple commercially available
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Figure 21: Nonspecific fluorescence in the substantia nigra, pars reticulata, and brainstem.
Fluorescent structures in the substantia nigra, pars reticulata (A) and brainstem (B) were observed in
three fluorescent channels, and examples of the latter are displayed in images captured with 4 and 20
objectives. This fluorescence is not attributable to specific pSer129 immunostaining, as it is present in
vehicle-infused groups and even in the GFP (green) channel, in which neither primary nor secondary
antibodies were applied, and was therefore not included in any of our analyses in other figures. (C)
Nonspecific fluorescence (yellow) in the substantia nigra, pars reticulata. Arrowhead points to specific
pSer129 immunofluorescence only present in the appropriate channel in the ventral hippocampus
(immunostaining with the EP1536Y pSer129 rabbit monoclonal antibody is pseudocolored in red; see
Table 2). Panel C is an enlargement of the images of the fibril-infused animal from panel B.

anti-pSer129 antibodies can label non-specific structures, even in α-synuclein knockout animals,
but also shows that the rabbit monoclonal pSer129 antibody employed in this Aim is the best one
on the market (Delic et al., 2018). Currently, there is no method better than pSer129
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immunostaining to label Lewy-like pathology (J. P. Anderson et al., 2006). The non-specific
labeled structures that we observed did not have the appearance of genuine pSer129 + aggregations,
fluoresced in the GFP channel even when no primary or secondary antibodies were applied, and
were present in PBS-infused animals. This nonspecific pathology was easily distinguishable for
genuine inclusions by the morphology (perinuclear tendrils and threadlike neurites) and the fact
that the nonspecific label fluoresced in the RFP, GFP, and Cy5 channels while genuine inclusions
only had a fluorescent signal in the RFP channel, corresponding to the appropriate secondary
antibody. This is evident in Figure 21C in a merged image of the DAPI, RFP and GFP channels.
In the ventral hippocampus, genuine inclusions only appear in red and have the typical perinuclear
and neuritic appearance, whereas the nonspecific label in the SN pars reticulata fluoresces in both
the RFP and GFP channel and appears yellow in the merged image.

Fibril-induced α-synucleinopathy causes cell loss in some brain regions

Female mice displayed fewer pSer129+ inclusions than males of the same age in the OB and AON
(Figure 22A-B). Older males exhibited fewer inclusions in the OB and olfactory tubercle
compared to the younger males at six months post-infusion (Figure 22A, C). The additional 4.5
month post-infusion interval in the older male group did not influence the overall inclusion density
in these structures. Only three fibril-infused mice survived to 10.5 months post-infusion, which
suggests that those mice displayed the mildest pathology. Our findings in aim 1 suggest that 17month-old animals did not exhibit significant increases in the extent or densities of pSer129 +
inclusions compared to 2 and 5 month-old animals at three months post-infusion, with the
exception of some additional pathology in the caudoputamen and nucleus accumbens (Table 1).

78

The pathology in mice sacrificed at six months post-infusion is comparable to those that survived
to 10.5-months post infusion, which suggests that the mice that survived to this time point are
“super-agers” likely exhibiting milder pathology than those that died.

Figure 22: Impact of α-synuclein fibril infusions in the mouse olfactory peduncle on pSer129 +
inclusion counts, NeuN+ neuron counts, and Hoechst+ cell numbers in the rostral rhinencephalon.
Three and eleven month old mice were infused in the right rear olfactory bulb with either preformed αsynuclein fibrils (5 μg/1 μL) or an equivalent volume of PBS (1 μL). A blinded observer manually
counted the number of pSer129+ structures (monoclonal 81A pSer129 Ab; see Table 2) per field of view
(200× magnification) and used cellSens software to count the number of NeuN+ and Hoechst+ nuclei in
the olfactory bulb (OB; A), the anterior olfactory nucleus (AON; B, E), the olfactory tubercle (Tub; C),
and the nucleus of the lateral olfactory tract (LOT; D) in the same field of view. Shown are the mean
and SEM of raw, unnormalized data. N = 4-8 mice per group, with the exception of the oldest males, in
which only 3 out of 8 fibril-infused mice survived to 21.5 months of age (see Figure 19). Two-way
ANOVAs were followed by the Bonferroni correction for multiple comparisons. Comparisons were
only made a priori across groups differing by a single independent variable (either gender, age at
surgery, or the passage of time since surgery). * p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs fibrils; + p≤0.05
++ p≤0.01 vs 3-9 month males; ~ p≤0.05 vs 11-17 month males.
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To determine if the pSer129+ inclusions cause neurotoxicity, we also counted NeuN + neurons and
Hoechst+ nuclei in the 17 brain regions most often exhibiting pathology. The major finding from
counting NeuN+ neurons and Hoechst+ nuclei is that fibril infusions did not elicit significant
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toxicity in any brain regions in females and induced a mild increase in Hoechst + cells in the OB in
females at six months post-infusion (Figure 22A). In the young male group, there was a loss of
NeuN+ neurons the lateral olfactory tract, and in the oldest male group there was a loss of NeuN +
neurons in the AON (Figure 22B, D). As the piriform cortex is a large brain region, we subdivided
it into the rostral-medial and caudal lateral areas. In the caudolateral piriform cortex, the
amygdalopiriform transition area, and the posteromedial cortical amygdala, female mice exhibited
significantly fewer pSer129+ inclusions than males (Figure 23B-D). Fibril-infusions resulted in a
loss of Hoechst+ cells in both subregions of the piriform cortex (Figure 23A-B), the posteromedial
cortical amygdala (Figure 23D), and the nucleus accumbens (Figure 23F), but only in the young
male group. This discrepancy could perhaps have arisen because the older males have lost more
cells in these regions as a result of aging. In the caudoputamen, the only group displaying
significant inclusions was the 17-month-old males that were sacrificed at 6 months post-infusion
(Figure 23E), but the overall amount of inclusions to develop in this region was relatively low.
Within the hippocampus, females developed similar
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Figure 23: Impact of α-synuclein fibril infusions in the mouse olfactory peduncle on pSer129 +
inclusion counts, NeuN+ neuron counts, and Hoechst+ cell numbers in the piriform cortex
(paleocortex), amygdala, and striata. Three and eleven month old mice were infused in the right rear
olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent volume of PBS (1
μL). A blinded observer manually counted the number of pSer129+ structures (monoclonal 81A pSer129
Ab; see Table 2) per field of view (200× magnification) and used cellSens software to count the number
of NeuN+ and Hoechst+ nuclei in the rostromedial piriform cortex (Pir Rm; A), caudolateral piriform
cortex (Pir Cl; B), amygdalopiriform transition area (APir; C), posteromedial cortical amygdala (PMCo;
D), caudoputamen (CPu; E), and nucleus accumbens (Acb; F). Shown are the mean and SEM of raw,
unnormalized data. N = 4-8 mice per group, with the exception of the oldest male group, in which only
3 out of 8 fibril-infused mice survived to 21.5 months of age (see Figure 19). Two-way ANOVAs were
followed by the Bonferroni correction for multiple comparisons. Comparisons were only made a priori
across groups differing by a single independent variable (either gender, age at surgery, or the passage of
time since surgery). * p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs fibrils; + p≤0.05, ++ p≤0.01 vs 3-9 month
males; ~~ p≤0.01 vs 11-17 month males.

number of pSer129+ inclusions as males in the CA1, CA2, and CA3 fields, but in the CA2, and
CA3 field, few inclusions developed overall (Figure 24A-C). In the dentate gyrus, females were
the only group that failed to develop a significant amount of pSer129 + inclusions (Figure 24D),
and in the subiculum, females developed significantly fewer inclusions than males of the same age
(Figure 24E). The entorhinal cortex developed significant inclusions in all groups (Figure 24F),
and in the older males, the ectorhinal cortex displayed significant inclusions at 6 but not 10.5
months post-infusion (Figure 24G). At 6 months post-infusion the older male group had decreased
Hoechst+ cell numbers in the ectorhinal cortex (Figure 24G), and at 10.5 months post-infusion,
the oldest males exhibited a significant decrease in NeuN + cells in CA2 and the subiculum (Figure
24B, E).
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Figure 24: Impact of α-synuclein fibril infusions in the mouse olfactory peduncle on pSer129 +
inclusion counts, NeuN+ neuron counts, and Hoechst+ cell numbers in the hippocampal formation
and perirhinal telencephalon. Three and eleven month old mice were infused in the right rear olfactory
bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent volume of PBS (1 μL). A
blinded observer manually counted the number of pSer129+ structures (monoclonal 81A pSer129 Ab;
see Table 2) per field of view (200× magnification) and used cellSens software to count the number of
NeuN+ and Hoechst+ nuclei in the pyramidal cell layers of hippocampal fields CA1 (A), CA2 (B) and
CA3 (C), the stratum granulosum of the dentate gyrus (DG; D), the subiculum (Sub; E), and entorhinal
cortex (Ent; F), and the ectorhinal cortex (Ect; G). Shown are the mean and SEM of raw, unnormalized
data. N = 5-8 mice per group, with the exception of the oldest male group, in which only 3 out of 8
fibril-infused mice survived to 21.5 months of age (see Figure 19). Two-way ANOVAs were followed
by the Bonferroni correction for multiple comparisons. Comparisons were only made a priori across
groups differing by a single independent variable (either gender, age at surgery, or the passage of time
since surgery). * p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs fibrils, + p≤0.05 vs 3-9 month males, ~ p≤0.05
vs 11-17 month males.

Fibril infusions in the OB/AON induce atrophy in some cell layers

In DLB, hippocampal atrophy is associated with the degree of cognitive dysfunction (Elder et al.,
2017). Therefore, in addition to counting Hoechst + nuclei we also examined regional changes in
the width of pyramidal and granule cell layers clearly visible with the Hoechst reagent. To measure
cell layer width, a blinded investigator used the “arbitrary line” tool in cellSens software to draw
lines across the width of the pyramidal layer of both subregions of the piriform cortex
(rostromedial and caudolateral), CA1, CA2, CA3, and the stratum granulosum of the ventral
portion of the dentate gyrus (Figure 25A-B). This area of the dentate gyrus was chosen because it
develops the most pSer129+ inclusions in this model. Here we observed that in the youngest males,
fibril infusions reduced the width of the rostromedial and caudolateral piriform cortex, CA1, and
the dentate gyrus. Compared to this group, fibril-infused females had significantly thicker
pyramidal cell layers of the rostromedial piriform cortex and CA1 as well as thicker granule cell
layers of the dentate gyrus. Fibril infusions also reduced the width of CA2 and CA3 in females
and the older males sacrificed at 6 months post-infusion. No fibril-induced changes in cell layer
85

widths were observed in the older males sacrificed 10.5 months post-infusion which may be a
result of a low n, or the result of higher mortality in this group, as only the least affected “superagers” remained. To determine if changes in regional size were related to changes in neuronal
processes or nuclei shrinkage, we also examined the area of Hoechst + nuclei in each region. In the
rostromedial and caudolateral piriform cortex as well as the dentate gyrus, the young male group
exhibited an increase in Hoechst+ nuclear area (Figure 25C). These same areas that exhibited
hypertrophy in Hoechst+ nuclei displayed shrinkage of the cell layers, which suggests that changes

Figure 25: Preformed α-synuclein fibril injections in the olfactory peduncle induce atrophy of
pyramidal and granule cell layers of the limbic allocortex in young male mice. Mice were infused
in the right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent
volume of PBS (1 μL). A blinded observer employed the “arbitrary line” tool in CellSens software to
measure the width of the compact Hoechst+ pyramidal cell layer in the rostromedial piriform cortex,
caudolateral piriform cortex, CA1, CA2, and CA3 of the hippocampus, or the stratum granulosum of
the dentate gyrus. Representative grayscale micrographs for the caudolateral piriform cortex and dentate
gyrus are displayed in panel A and the quantification of pyramidal and granule cell layers width (B) and
Hoechst+ nuclear size (C) is graphed below. Shown are the mean and SEM of raw, unnormalized data.
N = 4-8 mice per group, with the exception of the oldest male group, in which only 3 fibril-infused mice
survived to 21.5 months of age (see Figure 19). Two-way ANOVAs were followed by the Bonferroni
correction for multiple comparisons. Comparisons were only made a priori across groups differing by
a single independent variable (either gender, age at surgery, or the passage of time since surgery). *
p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs fibrils; + p≤0.05, ++ p≤0.01 +++ p≤0.001 versus vs 3-9 month
males; ~ p≤0.05, ~~ p≤0.01, ~~~ p≤0.001 vs 11-17 month males.
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to layer width are related to changes to cellular processes. An increase in nuclear volume could
indicate an increase in gene transcription whereas changes in the entire tissue layer may represent
a change in cell soma size possibly through osmotic shrinkage.

Perinuclear pSer129+ aggregates colocalize with Proteostat aggresome dye

As discussed in the introduction, an aggresome is a cellular structure that emerges to mitigate
proteotoxic stress when normal protein degradation mechanisms are insufficient. As Lewy bodies
are theorized to be failed aggresomes (Olanow et al., 2004), we immunostained tissue from fibrilinfused and PBS-infused animals with the anti-pSer129 antibody and applied the wellcharacterized Proteostat dye for aggresomes (Shen et al., 2011) and the Hoechst reagent. Here we
observed that the majority of perinuclear pSer129+ inclusions in the AON, piriform cortex,
amygdala, hippocampus, and entorhinal cortex were also labeled with the Proteostat dye (Figure
26A), suggesting that perinuclear inclusions in the model may represent a form of aggresome.
Neuritic inclusions were not labeled by the Proteostat dye, which agrees with the perinuclear
location of aggresomes (Figure 26B). In some cells of PBS animals, the Proteostat dye, but not
the anti-pSer129 antibody weakly labeled a structure near the nucleus, possibly the centrosome,
which may represent a low level of aggregated proteins in cells under physiological conditions.
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Figure 26: Preformed α-synuclein fibril injections in the mouse olfactory peduncle induce the
formation of aggregations that colocalize with perinuclear but not neuritic pSer129+ inclusions.
Mice were infused in the right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL)
or an equivalent volume of PBS (1 μL). Sagittal brain sections from young male mice were
immunostained for pathologically phosphorylated α-synuclein (monoclonal 81A pSer129 antibody; see
Table 2). The Proteostat detection reagent was also applied to the tissue and the Hoechst reagent was
used to stain nuclei. Images were captured with a 100× objective under oil immersion. (A) Perinuclear
inclusions in the anterior olfactory nucleus, piriform cortex, posteromedial cortical nucleus of the
amygdala, hippocampal CA1, and entorhinal cortex are displayed in young male mice infused with PBS
or fibrils six months earlier. (B) Lack of colocalization of neuritic inclusions with the Proteostat dye.
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Similar patterns of pSer129+ aggregations observed with two independent antibodies

Figure 27: Preformed α-synuclein fibril injections in the mouse olfactory peduncle elicit αsynucleinopathy in olfactory/limbic regions of the temporal lobe. Mice were infused in the right rear
olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent volume of PBS (1
μL). Sagittal brain sections were immunostained for pathologically phosphorylated α-synuclein
(EP1536Y rabbit monoclonal pSer129 antibody; see Table 2). The Hoechst reagent was used to stain
nuclei and identify anatomical boundaries. Images were captured at 40 and 200 (insets) magnification
in the anterior olfactory nucleus (A), tenia tecta (B), dentate gyrus (C), and hippocampal CA1 (C,D),
the posteromedial cortical amygdala (E), and the nucleus accumbens (F). All abbreviations are listed in
Table 4.
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The abovementioned pSer129 inclusion counts in this aim were performed with a mouse
monoclonal anti-pSer129 antibody to the same epitope as used in Aim 1. The following
experiments of this Aim were performed with a rabbit polyclonal anti-pSer129 antibody to the
EP1536Y epitope, which has been used effectively by other labs (Rey et al., 2018), and has been
shown to be the most sensitive and specific anti-pSer129 antibody of four commercially available
antibodies tested (Delic et al., 2018). Indeed, with this antibody, we observed a greater signal-tonoise ratio and more visible pSer129+ aggregates (Figure 27). In the rostral olfactory structures
(Figure 27A-B), the young male group typically exhibited the most pathology, while in more
caudal structures such as the hippocampus and amygdala, the older males exhibited the most
pathology (Figure 27C-D). Females overall developed fewer pSer129+ inclusions than males
(Figure 28), but there is some variability within the treatment groups (Figure 20).

Figure 28: Preformed α-synuclein fibril injections in the olfactory peduncle induce a similar
topographic extent of α-synucleinopathy in males and females. Mice were infused in the right rear
olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent volume of PBS (1
μL). Sections were immunostained for pathologically phosphorylated α-synuclein (EP1536Y rabbit
monoclonal pSer129 antibody; see Table 2). The nuclear marker Hoechst (pseudocolored blue) was
used to denote cytoarchitectonic boundaries. Stitched images of sagittal brain sections from young male
(top) and female (bottom) perfused 6 months post-infusion are displayed from medial to lateral. All
sections were processed in parallel and images were captured at the same camera and exposure settings.
All abbreviations are listed in Table 4.
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17-month-old male sacrificed 6 months post-infusion developed most robust and widespread
pSer129+ pathology

A 17-month-old animal sacrificed at 6 months post-infusion had developed the maximal extent of
α-synucleinopathy following OB/AON infusions of preformed α-synuclein of all mice examined
in this study (Figure 29). This series of stitched images includes sections from 3.00 to 3.72 mm
from the midline of the brain. In the most medial section, dense pathology is visible in the
amygdala, hippocampal CA1, and the ventral portions of dentate gyrus (Figure 29A). In the next
section, pathology is concentrated in the amygdala, and in the hippocampus. CA1 is primarily
occupied by perinuclear inclusions whereas the molecular layer of the dentate gyrus is filled with
neuritic inclusions (Figure 29B). In this section as well as the following one, the inclusions appear
in the entorhinal cortex as well as the ectorhinal cortex (Figure 29B-C). In all sections, pathology
is visible throughout the piriform cortex and in the amygdalopiriform transition area and is
primarily confined to brain regions within the limbic system (Figure 29A-D). The 21.5-monthold mice sacrificed 10.5 months post-infusion developed a similar pattern of α-synucleinopathy,
but it was less robust than this animal sacrificed 6 months post-infusion (Figure 30). This
observation agrees with other groups who have reported that at longer time points, the amount of
pSer129+ aggregations may diminish in some structures (Rey et al., 2018), suggesting that there is
some aggregated α-synuclein clearance over time possibly through an immune response.
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Figure 29: Specific α-synucleinopathy is centered in the limbic allocortex six months following
infusions of preformed α-synuclein fibrils in the olfactory peduncle. A series of stitched images of
sagittal brain sections from 11-month-old animals sacrificed six months after infusion of 1 µL PBS (left)
or 5 µg/1 µL fibrils (right) into the olfactory peduncle. All sections were stained in parallel with the
monoclonal EP1536Y pSer129 antibody for pathologically phosphorylated α-synuclein (see Table 2).
Anatomical labels are based on cytoarchitectonic details provided by the Hoechst nuclear marker (not
shown). All sections were and photographed at the same exposure and camera settings. All abbreviations
are listed in Table 4.

Figure 30: Preformed α-synuclein fibril injections in the olfactory peduncle induce αsynucleinopathy centered in the limbic system at 10.5 months post-infusion. Mice were infused in
the right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent
volume of PBS (1 μL). Sections were immunostained for pathologically phosphorylated α-synuclein
(EP1536Y rabbit monoclonal pSer129 antibody; see Table 2). The nuclear marker Hoechst
(pseudocolored blue) was used to denote cytoarchitectonic boundaries. Stitched images of sagittal brain
sections from 21.5 month-old mice perfused 10.5 months after fibril infusions are displayed. All
abbreviations are listed in Table 4.
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α-synucleinopathy can develop in the midbrain after 6 months following OB/AON infusions of
preformed α-synuclein fibrils

In a medial section from the same animal in Figure 29, pSer129+ aggregates are visible within the
midbrain (Figure 31A, D). Dense pathology is visible in the AON and nucleus accumbens at this
level (Figure 31A-C). Some pathology is also visible in the bed nucleus of stria terminalis and the
premammillary area, which are also part of the limbic system. Pathology in these areas was rare
and therefore was not included in the heatmap in Figure 20. Nonspecific label is visible in the
brainstem (Figure 31A), but as discussed earlier, we did not define this material as genuine
pSer129+ inclusions because it was morphologically distinct and also visible in the GFP channel,
which did not have any secondary antibodies (Figures 21A, 30). Within the ventral midbrain, this
animal developed somal as well as neuritic pSer129 + inclusions (Figure 31D-L). Tyrosine
hydroxylase, the rate-limiting enzyme for dopamine biosynthesis (pseudocolored green) exhibited
minimal colocalization with pSer129+ inclusions (Figure 31H, L). The arrow in

Figure 31: α-synucleinopathy is centered medially in limbic-related parts of the midbrain
following infusions of preformed α-synuclein fibrils in the OB/AON. A fibril-injected 17 month-old
mouse with the most widespread Lewy-related pathology of all cases is displayed in this figure. (A) A
stitched image containing the ventral midbrain is displayed. This type of specific α-synucleinopathy in
the boundary zone between the ventral tegmental area and substantia nigra, pars compacta (as identified
with antibodies against the dopaminergic marker tyrosine hydroxylase) was only observed in two out of
22 fibril-infused mice by six months post-infusion (see heatmap in Figure 20). Dense pSer129
inclusions were observed in the anterior olfactory nucleus (AON) and nucleus accumbens (Acb) in the
animal featured in panel A, and sparse inclusions were observed in the olfactory bulb (OB), bed nucleus
of stria terminalis (BST), frontal cortex, and ventral midbrain. Merged, higher-magnification images of
Hoechst+ cells (pseudocolored blue) and pSer129 immunostaining (pseudocolored red; EP1536Y rabbit
monoclonal pSer129 antibody; see Table 2) in the AON (B) and accumbens (C), respectively. (D)
Tyrosine hydroxylase (TH; pseudocolored green) and pSer129 (pseudocolored red) immunostaining in
the ventral midbrain of the same animal. (E-H) Lack of convincing colocalization of pSer129 and
tyrosine hydroxylase in confocal images of the same animal as shown in panels A-D. All abbreviations
are listed in Table 4.
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Figure 31L points to a single area of colocalization, but when examining this area via 3D video
generated on a confocal microscope, it was clearly in another plane of focus. This section is at the
boundary of the lateral ventral tegmental area and medial SN, whereas the ventrolateral posterior
subregion of the SN is reported to be more vulnerable in PD (Damier et al., 1999; Fearnley & Lees,
1991)., The ventral tegmental area harbored pSer129+ inclusions more frequently that the SN
(Figure 20), and this area also displayed minimal colocalization of tyrosine hydroxylase with
aggregated α-synuclein (Figure 32).

Figure 32: α-synucleinopathic inclusions in the ventral tegmental area are not found in tyrosine
hydroxylase+ neurons. Three-month-old mice were infused in the right rear olfactory bulb with either
preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent volume of PBS (1 μL). After 6 months,
sagittal brain sections were stained with the rabbit monoclonal EP1536Y pSer129 antibody
(pseudocolored red) for pathologically phosphorylated α-synuclein (see Table 2) and tyrosine
hydroxylase (pseudocolored green). No colocalization of the two markers was observed.

97

α-synucleinopathy in the limbic system affects dopaminergic markers in the nigrostriatal pathway

The same tissue used to generate the heatmap and stitched images in this Aim was also
immunostained for Tyrosine Hydroxylase (TH) and the Dopamine Transporter (DAT), and
analyzed on the Licor Odyssey scanner. A blinded observer traced the outlines of the nucleus
accumbens, caudoputamen, ventral tegmental area, and SN (pars compact and reticulata), and
determined the area of the traced shape (Figure 33A) and fluorescent signal for both dopaminergic
markers (Figure 33B, D). Using these measurements, the signal per area for both TH and DAT
was calculated (Figure 33C, E). In the older males that were sacrificed 10.5 post-infusion, fibril
infusions elicited a robust increase in the TH signal per area in every region. This pattern was also
seen in the older males sacrificed 6 months post infusion, except in the ventral tegmental area
(Figure 33C). Females also exhibited a fibril-induced increase in TH signal per area in the
caudoputamen and nucleus accumbens, whereas fibril infusions did not significantly increase TH
signal per area in the young males. A similar pattern observed with the DAT signal/area (Figure
33D-F), as males sacrificed 10.5 months post-infusion displayed a fibril-induced increase in DAT
signal per area in every region. The older males sacrificed 6 months post-infusion also displayed
increased DAT signal per area in the caudoputamen and SN and females only in the caudoputamen.
The young male group did not show any significant changes in DAT in any brain region.
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Figure 33: Preformed α-synuclein fibril injections in the olfactory peduncle increase dopaminergic
markers in the nigrostriatal and mesolimbic pathways in older male mice. Mice were infused in the
right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an equivalent volume
of PBS (1 μL). Sagittal brain sections were immunostained with antibodies against the dopaminergic
markers tyrosine hydroxylase (TH) and the dopamine transporter (DAT) and scanned on an
ultrasensitive infrared imager (LiCor). A blinded observer traced the anatomical boundaries of the dorsal
striatum (caudoputamen), ventral striatum (nucleus accumbens), the substantia nigra, and the ventral
tegmental area in LiCor ImageStudio software. (A) The shape areas drawn around the regions of interest
are shown as raw data (unnormalized, arbitrary units). (B) The fluorescence reflecting raw TH+ signal
is also displayed in raw, unnormalized, and arbitrary units. (C) TH signal is also displayed after
normalization to area, reflecting TH signal “density”. (D) The fluorescence reflecting raw DAT+ signal
is displayed as raw data (unnormalized, arbitrary units). (E) DAT signal per unit area is also shown,
reflecting DAT signal density. (F) Representative pseudocolored images of DAT immunostaining in all
groups. Two-way ANOVAs were performed and followed by the Bonferroni correction for multiple
comparisons. Shown are the mean and SEM. N = 4-8 mice per group, with the exception of the oldest
male group, in which only 3 fibril-infused mice survived to 21.5 months of age (see Figure 19).
Comparisons were only made a priori across groups differing by a single independent variable (either
gender, age at surgery, or the passage of time since surgery). * p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs
fibrils; + p≤0.05 ++ p≤0.01 vs 3-9 month males; ~ p≤0.05, ~~ p≤0.01, ~~~ p≤0.001 vs 11-17 month
males.

α-synucleinopathy in the limbic system increases TH expression in the ventral midbrain
To count the dopaminergic cells and Hoechst + nuclei in the ventral midbrain, we photographed
every available midbrain in high-resolution (200×) stitched images. Stitched images were
necessary because the entire brain region could not be photographed within the field of view with
objectives powerful enough to provide the resolution necessary to distinguish individual cells. In
624 high-resolution images, the TH staining was used to identify the retrorubral field (A8), SN
pars compacta (A9), and ventral tegmental area (A10). A blinded observer traced the boundaries
of each region (Figure 34A), and every TH+ cell and Hoechst+ nuclei within each region were
counted (Figure 34B, D). To ensure that differences in trace size were not confounding our results,
we also calculated TH+ cells and Hoechst+ nuclei per area (Figure 34C, E). In sagittal sections,
the ventral tegmental area presents as a single unit (Figure 34F), but at different levels the SN was
subdivided into anterior, posterior, and lateral sections with clearly identifiable neuroanatomical
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boundaries (Figure 34G). In both the TH+ cell counts and Hoechst+ nuclei counts, there were few
significant or robust differences attributable to fibril infusions, and no effects that were the same
across groups. To determine the TH signal per cell in the ventral tegmental area and SN pars
compacta (Figure 34H-I), we divided the TH signal for each animal in Figure 33B by the number
of TH+ cells for each animal in Figure 34B. Here we observed that all male groups exhibited a
significant

fibril-induced
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Figure 34: Impact of preformed α-synuclein fibril injections in the olfactory peduncle on
dopaminergic cell numbers in the substantia nigra, pars compacta, of the ventral mesencephalon.
Mice were infused in the right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL)
or an equivalent volume of PBS (1 μL). Sagittal brain sections were stained with antibodies against the
dopaminergic marker tyrosine hydroxylase (TH) (see Table 2) and the nuclear marker Hoechst and
200× images were stitched together to form large, high-resolution photomontages of the ventral
mesencephalon from every section of a 1-in-5 sagittal series. A blinded observer traced the anatomical
boundaries of the ventral tegmental area and the anterior, posterior, and lateral subregions of the
substantia nigra in cellSens software. (A) The shape areas drawn around the regions of interest are shown
as raw data (unnormalized, arbitrary units per stitched section) from cellSens software. (B) Every single
visible TH+ cell encompassing a Hoechst+ nucleus in all the ventral midbrain-containing sections was
manually counted by a blinded observer. In the medial substantia nigra, pars compacta, counts were
made separately in the anterior and posterior nigra based on boundaries in the TH staining (see panel
G). The lateral substantia nigra was counted separately, also based on boundaries in the TH staining.
Data are presented as area of the region of interest in arbitrary units (A), TH+ cell counts (B), and TH+
cell counts per unit area (cell densities); (C). Hoechst+ cell counts (D) and Hoechst+ cell densities (E)
within the boundaries of the area of interest, as traced with dotted lines in panels F-G. Note that two of
these panels are from fibril-infused mice exhibiting no pSer129 pathology in the ventral midbrain. Raw
TH+ cell counts per animal were divided by the total TH signal generated on the LiCor imager in Figure
33B for the ventral tegmental area (H) and substantia nigra pars compacta (I) as a measure of TH
expression per cell. Two-way ANOVAs were performed and followed by the Bonferroni correction for
multiple comparisons. Comparisons were only made a priori across groups differing by a single
independent variable (either gender, age at surgery, or the passage of time since surgery). Shown are the
mean and SEM from an n of 4-8 mice per group. * p≤0.05, ** p≤0.01, *** p≤0.001 for PBS vs fibrils;
+ p≤0.05 vs 3-9 month male group; ~ p≤0.05, ~~ p≤0.01, ~~~ p≤0.001 vs 11-17 month male group. All
abbreviations are listed in Table 4.

increase in TH expression per cell in the SN pars compacta (Figure 34I). The older males
sacrificed 10.5 month post-infusion were the only group to also display increased TH expression
per cell in the ventral tegmental area (Figure 34H).

Fibril infusions in the OB/AON induce more olfactory deficits in males and mild motor deficits in
females

Several behavioral tests were also employed in this study to examine olfaction, motor coordination,
and learning and memory function. At three months post-infusion the buried pellet test was
performed (Figure 35A-C). No differences in the latency to contact the visible treat were observed
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between groups (Figure 35A). The fibril-induced young male mice exhibited greater latencies to
contact the buried treat than fibril-infused females (Figure 35B). When the exposed-treat latency

Figure 35: α-Synuclein fibril injections in the olfactory peduncle elicit behavioral deficits. Mice
were infused in the right rear olfactory bulb with either preformed α-synuclein fibrils (5 μg/1 μL) or an
equivalent volume of PBS (1 μL). The buried pellet test was conducted at 3 months post-infusion and
measured the latency to approach an exposed peanut (A), the latency to approach a buried peanut (B),
and the “exposed latency” subtracted from the “buried latency” (C). The buried pellet test was performed
again at 10 months post-infusion in the older animals and the latter raw scores were contrasted with the
raw scores at 3 months post-infusion (D-F). Two-weeks later, the challenge beam test was performed in
the oldest animals (G). The cylinder test was performed at 4.5 months post-infusion (H-I). Shown are
the number of rears (H) and forelimb contacts (I) with the walls of the cylinder in 10 minutes. The novel
object/place test was performed at 5.5 months post-infusion (J-M). Shown are the mean and SEM from
an n of 3-16 mice per group. * p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs fibrils; + p≤0.05, ++ p≤0.01 +
++ p≤0.001 versus vs 3-9 month male group.

was subtracted from the buried-treat latency to account for individual preferences for the treat, the
older fibril-infused animals were also significantly faster at uncovering the buried treat than the
young males (Figure 35C). The buried pellet test was performed a second time in the older animals
at 10 months post-infusion and their scores compared to the test at three months (Figure 35D-G).
At 10 months post-infusion, the PBS-infused older males contacted the exposed treat faster than
the fibril-infused males (Figure 35D), and the fibril-infused older males took longer to find the
buried treat than they did at three months (Figure 35E). This effect was increased when accounting
for each animal’s preference for the treat (Figure 35F). Two weeks after the second buried pellet
test was performed, the mice were subjected to the challenge beam test. Here we observed the
fibril-infused males made significantly more slips when crossing the challenge beam (Figure
35G), but this effect was only observed in the second of three trials.

In the cylinder test for motor function, female fibril-infused mice reared onto their hind legs
significantly less often the male fibril-infused animals of the same age (Figure 35H). Females
were also the only group to exhibit a fibril-induced reduction in forelimb contacts within 10
minutes (Figure 35I), but this may be related to their decreased propensity to rear onto their hind
legs.

To examine spatial memory and learning, the novel object and novel place tests were performed.
The older fibril-infused males spent less time contacting the novel object than the younger fibrilinfused males (Figure 35J). Female PBS-infused mice spent more time contacting the novel object
as well as both objects compared to age-matched male mice (Figure 35J-K), and less time
exploring the novel place (Figure 35L). In the novel place test, the older fibril-infused males spent
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less time exploring the object in the novel place than PBS-infused males (Figure 35L) This effect
was significant by a two-tailed t test, but was only a trend (p=0.055) when applying a two-way
ANOVA with a Bonferroni post-hoc correction for multiple comparisons.

Discussion

The major findings of this aim are that the risk factors associated with Lewy body disorders are
recapitulated in this model. Female mice developed fewer pSer129 + protein aggregations than
males in response fibril infusions in the OB/AON, and older mice experienced greater mortality,
which is consistent with the increased risk of Lewy body disorders with age and male gender
discussed in the introduction. The pattern of pSer129 + inclusions following injection of PFFs into
the OB/AON was similar across groups and not dramatically more extensive at 6 and 10.5 months
post-infusion than we observed in Aim 1, at three months post-infusion. Even in the 11-month-old
mice that survived until 10.5 months post-infusion, the α-synucleinopathy was primarily
sequestered within the limbic system. Pathology in extralimbic sites was rare, sparse, and never
consistently observed among animals. Unlike in Aim 1, pSer129 + inclusions were observed in the
olfactory tubercle and ventral midbrain at 6 and 10.5 months post-infusion, specifically in the
ventral tegmental area, ventral premammillary area, and the most medial parts of the SN pars
compacta. The medial SN is associated with the limbic system (Haber & Knutson, 2010), and
therefore consistent with the “limbic-predominant” label. No pSer129 + inclusions were observed
in lateral sections of the SN, which are the most vulnerable to degeneration in PD (Damier et al.,
1999; Fearnley & Lees, 1991; Jellinger, 2012).
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An important finding of this aim is that female mice develop fewer inclusions than male mice in
several brain regions following the induction of α-synucleinopathy in the OB/AON. Female mice
did not develop significant inclusions in the olfactory tubercle or dorsal striatum, unlike their male
counterparts. If one assumes that pathology travels primarily in a retrograde direction, these brain
regions are more than one synapse away from the site of infusion, which suggests that females
may be more resistant to the cell-to-cell spread of pathology in addition to pathology that develops
from first-order circuitry from the site of infusion. Many of the inclusions that did develop in the
olfactory tubercle were perinuclear, suggesting retrograde transport from another brain region
rather than anterograde transmission from the OB/AON. Female mice did not exhibit significantly
more inclusions than male mice in any brain region. This observation concurs with the greater risk
of men to develop Lewy body disorders than women (Beach, Adler, et al., 2009; Savica et al.,
2017; Savica et al., 2013; K. M. Smith & Dahodwala, 2014; Twelves et al., 2003), and suggests
that this gender-dependent risk may be related to a reduced spread and development of α-synuclein
pathology in addition to the general neuroprotective effects of estrogens (Engler-Chiurazzi et al.,
2017).

Females also appeared resistant to fibril-induced neurodegeneration as fibril infusions failed to
cause a significant loss of Hoechst+ or NeuN+ cells in any brain region. In male mice of the same
age, a loss of NeuN+ and Hoechst+ cells was observed in the posteromedial cortical amygdala, a
region that develops particularly dense pSer129+ inclusions in this model. A loss of both markers
was also observed in the nucleus of the lateral olfactory tract. A loss of Hoechst + cells but not
NeuN+ cells was observed in the both subregions of the piriform cortex as well as in the nucleus
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accumbens, suggesting a reduction in non-neuronal cells. Females displayed an increased number
of Hoechst+ cells in the OB, which could be related to gliosis.

Nelson and colleagues reported that males are more than twice as likely to develop the limbicpredominant subtype of DLB, but that there was not difference in risk to develop the brainstempredominant subtype (Nelson et al., 2010). This suggests that the gender difference in propensity
to develop α-synucleinopathy may be unique to the limbic system. Another group reported no
difference between genders 6 months after PFF infusions into the striatum of nontransgenic mice
(Kim et al., 2016), but they used human α-synuclein fibrils, which typically do not seed as well in
mice as mouse α-synuclein fibrils (Luk et al., 2016; Rey et al., 2018). They also employed different
sonication parameters, which can greatly impact the pathogenicity of the fibrils (Polinski et al.,
2018). Nevertheless, this may suggest females are more protected from limbic than nigrostriatal
α-synucleinopathy. Indeed, female PD patients are more likely to experience dyskinesia, postural
instability, and a tremor-dominant phenotype, whereas male PD patients are more likely to
experience symptoms of hyposmia and cognitive impairment, which are more dependent upon the
limbic temporal lobe (Cholerton et al., 2018; Farhadi et al., 2017; Georgiev et al., 2017).

Olfactory dysfunction is more common in the limbic-predominant subtype of Lewy body disorders
than in the brainstem predominant subtype (Beach, White, et al., 2009; Wilson et al., 2011), and
as males are more likely to develop the limbic-predominant subtype, it is logical that they would
be more likely to experience olfactory dysfunction. Male PD patients typically perform worse than
female patients on olfactory exams (Stern et al., 1994). In the buried pellet test, male mice
exhibited fibril-induced olfactory dysfunction and females did not (Figure 35B-C), which
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suggests that the increased propensity for males to experience hyposmia was recapitulated in this
model. Likewise, female mice reared less often and made less forelimb contacts (Figure 35H-I),
perhaps suggesting that they were experiencing more postural instability, a symptom more
associated with women. As females exhibited only mild changes in TH and DAT expression in
compared to other groups, it is unlikely that changes in the nigrostriatal pathway are responsible
for these motor symptoms.

The older male animals performed the worst on the novel place recognition test, as PFFs reduced
their ability to recognize a familiar object in a novel place (p = 0.055). Dementia in patients with
Lewy body disorders is associated with pathology in the amygdala, cortex, hippocampus, and basal
forebrain (Aarsland et al., 2017; Hall et al., 2014; Hurtig et al., 2000). As dense hippocampal
Lewy-like pathology following infusions into the hippocampus failed to induce any overt memory
deficits (Nouraei et al., 2018), it is unlikely that pathology in the hippocampus alone is sufficient
to induce memory deficits. If memory impairment in this model is related to α-synuclein
aggregates, it likely requires their presence in multiple interconnected regions to elicit substantial
memory deficits. The mild memory deficit that we observed may also be related to the significant
loss of NeuN+ cells in the subiculum and CA2 field of the hippocampus in the oldest males.
However, the mild memory loss in this model might be also be an advantage in terms of modeling
early mild cognitive impairment (MCI) in ADLB.

The α-synucleinopathy was not dramatically more dense or widespread in the animals that were
11 months old at the time of fibril infusion, compared to those that were three months old, but the
older animals did exhibit significantly greater mortality in response to fibril infusion. Rey et al. did
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not report an increase in mortality following olfactory-seeded α-synucleinopathy (Rey et al., 2018;
Rey, Steiner, et al., 2016), but their mice were all three months old at the time of infusion. We also
did not observe any increased mortality in the mice that were three months old at the time of
infusion, at least for the six months that we followed them.

Mice in every fibril-infused group developed some pSer129 + inclusions within the ventral
midbrain, primarily within the ventral tegmental area. With both epifluorescent and confocal
microscopy, minimal colocalization was observed of the TH and pSer129 signal. This may be
related to α-synucleinopathy suppressing TH expression (Chu & Kordower, 2007; Chu et al.,
2006), or non-dopaminergic neurons in these regions developing pathology. Both the SN pars
compacta and ventral tegmental area have non-dopaminergic projections to the amygdala
(Loughlin & Fallon, 1983). A tract-tracing study in rats reported a direct projection from the SN
to the OB (Hoglinger et al., 2015), and following injection in the OB, the tracer appeared in the
medial part of the SN, similar to where we observe pSer129 + inclusions. Regardless of the route
of transmission, the medial SN pars compacta is less vulnerable to α-synucleinopathy and cell loss
in PD (Damier et al., 1999; Fearnley & Lees, 1991), which suggests that this model is more akin
to other Lewy body disorders.

Despite a relative dearth of inclusions in the nigrostriatal system compared to the limbic system,
we observed a dramatic increase in nigrostriatal TH and DAT signal per area, particularly in older
mice. An increase in striatal DAT binding has been reported in monkeys after MPTP injection but
before motor deficits appeared (Vezoli et al., 2014). In Lewy body disorders, TH and DAT levels
within the nigrostriatal pathway typically decrease as the disease progresses and cases of ILBD
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can have as much as a 50% decrease in TH expression without any apparent symptoms (Beach,
Adler, et al., 2009). Cases with the abovementioned Stage IIb pathology have the least nigrostriatal
degeneration. It is unclear if OB/AON fibril infusions induced the increase in dopaminergic
markers in the nigrostriatal pathway or if aged animals with the highest dopaminergic fiber
densities were more likely to survive the α-synucleinopathy. The former seems more likely as
fibril-induced increases in TH and DAT signal per area were observed in the younger mice without
significant mortality. Female mice were least vulnerable to the α-synucleinopathy and were the
only group that failed to demonstrate an increase in TH expression per TH + cell in the SN,
suggesting that the presence of pSer129+ aggregates and changes in dopaminergic markers in the
nigrostriatal pathway may be related.

Many of the perinuclear pSer129+ aggregates in the tissue colocalized with the Proteostat
aggresome dye. Aggresomes are thought to be a transient protective structure that helps the cell
survive conditions of high proteotoxic stress (M. Tanaka et al., 2004; Taylor et al., 2003), by
sequestering misfolded and insoluble material at a single location within the cell and helping
facilitate degradation. Human Lewy bodies tend to be spherical and not perinuclear, which
suggests that somal aggregations in this model may be a less toxic form, more akin to an
aggresome. LRRK2 mutations, which increase the likelihood of developing PD, are reported to
reduce the formation of aggresomes (Bang et al., 2016), suggesting that the ability to form
aggresomes may reduce the toxicity associated with α-synuclein accumulation. It is perhaps for
this reason that we observe little to no cell loss in brain regions that are heavily occupied with
perinuclear pSer129+ aggregations.
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Given the potential for cross-reaction of anti-pSer129 antibodies (Sacino et al., 2014), and that
many such antibodies display nonspecific bands in Western blots (Delic et al., 2018), we were
very conservative in our approach to identifying and counting inclusions. For the regional counts
using the 81a antibody (See Table 2) in Figures 22-24, no pSer129+ structures were excluded
from the blinded counts, even in PBS-infused animals, and when qualitatively scoring pathology
with the EP15365 antibody used to generate the heatmap figure (Figure 20), the GFP channel was
always checked for nonspecific label. It is important to note that pSer129 + structures that
fluoresced in multiple channels were always excluded from the blinded analysis. Thus, the ability
to observe nonspecific staining by checking multiple fluorescent channels is an advantage of our
method of histological examination. Rey and colleagues reported a more extensive spread of
pathology at 6 and 12 months post-infusion into the rostral OB (Rey et al., 2018; Rey, Steiner, et
al., 2016), but we observed a greater of abundance of inclusions within our tissue. These
differences in reported α-synucleinopathy may be attributable to difference in the injection site,
strain of mouse, fibril sonication parameters, and immunohistochemical methodology.

We were somewhat limited in this aim by the high level of mortality in our oldest cohort. The
histopathology in the animals sacrificed at 6 and 10.5 months post-infusion agrees with Aim 1, but
we do not know if the animals that died prematurely exhibited a different pattern of staining or a
concentration of pathology in any particular region. Therefore, while the pathology in the perfused
animals corresponds with Beach’s Stage IIb pathology, it is possible that the animals that died
prematurely had pathology in additional regions, such as the brainstem. We can only speculate as
to the cause of mortality in the aged animals. It may be related to the particularly dense pathology
we observe in the amygdala as this region is involved with regulating endocrine and autonomic
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functions (Braak et al., 1994). The caudoputamen was the only region to develop significantly
more inclusions in 11-month-old fibril-infused mice than in the 3-month-old mice at 6 months
post-infusion, and the ectorhinal cortex only developed significant pathology at this time in the
11-month-old animals. This could suggest that the development of pathology in these regions is
related to mortality in this model, as the animals that survived for an additional 4.5 months had
few inclusions in these regions.

Chapter 3
Rationale
N-Acetyl Cysteine (NAC) is an inexpensive and off-patent medication with an excellent safety
profile and minimal side effects. In PD patients, NAC can reduce striatal dopamine transporter
loss, provide a mild reduction in motor deficits (Monti et al., 2016), and boost GSH levels in the
brain (Holmay et al., 2013). While NAC supplementation may be beneficial to PD patients, the
mechanism of action is thought to be upregulation of GSH synthesis via the rate-limiting cysteine
precursor. Although the Leak lab reported NAC-induced protection against proteotoxicity in
multiple cell types (Heinemann et al., 2016; Jiang et al., 2013; Unnithan et al., 2014), we also
found that inhibition of GSH synthesis does not necessarily abolish NAC-mediated protection
(Gleixner et al., 2017). Furthermore, it is not known if NAC can reduce the development and
spread of α-synucleinopathy in non-transgenic mice that do not overexpress α-synuclein. Thus, the
goal of this Aim is to begin to address these gaps.
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As detailed in the Introduction, Lewy body disorders are characterized by both proteotoxic and
oxidative stress. Our lab published data reporting that NAC can protect neurons from proteotoxic
and oxidative stress in GSH-dependent and GSH-independent manners. In N2a neuroblastoma
cells, NAC was able to attenuate the loss of GSH after dual treatments of the oxidative stressor
hydrogen peroxide (Unnithan et al., 2014). However, NAC also protected against a single
treatment of the proteasome inhibitor MG132 without affecting GSH levels (Unnithan et al., 2012).
When multiple treatments of MG132 were applied, NAC was still protective and GSH levels were
only then upregulated. The collective data suggested that NAC can protect against the proteotoxic
stress of one treatment of MG132 independent of any changes in GSH. Consistent with this
hypothesis, Jiang et al. later showed that NAC facilitates the heat shock protein response to injury
and increases Hsp70 expression (Jiang et al., 2013). NAC was able to reduce the accumulation of
ubiquitin-conjugated proteins in response to MG132 treatment, and Hsp70 inhibition attenuated
NAC mediated protection against the proteotoxicity.

Heat shock proteins are anti-apoptotic chaperones that can be upregulated in neurodegenerative
diseases. Misfolded proteins will often expose a hydrophobic motif with multiple Hsp70 binding
sites (Rudiger et al., 1997). Hsp70 binding promotes proteasomal degradation by coordinating the
interaction between the misfolded proteins and the 20s proteasome (Shiber & Ravid, 2014). Hsc70
is the constitutively expressed form of Hsp70, and Hsc70 levels decline in the SN and amygdala
in PD patients (Alvarez-Erviti et al., 2010). Hsp70 is the stress-inducible form, but it becomes less
inducible with age (Fargnoli et al., 1990), possibly contributing to the higher risk of developing
neurodegenerative diseases with advancing age. Hsp70 is reported to reduce α-synuclein toxicity
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(Danzer et al., 2011; Klucken et al., 2004), inhibit the assembly of α-synuclein fibrils (Luk et al.,
2008), and reduce α-synuclein aggregates in vitro (Kilpatrick et al., 2013).

In primary OB neurons, Crum et al. demonstrated that both proteotoxic and oxidative stressors
increase Hsp70 levels. The proteasome inhibitors MG132 and lactacystin and the oxidative stressor
paraquat increased levels of Hsp70, Hsp25, Hsp32 (Crum et al., 2015). The Hsp70 inhibitors
MAL3-101 and VER155008 exacerbated the toxicity of the proteasome inhibitors but not of
paraquat, suggesting that Hsp70 is better able to mitigate proteotoxic than oxidative stress.
Similarly, in primary hippocampal neurons, NAC was reported to be protective against multiple
hits of MG132 but not paraquat (Heinemann et al., 2016).

The abovementioned findings reveal that NAC may protect cells against proteotoxicity and
oxidative stress. However, studies of the mechanism underlying the protective effects of NAC
were only conducted in neuroblastoma cell lines, which are immortalized and display a number of
pro-survival mutations, unlike post-mitotic neurons. Therefore, the first goal of this aim was to
build on previous findings, examine the ability of NAC to protect postnatal primary OB and
hippocampal neurons from proteasome inhibition and oxidative stress in vitro, and determine the
underlying mechanism of action, using three independent measures of cell viability. The OB and
hippocampus were chosen because the OB is affected in the early stages of Lewy body disorders,
whereas the hippocampus is affected in the later stages, allowing us to study the two temporal
extremes of these conditions. Pathology in the olfactory structures is associated with a declining
sense of smell (Wilson et al., 2011), and starting a treatment when this symptom first emerges may
help delay the more debilitating symptoms associated with Lewy body disorders. Dementia is a
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common symptom at the end stages of Lewy body disorders and it is associated with Lewy
pathology in the hippocampus (Hall et al., 2014). Preserving the functional integrity of this region
may help delay this debilitating and costly outcome. Both regions develop pathology in the in vivo
model of limbic α-synucleinopathy developed in Aim 1.

As Jiang and colleagues had demonstrated that the GSH-independent protective actions of NAC
may be mediated by Hsp70 induction in N2a cells that are derived from a murine sympathetic
nervous tissue (Schubert et al., 1969), we tested the hypothesis that NAC might protect primary
OB and hippocampal neurons against proteasome inhibition by upregulating Hsp70. To this end,
we used multiple Hsp70 inhibitors with different mechanisms of action. VER155008 is an
adenosine-derived ATP-competitive inhibitor that binds to the nucleotide-binding domain of
Hsp70 and inhibits its ATPase and chaperone activity (Schlecht et al., 2013). MAL-3101 is a
pyrimidinone that blocks Hsp40-dependent ATP hydrolysis by Hsp70 (Fewell et al., 2004).
MAL3-101 treatment was also reported to increase α-synuclein aggregation in neuroglioma cells,
whereas the Hsp70 activator 115-7c reduced α-synuclein aggregation (Kilpatrick et al., 2013).

As α-synuclein fibril treatment is typically not lethal to cells, we employed multiple toxicants to
recapitulate the cell loss that is frequently observed in Lewy body disorders. MG132 and
lactacystin are proteasome inhibitors that block the proteolytic activity of the proteasome (D. H.
Lee & Goldberg, 1998). MG132 can also inhibit cathepsins and calpains, which are also involved
with protein degradation, but it is approximately 10-fold more selective for the proteasome
(Kisselev & Goldberg, 2001). Lactacystin is a bacterial toxin that can also inhibit cathepsin A
(Aikawa et al., 2006). Paraquat inhibits complex 1 of the mitochondria and increases the generation
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of ROS (Castello et al., 2007; Jenner, 2003). Paraquat exposure increases the risk of developing
PD (Tanner et al., 2011).

NAC was reported to decrease the levels of human α-synuclein and attenuate the loss of
dopaminergic terminals in transgenic mice over-expressing human α-synuclein (J. Clark et al.,
2010). In that study, the mice received approximately 1000 mg/kg/day for over 10 months while
in clinical trials in Alzheimer’s and PD patients, the typical oral dose is between 50 and 100
mg/kg/day (Adair et al., 2001) (NCT02212678; NCT01470027). Clark et al. also did not examine
the effect of NAC on cell loss in vivo, because the animal models of α-synuclein overexpression
typically do not recapitulate the dopaminergic cell loss that characterizes PD. Therefore, the
second goal of this aim is to test the hypothesis that NAC can reduce the development and spread
of α-synucleinopathy and protect against cell loss in a non-transgenic mouse model at a more
translatable dosage. Thus, we fed a cohort of mice a specially formulated diet consisting of 0.15%
NAC, beginning immediately after stereotaxic injection with preformed α-synuclein fibrils. Our
final measurements suggested that the dose was ~200 mg/kg/day per mouse, which is comparable
to human studies. After three months, the animals were sacrificed and Lewy-like inclusions were
counted to examine if NAC can reduce the development and spread of α-synucleinopathy. The
number of NeuN+ neurons and Hoechst+ cells were also counted to determine if NAC prevented
proteotoxicity-induced cell loss in vivo. If successful at facilitating the Hsp70 response to
proteotoxicity and reducing limbic α-synucleinopathy, NAC may be a potentially viable treatment
strategy for other neurodegenerative diseases.

116

Specific Aim 3 – To test the hypothesis that NAC can decrease the development and spread of PDrelated pathology in vivo and in vitro.

Results
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Figure 36: Concentration response curves for MG132 in olfactory bulb and hippocampal
cultures. Cultures were treated with MG132 on DIV5 and assayed for viability on DIV7. (A) The
Cell Titer Glo luminescent assay for ATP. (B) In-Cell Western assay for DRAQ5 levels with (C)
representative image. (D) In-Cell Western assay for MAP2 levels with (E) representative image.
Displayed are the mean and SEM of 3-4 independent experiments that were performed in
triplicate. One-way ANOVA with Bonferroni post hoc correction. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001 vs 0 μM MG132.
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Figure 37: Concentration response curves for lactacystin in olfactory bulb and hippocampal
cultures. Cultures were treated with lactacystin on DIV5 and assayed for viability on DIV7. (A) The
Cell Titer Glo luminescent assay for ATP. (B) In-Cell Western assay for DRAQ5 levels with (C)
representative image. (D) In-Cell Western assay for MAP2 levels with (E) representative image.
Displayed are the mean and SEM of 3-4 independent experiments that were performed in triplicate.
One-way ANOVA with Bonferroni post hoc correction. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs 0
μM lactacystin.
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Figure 38: Concentration response curves for paraquat in olfactory bulb and hippocampal
cultures. Cultures were treated with paraquat on DIV5 and assayed for viability on DIV7. (A)
The Cell Titer Glo luminescent assay for ATP. (B) In-Cell Western assay for DRAQ5 levels with
(C) representative image. (D) In-Cell Western assay for MAP2 levels with (E) representative
image. Displayed are the mean and SEM of 3-4 independent experiments that were performed in
triplicate. One-way ANOVA with Bonferroni post hoc correction. * p ≤ 0.05, ** p ≤ 0.01, *** p
≤ 0.001 vs 0 μM paraquat.
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MG132, lactacystin, and paraquat exhibit concentration-dependent toxicity in primary OB and
hippocampus neurons

In both OB and hippocampus primary neuron cultures, MG132, lactacystin, and paraquat elicited
significant concentration-dependent toxicity that was similar in neurons from both brain regions
(Figures 36-38). As lactacystin was not consistently significantly toxic in all viability assays at
concentrations as high as 16 μM (Figure 37), and Crum et al. demonstrated that Hsp70 inhibition
potentiates the toxicity of MG132 more than lactacystin (Crum et al., 2015), we chose to use
MG132 as our proteasome inhibitor in subsequent studies. Paraquat treatment did not result in a
consistent IC50 across all assays (Figure 38), and Heinemann et al subsequently showed that NAC
is not protective against paraquat toxicity (Heinemann et al., 2016). For these reasons, we did not
pursue the effects of NAC on paraquat toxicity further.

NAC protects primary OB and hippocampal neurons from MG132-induced proteotoxicity
independent of GSH

After deciding to use MG132 to model proteotoxic stress in primary neurons, we examined the
effect of increasing concentrations of NAC in the presence of the IC 50 value determined with the
concentration-response curve in Figure 34 (0.5 μM MG132). Here we observed a concentrationdependent increase in cell viability with the highest viability at 1000 μM NAC. Significant
protection from MG132 toxicity was observed in both the OB and hippocampus cultures in the
ATP and MAP2 assays at this concentration. DRAQ5 is less specific for neurons and did not reveal
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any protection at this concentration of NAC. When the GSH signal was normalized to the DRAQ5
signal for cellular nuclei, we observed that MG132 significantly increased GSH levels per cell at
lower concentrations of NAC but not at higher concentrations in cultures from both brain regions.
This could suggest that as NAC can act as an antioxidant on its own, and that high levels of NAC
may reduce the cellular demand for GSH production.

Figure 39: N-acetyl cysteine protects OB and hippocampal neurons against proteotoxicity
without increasing glutathione levels. Primary OB and hippocampus cultures were treated with
MG132 and increasing concentrations of NAC on DIV5 and assayed on DIV7. (A) The Cell Titer
Glo luminescent assay for ATP. (B) In-Cell Western assay for DRAQ5 levels with representative
image. (C) In-Cell Western for GSH expressed as a function of nuclear staining with DRAQ5 and
representative GSH image. (D) In-Cell Western assay for MAP2 levels with representative image.
Displayed are the mean and SEM of 3-4 independent experiments that were performed in triplicate.
Two-way ANOVA with Bonferroni post hoc correction. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs 0
μM MG132. + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 vs 0 μM NAC
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Hsp70 inhibition reduces the protective effect of NAC

As 1000 μM was the most protective NAC concentration examined here, and hippocampal cultures
were more responsive to NAC and survived the culturing process more readily, we performed the
Hsp70 inhibitor studies at this concentration in primary hippocampal neurons. MAL-3101 blocks
Hsp40-dependent ATP hydrolysis by Hsp70 (Fewell et al., 2004), and therefore inhibits its protein
chaperone function. In the absence of MAL3-101, NAC was able to provide significant protection
against MG132 toxicity in the Cell Titer Glo assay for ATP levels and MAP2 In-Cell Western

Figure 40: Heat shock protein 70 inhibition by MAL3-101 reduces NAC mediated protection
against MG132. Primary hippocampus cultures were treated with MG132, NAC, and MAL3-101 on
DIV5 and assayed on DIV7. (A) The Cell Titer Glo luminescent assay for ATP. (B) In-Cell Western
assay for DRAQ5. (C) In-Cell Western assay for MAP2 levels. (D) Representative DRAQ5 image.
(E) Representative MAP2 image. Displayed are the mean and SEM of 3-4 independent experiments
that were performed in triplicate. Three-way ANOVA with Bonferroni post hoc correction.* p ≤
0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs 0 μM MG132. + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 vs 0 μM
NAC, ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 vs 0 μM MAL3-101
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(Figure 40A, C, E). In the presence of 30 μM of MAL3-101, NAC was no longer able to protect
hippocampal neurons. A similar effect was observed when Hsp70 inhibitor VER155008 was used
(Figure 41). However, in the VER155008 experiments, a reduction in NAC-mediated protection
was only observed in the Cell-Titer Glo assay for ATP levels (Figure 41A). It is possible that the
VER155008 compound had degraded to some degree, and both MAL-3101 and VER155088
display some basal toxicity in primary neuron cultures.

Figure 41: Heat shock protein 70 inhibition by VER155088 reduces NAC mediated protection
against MG132. Primary hippocampus cultures were treated with MG132, NAC, and VER155088
on DIV5 and assayed on DIV7. (A) The Cell Titer Glo luminescent assay for ATP. (B) In-Cell
Western assay for DRAQ5. (C) In-Cell Western assay for MAP2 levels. (D) Representative DRAQ5
image. (E) Representative MAP2 image. Displayed are the mean and SEM of 3-4 independent
experiments that were performed in triplicate. Three-way ANOVA with Bonferroni post hoc
correction.* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs 0 μM MG132. + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤
0.001 vs 0 μM NAC, ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 vs 0 μM VER155088
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NAC reduces the number of pSer129+ inclusions in response to α-synuclein fibril treatment in
primary OB neurons

Figure 42: N-acetyl cysteine reduces the development of pSer129+ inclusions in primary
OB neurons. Primary OB neuron cultures were treated 4 μg/mL α-synuclein fibrils and NAC
on DIV2 and on DIV7, the plates were fixed and immunostained for anti-pSer129. Hoechst
reagent was applied to visualize nuclei. Images were captured with the 20× objective on the
EVOS microscope and analyzed with ImageJ software (A) Representative images of Hoechst+
cells and pSer129+ inclusions. (B) Pser129+ inclusion counts expressed as a fraction of Hoechst+
cells. (C) Percent area of pSer129+ inclusions (monoclonal 81A pSer129 antibody; see Table 2)
expressed as a fraction of Hoechst+ cells. Displayed are the mean and SEM of 3-4 independent
experiments that were performed in triplicate. Two-way ANOVA with Bonferroni post hoc
correction. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 vs 0 μM NAC. + p ≤ 0.05, ++ p ≤ 0.01, +++
p ≤ 0.001 vs 0 μg/mL α-synuclein fibrils
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In OB neuron cultures, we then examined if NAC can reduce the amount of pSer129 + inclusions
that develop in response to treatment with preformed α-synuclein fibrils. Here we observed a
concentration-dependent decrease in the amount of pSer129+ inclusions with increasing NAC
(Figure 42A). When normalized to the number of Hoechst + nuclei, both the amount and area
fraction of the inclusions were significantly reduced (Figure 42B-C). These studies provided
precedence for an extensive in vivo analysis of the therapeutic potential of NAC.

NAC supplemented diet does not affect food consumption or weight gain

The in vivo portion of this Aim involved stereotaxic infusions into the OB/AON of 40 CD-1 mice.
The mice were three months old at the time of infusion and were sacrificed after three months of
oral NAC treatment. Twenty mice were infused with 1 μL of 5 μg/μL of preformed α-synuclein
fibrils and 20 mice were infused with an equivalent volume of PBS. Half of the mice in each
treatment group received control rodent chow or a specially formulated diet containing 0.15%

Figure 43: N-acetyl cysteine supplemented diet does not affect food consumption or
bodyweight. CD-1 mice received either a specially formulated diet with 0.15% NAC (n = 20) or
normal rodent chow (n = 20) for three months. Half of the mice on each diet were stereotaxically
infused with either 1 μL of 5 μg/μL preformed α-synuclein fibrils or an equivalent volume of
PBS for a total of 10 mice per group (A) Daily grams of food consumed over the course of the
study. (B) Percent change in bodyweight over the course of the study
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NAC. The amount of food consumed and the weight of each animal were measured every 5-7
days. Over the course of three months, no differences in the amount of food consumed or the
weight gained were observed across treatment groups (Figure 43), suggesting that the NAC diet
did not affect how much food the animals consumed. We did not collect plasma or CSF for
measurements of NAC entry into the blood and brain to avoid disruption of the behavioral tests.

NAC only reduces the number of pSer129+ inclusions that develop in the anterior olfactory nucleus
after α-synuclein fibril infusions

At approximately three months post-infusion, the mice were sacrificed by perfusion under
anesthesia and their brains were dissected. The brains were cut into sagittal sections in a 1-in-5
series and immunostained for pSer129 and NeuN. The Hoechst reagent was also applied to the
tissue. This tissue was photographed on the Olympus microscope at 40× magnification and
analyzed by a blinded observer using ImageJ software. In this experiment, the only region
exhibiting a significant reduction in pSer129+ inclusions with the NAC diet was the AON (Figure
44A-B), which is the site of the densest Lewy-like pathology in the brain. No loss of NeuN + of
Hoechst+ cells was observed in this region at three months post-fibril infusion. In all other regions
examined, the NAC diet did not affect the amount of inclusions that developed, but the NAC diet
did not significantly increase the amount of inclusions that developed in any brain region compared
to the fibril-infused animals receiving the control diet. In the entorhinal cortex, the NAC diet
appeared to significantly reduce both NeuN+ and Hoechst+ cell numbers (Figure 44J), although
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Figure 44: N-acetyl cysteine supplementation only reduces pSer129+ inclusions in the AON after
three months. Mice were infused in the right rear olfactory bulb with either preformed α-synuclein fibrils
(5 μg/1 μL) or an equivalent volume of PBS (1 μL). A blinded observer counted the number of pSer129+
structures (rb polyclonal antibody, see Table 2), NeuN+ cells, and Hoechst+ nuclei per field of view (40×
magnification) using ImageJ software. The anterior olfactory nucleus (A,B) was the only region to exhibit
a significant reduction in pSer129+ inclusions with NAC supplementation. Data for the tenia tecta (C),
rostral and caudal portions of the piriform cortex (D,E), nucleus of the lateral olfactory tract, (LOT, F)
CA1 (G), combined CA2/CA3 (H), subiculum (Sub, I) and entorhinal cortex (Ent, J) are also included.
Shown are the mean and SEM of 10 mice per group, Two-way ANOVA was followed by the Bonferroni
correction for multiple comparisons. * p≤0.05, ** p≤0.01, *** p≤0.001 PBS vs fibrils, + p≤0.05 control vs
NAC diet. All abbreviations are listed in Table 4.

the dose was five-fold lower than that of the Clark et al. study (J. Clark et al., 2010). These largely
negative findings may partly explain the lack of dramatically protective effects of NAC in PD
patients (Monti et al., 2016) and reveal some degree of toxicity of dietary NAC, similar to
intraperitoneally delivered NAC in our previous work (Nouraei et al., 2016).
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Dietary NAC and α-synuclein fibril infusions had no effect on olfactory or learning and memory
tests in the first three months post-infusion
In addition to histological analyses, behavioral analyses were also performed. The buried pellet
test for olfactory function was performed at 1, 2, and 3 months post-infusion (Figure 45A-C) and

Figure 45: No significant changes in olfactory ability or learning and memory observed in any
treatment group. Mice were infused in the right rear olfactory bulb with either preformed α-synuclein
fibrils (5 μg/1 μL) or an equivalent volume of PBS (1 μL). The buried pellet test was performed at 1, 2,
and 3 months post-infusion (A,B,C). The average latency to contact the buried peanut (D) and total latency
(E) for all three trials are also included. The novel object/place test was performed at 2.5 months postinfusion (F-I). Shown are the mean and SEM from an n of 10 mice per group. Two-way ANOVA was
followed by the Bonferroni correction for multiple comparisons.
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the novel object/novel place tests for learning and memory were performed at 2.5 months postinfusion (Figure 45F-I). No significant differences in olfactory or learning and memory were
observed between the groups. At three months post-infusion, there was a trend for fibril-infused
animals in the NAC treated group to be slower in finding the buried peanut compared to fibrilinfused animals on the normal diet (Figure 45C). This suggested that the NAC diet may have
inhibited olfactory sensory processing. One might speculate that the strong odor of NAC may have
masked any other odors. When the latency for all three trials was averaged (Figure 45D), or
summed (Figure 45E), no differences in olfactory capability were observed between groups.

Discussion

As no one model adequately recapitulates all of the various pathologic aspects of Lewy body
disorders, we examined multiple toxicants that model specific features of these disorders in vitro.
The goal of our studies was to test the efficacy of the neuroprotective compound NAC against
different forms of proteotoxic stress. Ensuring therapeutic efficacy in multiple models might
facilitate the clinical translation of the compound. In the present study we tested the hypothesis
that NAC could reduce the development of α-synucleinopathy by inducing the Hsp70 response
and reducing proteotoxicity associated with proteasome inhibition. Here, were confirmed that
NAC is able to protect neurons from proteasome inhibition partly through Hsp70. We also
established that NAC is able to reduce pSer129+ inclusions in vitro. However, a significant
reduction in inclusions was only observed at relatively high concentrations (500 and 1000 μM),
which would be difficult to achieve in the CNS in vivo without toxicity, as discussed further below.
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Oral NAC supplementation did not affect the amount of food the mice ate or the amount of weight
gained over the course of three months. This suggests that there was minimal aversion to the
unpleasant odor/taste of NAC when mixed into food at a relatively low concentration. We
calculated the dose of NAC per animal to be approximately 200 mg/kg/day, but NAC only has an
oral bioavailability of approximately 4-10% (Giustarini et al., 2012). Sixty minutes after a 10
mg/kg administration of NAC in a healthy human, the plasma concentration of NAC was 8.1 μM
and the plasma concentration of its metabolite cysteine was 21.2 μM (Tsikas et al., 1998),
approximately two fold higher than the basal levels. This suggests that, as NAC is rapidly
metabolized in vivo, the beneficial effects of oral supplementation may be largely attributable to
its thiol metabolite cysteine.

The pattern of pSer129+ inclusions that developed in this study is consistent with the limbicpredominant pattern observed in Aims 1 and 2. A significant reduction in pSer129 + inclusions in
vivo was only observed in the AON, which is the region that develops the most inclusions in our
model. This suggests that NAC was more effective at reducing the development of a high density
of inclusions within this structure rather than the regional spread of α-synucleinopathy. The
beneficial effect of NAC supplementation may have been limited to the AON due to the proximity
of the AON to the site of infusion. The concentration of NAC may have been higher in the AON
than in other brain regions due to the nearby disruption in the blood brain barrier. The lack of
robust neuroprotective effects of NAC in the present study corresponds to the relatively mild
benefits seen in clinical trials (Monti et al., 2016). Our study was conducted over a relatively short
period (3 months), but the aggregation and spread of α-synucleinopathy in this model is more
aggressive than in humans. Therefore, the mild effect of NAC at reducing pSer129 + inclusions in
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vivo may still be clinically relevant, as Lewy body disorders typically take years or even decades
to develop. Oral NAC supplementation of 70 mg/kg for two days resulted in a CSF concentration
of approximately 10 μM (Katz et al., 2015), but the NAC was consumed in a single dose each day
and not over the course of 24 hours, as is the case with the mice in our study. As NAC is rapidly
metabolized in vivo, it is unlikely that the concentration of NAC in the CNS of the mice in our
study surpassed 10 μM, which is far less than the minimum concentration required to reduce αsynucleinopathy in vitro. In our in vitro treatments, there was a greater percentage of
unmetabolized NAC, which we expect may upregulate Hsp70. In vivo, NAC goes through
extensive first pass metabolism, and a greater percentage is present as the metabolite cysteine may
not upregulate Hsp70.

It is also possible that NAC only induces Hsp70 transiently at the initial proteotoxic insult, which
is not sustained in our chronic in vivo model. Hsp70 is indeed known to inhibit its own production
through a negative feedback loop (Vjestica et al., 2013; Zorzi & Bonvini, 2011) and it may
therefore be beneficial to supply exogenous Hsp70 to overcome the feedback loop. The
development of many aggresome-like structures (perinuclear inclusions) may also reduce
proteotoxic stress and therefore decrease Hsp70 production and activity.

In the behavioral tests in this aim, we did not observe any reduction in olfaction or learning and
memory from fibril infusions or the NAC diet. We expected to observe olfactory deficits at three
months post-infusion as we noted a significant increase in latency to find the buried treat in the
three-month-old males in Aim 2. This discrepancy is likely due to performing the buried pellet test
each month in this Aim, as multiple tests increase the likelihood that the mice will remember the
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test and respond differently in subsequent trials (Hanell & Marklund, 2014). By the time olfactory
deficits would have been apparent at three months post-fibril infusion, the mice had already been
exposed to the test twice before. The novel object and novel place tests were performed three
months earlier than in Aim 2, and there was no effect of fibril infusions at this earlier time point,
perhaps consistent with the progressive nature of PFF-induced α-synucleinopathy.

The strength of our in vitro studies is that we performed three independent viability assays, which
have been shown to correlate linearly with cell density in primary neuron cultures (Posimo et al.,
2013; Posimo et al., 2014b). We also showed that NAC reduces MG132-induced proteotoxicity
and reduces the amount of inclusions that develop in primary OB cultures from PFF treatment.
PFFs led to no cell loss and, therefore, we could not examine any reduction in cell loss in this
particular model of Lewy-like pathology. For partly these reasons, MG132 was employed to kill
cells in vitro and test the neuroprotective capacity of NAC.

We employed two different Hsp70/Hsc70 inhibitors with different mechanisms of action to
support our hypothesis that NAC promotes the activity of Hsp70 to inhibit proteotoxic stress and
cell loss in neuronal cultures, as shown previously for astroglial and N2a cells (Gleixner et al.,
2017; Jiang et al., 2013). Our studies identify a protective role for Hsp70 and a protective effect
of NAC in OB and hippocampal neurons. NAC is theorized to provide protection through several
mechanisms and, therefore, a total loss of protection through Hsp70 inhibition alone would not be
expected. Although we measured Hsp70 levels in our in vitro model of NAC-mediated protection
against proteotoxicity, there was no NAC-induced upregulation of Hsp70 protein by Western
immunoblotting methods (data now shown), unlike the findings in N2a cells (Jiang et al., 2013).
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Measurements of Hsp70 activity cannot be made in lysates of cells, but only with purified protein,
as they are all dependent upon its ATPase activity and there are innumerable other ATPases
present. Based upon the observation that Hsp70 activity loss reduced the protective effects of
NAC, we then hypothesized that NAC directly influences the activation state of Hsp70 through
acetylation and commissioned the production of an antibody against the acetylated form of Hsp70,
but it was nonspecific. Given the lack of NAC-mediated protection in our model in the majority
of brain regions examined, we abandoned this line of inquiry.

There are a number of caveats in the interpretation of the in vitro data. First, the in vitro cultures
are primary neuronal. Astrocytes are the most abundant cell type in the brain (Sofroniew & Vinters,
2010), and therefore the primary neuron cultures are lacking physiological levels of this crucial
support cell. Our primary neuron cultures are also inherently acutely injured from the culturing
process and fundamentally different from neurons that have survived decades of proteotoxic and
oxidative stress events. The three-dimensional network of different neuron types and
interconnectedness of brain regions can also never be fully recapitulated in vitro. Nevertheless,
our in vitro studies provided justification to examine NAC in an in vivo study. While NAC was
not as protective against α-synucleinopathy as we expected, the in vivo study confirmed that our
model can serve as an acceptable platform to examine therapies to treat Lewy body disorders.
Conclusions
In this dissertation, we have helped characterize the PFF model and reported a unique
neuroanatomical pattern of α-synucleinopathy following infusions into the OB/AON. This pattern
of limbic-predominant α-synucleinopathy is congruent with a subset of human Lewy body
disorders (i.e. Beach’s Stage IIb) and was reproduced in separate in vivo experiments in each aim
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of this dissertation. PFF injections allow for the examination of the development and spread of αsynucleinopathy through interconnected brain regions, which cannot be accomplished with toxinbased or transgenic models. Our work has helped establish a model of early stage αsynucleinopathy that recapitulates many of the features seen in human Lewy body disorders and
can potentially serve as a platform to investigate therapies.

Much of the work in this dissertation would not have been possible had we not optimized our PFF
sonication parameters in vivo. By examining different sonication parameters, we were able to find
a reproducible method for generating α-synucleinopathy in nontransgenic animals that is more
robust than it typically reported in the literature. The pathology is so dense that it is even visible
at relatively low magnification, which is conducive to generating stitched images of entire brain
sections. Viewing the α-synucleinopathy in this manner is more useful to neuroanatomists than
highly magnified images as it provides a snapshot of the spread through interconnected brain
regions and the viewer can independently verify our interpretation of the boundaries anatomical
subregions and the topography of the Lewy-like pathology.

By using the tract-tracer FluoroGold, we confirmed first-order efferent projections from the site of
infusion to many of the brain regions that developed dense pSer129+ inclusions. For example,
within the hippocampus, the CA1 field and subiculum frequently developed inclusions, and these
were the regions also displaying FluoroGold signal. The CA2 and CA3 fields develop the most
pathology in PD, and in our model did not display FluoroGold label and exhibited fewer, if any
pSer129+ aggregations. The pathological distribution of pSer129+ aggregates suggests that our
model is more comparable to Lewy body disorders other than PD.
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The FluoroGold study supports the hypothesis that α-synucleinopathy travels primarily in a
retrograde direction as the regions that develop the most pathology have first-order projections to
the site of infusion and areas that receive projections from the OB but do not project back to it,
such as the olfactory tubercle, do not develop pathology at early time points. At 6 and 10.5 months
post-infusion, when pathology in the olfactory tubercle emerged, much of it was perinuclear,
suggesting retrograde transport to the soma from another brain region rather than anterograde
transport from the OB/AON to axon terminals. Our results also support the selective vulnerability
hypothesis, as the horizontal diagonal band of Broca remained free of pSer129 + inclusions even at
10.5 months post-infusion, despite harboring intense FluoroGold label. Future studies to
investigate the unique features of this brain region that make it resistant to the development of
pSer129+ aggregations are warranted.

In addition to characterizing the pattern of α-synucleinopathy throughout the brain, we also
characterized the inclusions with co-immunolabeling and high-resolution microscopy. Consistent
with the literature, we observed that some but not all of the pSer129 + aggregates are labeled with
ubiquitin and Thioflavin S labeled protein aggregates, primarily near the site of infusion. By using
the Proteostat dye, we observed that many of the perinuclear inclusions overlap with the
cytoprotective structure called the aggresome, which may help explain why only minor cell loss
and behavioral deficits are observed in our model despite dense α-synucleinopathy. We are
confident in our identification of Lewy-like inclusions, as we performed several control
experiments on our anti-pSer129 antibodies and the specific anatomical morphology of the
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inclusions (perinuclear and neuritic threads) are in agreement with the literature (Osterberg et al.,
2015).

There were few significant behavioral outcomes that could be attributed to fibril infusions, which
suggests that behavioral changes are more likely to be a function of neuronal cell loss rather than
the presence of pSer129+ aggregates. The younger male mice exhibited fibril-induced olfactory
deficits at three months post-infusion, and the older male mice also exhibited olfactory deficits at
10 months post-infusion that were significantly greater than at three-months post infusion,
suggesting a progressive loss of olfactory capability. Fibril-infused females were not as impaired
as males in the buried pellet test, but made fewer forelimb contacts and reared less often, perhaps
indicating postural instability, a symptom more commonly associated with female patients with
Lewy body disorders (Georgiev et al., 2017). A limitation to our behavioral testing is that the
animals received unilateral infusions and the contralateral hemisphere may be able to compensate
for dysfunction in the ipsilateral hemisphere. However, bilateral infusions in the CA2/CA3 region
using 1-hour waterbath sonicated PFFs elicited dense pathology in both hemispheres with minimal
behavioral deficits (Nouraei et al., 2018), supporting the theory that cell loss is required for changes
in behavior.

Female mice tended to develop fewer pSer129+ inclusions in some brain regions and experienced
less cell loss than male mice. There was a significant reduction in α-synucleinopathy in the OB,
AON,

caudolateral

piriform

cortex,

amygdalopiriform

transition

area,

posteromedial

corticoamygdala, and subiculum in females compared to males. Females did not develop
significantly more inclusions than males in any brain region and did not exhibit significant cell
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loss in any brain region, strongly suggesting an important effect of gender. To our knowledge, this
is the first example of a non-transgenic PFF mouse model of Lewy body disorders in which females
are more resistant to histopathology than males.

At 6 and 10.5 months post-infusion, we observed pathology in the midbrain, most often in the
ventral tegmental area, but also occasionally in the medial parts of the SN pars compacta.
Degeneration of the SN pars compacta is responsible for the motor symptoms associated with
Parkinson’s disease (Alexander, 2004; Jankovic, 2008). In this model we do not observe pSer129 +
aggregates in the lateral subregions of the SN pars compacta that are most vulnerable to
degeneration in PD (Damier et al., 1999; Fearnley & Lees, 1991). This may be attributable to the
ventrolateral SN projecting more to the dorsal striatum (Zhang et al., 2017), where fewer pSer129 +
inclusions are observed in this model. It may also suggest that pathology in the lateral parts of the
SN may arise in caudal brain structures, most likely the brainstem. This agrees with Beach’s
unified staging theory, as most cases of PD and DLB are classified as Stage III or Stage IV, with
both limbic and brainstem pathology. In our model, the pathology is almost exclusively confined
to the limbic system and absent from the brainstem. The nigrostriatal pathway may have been
relatively spared from the development pSer129+ inclusions because of an absence of pathology
emanating from the brainstem.

Despite an overall lack of α-synucleinopathy in the nigrostriatal pathway compared to brain
regions of the limbic system, we observed dramatic changes to dopaminergic markers, particularly
in the oldest mice. It is unclear if the “superager” mice that survived until 10.5 months postinfusion always exhibited high levels of these markers or survived because they were able to
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upregulate the expression of TH and DAT. We observed a fibril-induced increase in TH expression
per cell in all male groups in the SN pars compacta and an increase in this metric in the ventral
tegmental area of the oldest mice. This suggests that there are changes in dopamine metabolism in
the nigrostriatal pathway in response to fibril infusions that may or may not be associated with αsynucleinopathy.

We were limited by the substantial mortality that fibrils elicited in mice that were 11 months old
at the time of infusion, although it was a key finding of Aim 2. To our knowledge, we are the first
to report that higher mortality from olfactory/limbic synucleinopathy in older animals. While the
α-synucleinopathy was not dramatically more dense or extensive than in the younger animals, the
older animals were the only group with significant mortality following fibril infusions. This is
important because age is associated with increased mortality in PD (Oosterveld et al., 2015).
Therefore, our model also simulates the increased risk of mortality with age in human Lewy body
disorders.

For our in vitro experiments, we applied multiple toxicants as well as PFFs to primary neurons
from two different brain regions. The OB was chosen because the region is most often affected
early in Lewy body disorders. The hippocampus also examined because this region is affected in
the end stages of Lewy body disorders, and dysfunction in this region contributes to cognitive
deficits (Hall et al., 2014). We investigated the response to multiple toxicants in neurons from
multiple brain regions because no single model mimics the complex nature of Lewy body
disorders. As discussed in the Introduction, α-synucleinopathy can be toxic through several
mechanisms. Therefore, a potential treatment will likely be clinically relevant if it is protective
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against multiple types of neurotoxicity. Our in vitro experiments established that NAC can protect
primary neurons through GSH-independent means and that there is a beneficial interaction
between NAC and Hsp70. These experiments provided justification for our in vivo study and
confirmed the utility of our model in serving as a platform to test potential therapies.
In conclusion, we have developed an in vivo model of α-synucleinopathy that corresponds to a
distinct subset of patients with Lewy body disorders. The strengths of this model are that it is
reproducible and mimics two major risk factors associated with Lewy body disorders—age and
gender. To our knowledge, no other wild-type mouse model as closely replicates the human
condition. Further experiments with the PFF model may elucidate the mechanisms responsible for
the induction of misfolding, aggregation, and neuronal toxicity caused by non-pathogenic
endogenous α-synuclein. They may also reveal why some brain regions appear resistant to the
development of pathology. Future therapies that are efficacious in this model may have greater
potential for clinical translatability.
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Appendix

Table 2: Primary antibodies
Primary Antibody

Source

Company

Catalog #

Lot #

Dilution

Anti-α-syn 81a
(pSer129)

Mouse

Gift from Kelvin Luk (81A)
(Waxman & Giasson, 2008)

-

-

1:5000

Anti-α-syn
(pSer129)

Rabbit

Abcam

Ab59264

GR5247625

1:300

Anti α-syn 81a
(pSer129)

Mouse

Biolegend

825701

B213120

1:1000

Anti-α-syn
EP1536Y (pSer129)

Rabbit

Abcam

Ab51253

GR2856188

1:1000

Anti-total-α-syn

Rabbit

Abcam

Ab155038

GR1178159

1:500

Anti-K48-linked
poly-ubiquitin

Rabbit

Millipore

05-1307

2299608

1:500

Anti-Tyrosine
Hydroxylase

Mouse

Millipore

MAB318

2742733

1:2000

Anti-DAT

Rat

Millipore

MAB369

2701007

1:4000

Anti-NeuN

Guinea pig

Millipore

ABN90

2031353

1:6000

Anti-Glutathione

Rabbit

Millipore

AB5010

2195968

1:500

Anti-Hsp70

Rabbit

Millipore

AB9920

2278553

1:500

Anti-MAP2

Mouse

Sigma Aldrich

M9942

031M4825

1:2000
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Table 3: Secondary antibodies
Secondary Antibody

Source

Company

Catalog #

Lot #

Dilution

Anti-mouse
@ 488

Donkey

Life Technologies

A21202

1423052

1:800

Anti-mouse
@ 555

Goat

Invitrogen

A21424

1141876

1:1000

Anti-mouse
@ 647

Donkey

Jackson Laboratories

712-605-150

127706

1:1000

Anti-mouse
@680

Donkey

Jackson Laboratories

715-625-151

106244

1:1000

Anti-mouse
@ 790

Donkey

Jackson Laboratories

715-655-150

106037

1:1000

Anti-guinea pig
@ 488

Donkey

Jackson Laboratories

706-545-148

108077

1:1000

Anti-guinea pig
@ 647

Donkey

Jackson Laboratories

706-605-148

123960

1:700

Anti-guinea pig
@ 790

Donkey

Jackson Laboratories

706-655-148

106036

1:1000

Anti-rabbit
@ 488

Donkey

Jackson Laboratories

711-545-152

120705

1:700

Anti-rabbit
@ 555

Goat

Life Technologies

A21429

1562309

1:800

Anti-rabbit
@ 647

Donkey

Jackson Laboratories

711-605-152

123104

1:1000

Anti-rabbit
@ 790

Donkey

Jackson Laboratories

711-655-152

106035

1:2000

Anti-rat
@ 790

Donkey

Jackson Laboratories

712-655-150

106408
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Table 4: Abbreviations
5N
7n
7N
8n
A30
AA
ac
aca
Acb
AcbC
AcbSH
aci
acp
ADLB
AHi
AID
AIV
AMG
AOB
AOD
AOE
AOL
AOM
AON
AOP
AOV
APir
AV
BLA
BMA
BST
CA1
CA2
CA3
cc
CEA
CEnt
CNS
cp
CPu
cst
DA
DAT
DG
DLB
DOPAL
DS

motor trigeminal nucleus
facial nerve
facial nucleus
vestibulocochlear nerve
cingulate cortex, area 30
anterior amygdaloid area
anterior commissure
anterior commissure, anterior part
nucleus accumbens
nucleus accumbens core
nucleus accumbens shell
anterior commissure, intrabulbar
anterior commissure, posterior part
Alzheimer’s disease with Lewy bodies
amygdalohippocampal area
dorsal agranular insular cortex
ventral agranular insular cortex
amygdala
accessory olfactory bulb
anterior olfactory area, dorsal
anterior olfactory nucleus, external
anterior olfactory nucleus, lateral
anterior olfactory nucleus, medial
anterior olfactory nucleus
anterior olfactory area, posterior
anterior olfactory area, ventral
amygdalopiriform transition area
anteroventral thalamic nucleus
basolateral nucleus of amygdala
basomedial nucleus of amygdala
bed nucleus of the stria terminalis
cornu ammonis, field 1
cornu ammonis, field 2
cornu ammonis, field 3
corpus callosum
central nucleus of amygdala
caudomedial entorhinal cortex
central nervous system
cerebral peduncle
caudoputamen
commissural stria terminalis
dopamine
dopamine transporter
dentate gyrus
dementia with Lewy bodies
3,4-dihydroxyphenylacetaldehyde
dorsal subiculum
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HP
ic
IC
ILBD
LAS
lfp
LH
lo
LO
LOT
LPMR
Lrt
LSd
LSv
LTDg
LV
M2
MD
MDL
MEA
MEnt
ml
mlf
MoDG
MVe
NAC
OB
och
ot
PBS
PD
PDD
PFF
Pir
PMCo
Pn
PnO
Pr5
RBD
REM
rf
rms
ROS
Sub
S1
SC
scp

hippocampus
internal capsule
inferior colliculus
incidental Lewy body disease
lysosome-autophagy system
longitudinal fasciculus of pons
lateral habenula
lateral olfactory tract
lateral orbital cortex
nucleus of the lateral olfactory tract
lateral post thalamic nu, mediorostro
lateral reticular nucleus
lateral septal nucleus, dorsal part
lateral septal nucleus, ventral part
laterodorsal tegmental nucleus
lateral ventricle
secondary motor cortex
mediodorsal thalamic nucleus
mediodorsal thalamic nucleus, lateral
medial amygdala
medial entorhinal cortex
medial lemniscus
medial longitudinal fasciculus
molecular layer of dentate gyrus
medial vestibular nucleus
N-acetyl cysteine
olfactory bulb
optic chiasm
optic tract
phosphate buffered saline
Parkinson’s disease
Parkinson’s disease dementia
preformed fibril
piriform cortex
posteromedial cortical amygdala
pontine nuclei
pontine reticular nucleus, oral part
principal trigeminal nucleus
REM sleep behavior disorder
Rapid eye movement
rhinal fissure
rostral migratory stream
reactive oxygen species
subiculum
primary somatosensory cortex
superior colliculus
superior cerebellar peduncle

DTT
Ect
Ent
EPl
FC
fi
fmi
fmj
fr
Gl
GP
GrA
GrDG
GrO
GSH
HDB
hf

dorsal tenia tecta
ectorhinal cortex
entorhinal cortex
external plexiform layer, olfactory bulb
frontal cortex
fimbria
forceps minor of the corpus callosum
forceps major of corpus callosum
fasciculus retroflexus
glomerular layer, olfactory bulb
globus pallidus
granule cell layer of accessory OB
granule cell layer of dentate gyrus
granule cell layer of olfactory bulb
glutathione
horizontal limb of the diagonal band
hippocampal fissure
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sm
SN
SNpc
SNR
sp
Sp
SVZ
TeA
TH
TT
Tub
tz
UPS
VDB
VM
VMH
VTT

stria medullaris
substantia nigra
substantia nigra, pars compacta
substantia nigra, pars reticulata
spinal trigeminal tract
spinal trigeminal nucleus
subventricular zone
temporal association cortex
tyrosine hydroxylase
tenia tecta
olfactory tubercle
trapezoid body
ubiquitin-proteasome system
ventral diagonal band
ventromedial thalamic nucleus
ventromedial hypothalamic nucleus
ventral tenia tecta

